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Abstract 
Trypanosoma brucei is a parasitic protozoan that can cause human African 
trypanosomiasis (HAT) and Nagana in cattle. Human African trypanosomiasis is deadly 
when left untreated, and thus there is an urgent need to develop new drugs against this 
disease. As trypanosomes are early diverged eukaryotes, it is anticipated that studying their 
metabolism can identify novel drug targets. The main drug currently in use against the late 
encephalitic stage, Eflornithine, was shown to inhibit an essential pathway in 
trypanosomes (Yarlett and Bacchi, 1989). 
 
In this Thesis three approaches were used to apply metabolomic and proteomic techniques 
for protein function identification and to investigate metabolic pathways. The genome of T. 
brucei has been published (Berriman et al., 2005) and data is available via databases, such 
as TriTrypDB, a database dedicated to the trypanosomatids (Aslett et al., 2009). An 
estimated 40% of the identified genes in this organism are annotated with an unknown or 
putative function. In 2006, Saito et al.
 
developed a systematic method to ascertain enzyme 
function based on an in vitro assay, in combination with metabolite profiling. This 
approach was successfully applied in several other studies. Here, I investigate the use of 
this method for its application in a high throughput approach for unknown enzyme 
identification in trypanosomes. Seven putative identified enzymes were randomly selected 
from TriTrypDB, cloned and expressed in E. coli and a function could be attributed to at 
least one of the enzymes. Furthermore, the amino acid metabolism in trypanosomes was 
investigated; using stable isotope labelling combined with metabolomics. The flux of 
labelled compounds could be traced through the organism showing the active metabolic 
pathways of L-methionine, L-proline and L-arginine in T. brucei. 
 
Two T. b. brucei strains used in this study, GVR35 and 427, cause different forms of 
infections in their mammalian host. GVR35 causes a chronic infection and invades the 
central nervous system (CNS) with varying parasitemia in mice, whereas infection with 
strain 427 presents an acute form with high parasitaemia, causing high mortality, without 
invading the CNS. What causes this difference in the progression of infection? Secreted or 
excreted proteins from the parasites, referred to as the secretome, have been described as 
being important factor for virulence and avoiding the host immune response (Geiger et al., 
2010) and Garzon et al. (2006) showed that excreted/secreted proteins can inhibit the 
maturation of dentritic cells and stop them from inducing a lymphocytic allogenic 
II 
 
response. Significant differences in proteins secreted from these two strains are discussed; 
although the results are preliminary. 
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Chapter 1 
1. Introduction 
1.1. Human African trypanosomiasis 
Human African trypanosomiasis (HAT), also known as sleeping sickness, is a parasitic 
disease endemic to sub-Saharan Africa.  The disease is fatal when untreated and it affects 
mainly rural populations.  
 
HAT belongs to the neglected tropical diseases (NTDs), a group of 17 diseases affecting 
mainly the world’s poorest population in 149 countries. Included in those are infections 
caused by protozoan parasites, leishmania, Chagas disease and HAT, as well as others 
caused by bacteria (like leprosy), viruses (including dengue and rabies) and helminths (e.g. 
onchoceriasis and schistosomiasis). The World Health Organisation (WHO) estimates that 
about 1.4 billion people are affected by at least one of those diseases 
(http://www.who.int/neglected_diseases/diseases/en/). As those NTDs only affect 
populations in underdeveloped countries, little resources are spent to develop drugs or 
vaccines.  
 
In the case of HAT, the WHO estimated that about 70 million people are at risk of 
acquiring this disease in sub-Saharan Africa. While the risk for the population varies 
depending on the location, five million people live in high risk areas for HAT (Figure 1.1) 
(Franco et al., 2014). Several major HAT outbreaks have been reported since the late 19th 
century and, although HAT was thought to be under control in the mid-20th century, HAT 
re-emerged in the 1990s due to political instabilities in the affected regions (Barrett, 2006; 
Brun et al., 2010). Recent figures show the numbers of reported cases of HAT dropping 
below 10,000 since 2009 after being as high as over 30,000 in the late 1990s (Franco et al., 
2014). 
 
HAT is caused by an infection with subspecies of the protozoan parasite Trypanosoma 
brucei. The parasite is transmitted to the human host by the bite of the tsetse fly (Genus 
Glossina). As it is a vector borne disease, the occurrence of HAT is limited to the 
distribution area of the tsetse fly.  
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Figure 1.1: Population at risk from infection of HAT.  HAT caused by T.b.gambiense is marked in red 
and infections caused by T.b.rhodesiense in blue. Distribution area of the tsetse fly is highlighted in yellow  
(Simarro et al., 2012).  
 
The occurrence of HAT in Africa can be divided in two areas: Central-west Africa, where 
Trypanosoma b. gambiense causes a chronic form of HAT and east Africa for 
Trypanosoma b. rhodesiense causes an acute form of HAT. Only in Uganda are both 
subspecies present. After the parasites get transmitted by the tsetse fly they proliferate at 
the site of infection, causing an inflammatory nodule. This trypanosomal chancre rarely 
occurs in infections caused by T. b .gambiense, but in 50 % of infections with T.b. 
rhodesiense (Barrett et al., 2003). 
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The disease manifests itself in two stages: 
Stage 1, also early haemolymphatic stage, starts when the parasites spread from the 
trypanosomal chancre to the lymph nodes and enter the bloodstream. Multiple organs 
might also be infected (Barrett et al., 2003; Kennedy, 2004). Early symptoms of HAT are 
non-specific, including episodes of fever, malaise and headaches. A typical symptom for 
HAT is lymphadenopathy, which develops in T. b. gambiense infections after several 
weeks. Slave traders in the 18th century used neck swellings as signs for this infection, as 
described by Thomas Masterman Winterbottom (Barrett et al., 2003). Stage 2, also called 
late encephalitic stage, starts when the parasites invade the central nervous system (CNS). 
In infections caused by T. b. rhodesiense this happens within a few weeks, while it could 
occur between several months and years when infected with T. b. gambiense. Symptoms 
during second stage of HAT include disturbances to sleeping patterns, which gives the 
disease its name of ‘sleeping sickness’.  Other symptoms can include mental and 
psychiatric disturbances (Rodgers, 2009). Untreated HAT will lead to coma and eventually 
death. Although treatment of early stage HAT is relatively effective (Rodgers, 2009), HAT 
becomes more symptomatic during the second stage. 
 
There are currently four licensed drugs for the treatment of HAT, which can be 
administered depending on sub-species and stage of the disease. The drugs for the 
treatment of stage 1 HAT are suramin and pentamidine. Suramin was first used against 
HAT in 1922 (Miézan et al., 1994) and can be used against both sub-species. Pentamidine, 
a drug from the early 1940s, is only effective against T. b. gambiense. Both drugs are easy 
to administer and are also relatively safe compared to their counterparts for stage 2 
treatment (Barrett et al., 2007). However, due to HAT becoming more symptomatic during 
the second stage of the disease safer drugs are urgently needed. 
 
Once the parasites invade the CNS the drugs available are melarsoprol and eflornithine. 
Melarsoprol was first synthesised in 1949 and acts against both T. b. gambiense and T. b. 
rhodesiense. However, it has severe side effects that can result in the death of about 5% of 
the patients (Blum and Burri, 2002). Eflornithine, a drug developed as a potential 
antineoplastic agent in the 1970s, is recommended by the WHO for the treatment of HAT 
caused by T. b. gambiense. Recently a combination therapy of eflornithine and nifurtimox 
(a drug used for the treatment of Chagas disease) has been developed and has been shown 
to cure 98% during clinical trials (Priotto et al., 2007). 
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Of all the drugs available for HAT treatment, only eflornithine has a known mode of action 
(Poulin et al., 1992; Vincent et al., 2012) 
 
1.2. Trypanosomes 
Trypanosomatida is a group of kinetoplastid protozoa that are exclusively parasitic and are 
mainly found in insects. However, a few do have a two host life cycle and can infect a 
wide range of hosts, from vertebrates to invertebrates and plants. Species of this order 
known to infect humans are members of the genus Leishmania, with approximately 12 
million people in South America, Middle East and India infected (Singh et al., 2012). 
Trypanosoma cruzi, causing Chagas disease in South America, affecting an estimated 10 
million people (Barfield et al., 2011) and Trypanosoma brucei, causative agent of sleeping 
sickness in Africa (Barrett et al., 2003). Trypanosomes are ubiquitous parasites that can 
cause disease not only in humans but also in animals. They occur mainly in Africa; 
however, species are also known to cause human disease in South America and other 
animal disease outside Africa (Gibson, 2007). 
 
The species Trypanosoma equiperdum, which causes dourine in equines, is thought to be 
closely related to T. evansi, (causative agent of surra in equines). Both T. equiperdum and 
T. evansi have a wider distribution than other trypanosome species, being reported in 
Africa, most of Asia, Russia, parts of the Middle East, South America and southeastern 
Europe ((Gibson, 2007); Animal Health Information Database). T. equiperdum is thought 
to be the only member of the trypanosome family to be exclusively sexually transmitted.   
Trypanosoma cruzi, as mentioned above, is only found in South America and causes 
Chagas disease in humans.  
 
1.2.1. Trypanosoma brucei 
There are three subspecies of T. brucei, two of which are infectious to humans and are 
associated with the disease HAT.  
T. b. gambiense, responsible for 98% of all cases, causes a chronic form of HAT in Central 
and West sub-Saharan Africa.  
T. b. rhodesiense, accounts for 2% of HAT, causing an acute infection in East sub-Saharan 
Africa. 
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 T. b. brucei causes nagana in cattle and other wild and domestic animals; however it fails 
to infect humans due to its sensitivity to an innate immune complex found in human serum.  
There are two trypanolytic factors (TLF) found in human serum, TLF1 and TLF2, causing 
lysis of trypanosome parasites. TLF1 is a component of high density lipoprotein (Hajduk et 
al., 1994) and TFL2 is an apolipoprotein-A1/IgM complex (Tomlinson et al., 1995). The 
lytic component in both is Apolipoprotein L-1 (APOL1)(Vanhamme et al., 2003). Lysis of 
the parasites occurs after uptake of the TLFs into the parasite when APOL1 is taken up into 
endosomal and lysosomal membranes, causing osmotic swelling and lysis by forming 
cation selective pores in membranes (TLF1) (Molina-Portela et al., 2005). The human 
infective subspecies T. b. gambiense and T. b. rhodesiense show resistance against lysis by 
human TLFs. In T. b. gambiense reduced TLF binding or uptake was described due to 
reduced expression of HpHbR (Kieft et al., 2010). In T. b. rhodesiense resistance of 
APOL1 is achieved by expression of a serum resistance-associated protein (SRA).  
 
1.2.2. Life cycle 
Trypanosoma brucei has a two host life cycle; an insect host (tsetse fly) and a mammalian 
host (see Figure 1.2). The two subspecies infectious to humans, T. b. gambiense and T. b. 
rhodesiense, can also infect wild animals. Although they do not fall ill, animals can serve 
as a reservoir for these parasites. This is particularly true for T. b. rhodesiense (Enyaru et 
al., 2006); while T. b. gambiense is more reliant on human to human transmission via the 
tsetse fly (Brun et al., 2010).  
 
Trypanosomes get transmitted during the blood meal of the tsetse fly. Transmition to the 
mammalian host is in form of metacyclic trymastigotes present in the saliva of the tsetse 
fly. In the mammalian (or human) host, metacyclic trypomastigotes differentiate into 
bloodstream trymastigotes (long, slender form) and proliferate at the site of infection for a 
few days, forming a trypanosomal chancre. From there, the fast dividing bloodstream form 
trypomastigotes spread to the lymph nodes and the bloodstream where they can also infect 
multiple organs. The long slender bloodstream form rapidly multiplies and the parasitemia 
in the blood increases. The parasites then differentiate into non-dividing short stumpy 
trypomastigotes which can be taken up by the tsetse fly during a blood meal. In the midgut 
of the tsetse fly the parasites differentiate into procyclic trypomastigotes and proliferate. 
Epimastigotes leave the midgut and differentiate into metacyclic trypomastigotes, 
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migrating to the salivary gland where they can be transferred to the mammalian host when 
the tsetse fly takes another blood meal. 
 
 
Figure 1.2: Representation of the two host life cycle of Trypanosoma brucei in the tsetse fly and human 
host (Blum et al., 2008).  Permission to reproduce this image has been granted by Elsevier. 
 
1.2.3. Trypanosoma brucei strains (used in research) 
From the three subspecies of Trypanosoma brucei only two cause the human disease 
sleeping sickness. However, the human infectious strains T. b. gambiense and T. b. 
rhodesiense share >99% genome sequence identity with T. b. brucei  (Jackson et al., 2010) 
making the non-infectious form a safe model organisms to use in research. 
 
Trypanosoma brucei brucei strains commonly used in the laboratory environment:   
 ‘TREU 927’ originated in Kiboko, Kenya, is a pleomorphic strain that was used for 
the whole genome sequencing program (Berriman et al., 2005) Although the strain 
427 is more commonly used in laboratories the ability of TREU 927 to complete 
the whole two host life cycle made it a better candidate for the sequencing project 
(Peacock et al., 2008). 
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 ‘427’ or ‘Lister 427’ is a monomorphic strain, which lost its ability to differentiate 
into short stumpy forms reportedly due to frequent passage in the lab (Peacock et 
al., 2008). There are mixed information in the literature regarding the origin of the 
‘commonly used 427’ strain. ‘Lister 427’, a T.b.brucei strain, was isolated from 
cattle in former Tanganyika (now Tanzania) in 1956. ‘s427’, is thought to be 
T.b.rhodesiense, isolated from sheep in 1960 (South East Uganda).  
(http://tryps.rockefeller.edu/trypsru2_pedigrees.html) 
 GVR35, originally isolated from wildebeest in the Serengeti (1966), causes a 
chronical infection in mice and when infected mice are left untreated the parasite 
manifest itself in the CNS within 21 days. This makes it a good model organism for 
studying trypanocidal drugs for the late encephalitic stage of this disease (Frevert et 
al., 2012; Jennings et al., 2002) 
 
1.3. Biology of trypanosomes 
Trypanosomes are considered to be very early diverged eukaryotes and make very good 
model organisms for studying biological processes. But what makes trypanosomes good 
model organisms? First, reliable culture methods exist for both life cycle stages. Host-
pathogen interaction can also be studied in suitable animal models - tsetse fly for the insect 
stage and rodents, mice or rat, for the bloodstream form. There is a wide range of 
molecular techniques available for trypanosomes; gene knockout by homologous 
recombination can be performed, as well as RNA interference for gene knockdown 
(Alsford and Horn, 2008). Trypanosomes also have some very distinctive features and 
organelles, making them an interesting model to study and compare biological processes in 
eukaryotes (Smith and Bütikofer, 2010). A few biological processes initially described in 
trypanosomes are antigenetic variation for evading the immune system (Cross, 1975), 
glycosylphosphatidylinositol (GPI) anchoring for VSGs (Ferguson and Williams, 1988), 
trans-splicing (Sutton and Boothroyd, 1986) and RNA editing (Benne et al., 1986). Their 
unique method of evading the human immune system through antigenetic variation has 
been extensively studied and uncovered several other aspects about this parasite, such as 
mechanisms of exocytosis. The genome, sequenced in 2005, is organised differently from 
other eukaryotes and they have a streamlined metabolism, consistent to their parasitic 
lifestyle. 
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1.3.1. Genome of trypanosomes 
The nuclear genome of T. brucei is composed of three classes of chromosomes, which are 
distinguished by size. It contains 11 pairs of diploid megabase chromsosomes, which have 
been sequenced and published (Berriman et al., 2005), a variable number of intermediate 
chromosomes (IC) and between 50-100 mini-chromosomes (MC) (Melville et al., 1998). 
The megabase chromosomes contain housekeeping genes as well as telomeric VSG 
expression sites (Melville et al., 2000). Approximately 9,000 genes were discovered, with 
around 900 pseudogenes. Around 1,700 genes are thought to be T. brucei specific genes 
(Berriman et al., 2005). In most T. brucei strains the copy number of ICs are 1-7 and the 
size varies between 200-700 kb, while the MCs are more numerous and between 30-150 kb 
(Wickstead et al., 2004). Both ICs and MCs play a major role in the recombination of 
bloodstream form VSGs and therefore the parasites ability to avoid the human immune 
system. While the ICs contain VSG expression sites, MCs contain non-transcribed basic 
copies of VSG genes (Melville et al., 1998). 
 
The results of whole genome sequencing project has been made available from several 
sources, the most commonly used is the trypanosomatidae specific database TriTrypDB, 
which grants easy access to genome annotations (Aslett et al., 2010). Recently ‘-omics’ 
datasets have been added to this database. 
 
1.3.2. Evading the immune system 
The bloodstream form T.brucei is a solely extracellular parasite, exposing them to the 
mammalian immune system. Therefore trypanosomes need to have a mechanism in place 
to avoid destruction. Variant Surface Glycoproteins (VSG) are expressed by the parasites, 
during their life cycle in the mammalian host, which form a dense surface coat covering 
the cell (Englund et al., 1982). Each trypanosome expresses only one VSG gene at any 
given time from a telomeric expression site (Horn and McCulloch, 2010). Those VSGs can 
be detected by the host’s immune system and antibodies are produced against those. 
However, trypanosomes use antigenic variation of their surface coat to change the 
composition of those VSGs, which allows some parasites to evade the immune system 
(Horn, 2004).  
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1.3.4. Organelles 
Trypanosomes are single celled flagellates, with an elongated cell shape which is defined 
by their microtubule cytoskeleton (Sherwin and Gull, 1989). Their organelles differ in 
some aspects to most eukaryotic cells (Figure 1.3). Morphological features of this parasite 
include two areas of DNA, one the nucleus and the other the kinetoplast, giving the group 
kinetoplastidae (which trypanosomes belong to) their name. The kinetoplast is a DNA 
containing region at the posterior end of a single elongated mitochondrium which is 
another striking morphological feature of trypanosomes (Kilgour, 1980). 
 
 
Figure 1.3: Schematic diagram of bloodstream form T. brucei illustrating major organelles. This picture 
originally appeared in ILRAD Reports. Vol7 (1), January 1989 and is available online 
http://www.ilri.org/InfoServ/Webpub/fulldocs/Ilrad90/Trypano.htm  
 
The kinetoplast accounts for 10-20% of the cell’s DNA and is arranged in mini and maxi 
circles (Stuart and Gelvin, 1982). The maxi circles (~30-50 copies/cell) contain genes 
encoding for some mitochondrial proteins, whereas the mini circles (~10,000 – 50,000 
copies/cell) encode for short guide RNAs which are used as templates for the post-
transcriptional editing of maxi circle transcripts (Simpson and Shaw, 1989).  The single 
mitochondrion stretches from the posterior to the anterior end of the cell. The form and 
function of the mitochondrion differs between the different life stages of trypanosomes. In 
bloodstream form the mitochondrion lacks cristae, folds of the inner membrane, reflecting 
the absence of mitochondrial respiration (Matthews, 2005).  
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At the posterior end of the trypanosome lies the flagellar pocket, the only site for endo – 
and exocytosis in trypanosomes (Overath and Engstler, 2004). Also, the flagellar pocket is 
the exit point for the flagellum, which is an essential organelle for the viability of 
trypanosomes (Kohl et al., 2003). The flagellum is not only the sole means of motility, but 
also plays an important factor in development, transmission and pathogenesis (Langousis 
and Hill, 2014). 
A unique feature to trypanosomatidae is the glycosome, an organelle where part of the 
glycolysis takes place.  
 
1.3.5. Metabolism 
Due to their complex life cycle (switch between mammalian and insect host), 
trypanosomes must have the ability to adapt quickly to their changing environment. This is 
not only important for the developmental cell biology (Matthews, 2005) but also applies to 
the changes in metabolism between procyclic and bloodstream form cells. Also, 
trypanosomes show a reduced metabolism coinciding with their parasitic life style (Nerima 
et al., 2010). They lack pathways for purine biosynthesis and until recently it was thought 
that they rely solely on the host for components such as fatty acids and sterols as well 
(Fairlamb, 1989). However, it was shown that trypanosomes are capable of de novo 
synthesis of fatty acids (Smith and Bütikofer, 2010). 
 
Lipids make between 11-18% of the dry weight of T. brucei, with a distribution similar to 
the range of lipids found in other eukaryotes, namely phospholipids, neutral lipids, fatty 
acids, isoprenoids and sterols (Smith and Bütikofer, 2010). After discovering that the fatty 
acid molecules of the glycosylphosphatidylinositol (GPI) anchors of the VSGs are 
exclusively myristate (Ferguson and Cross, 1984), it was speculated that bloodstream form 
trypanosomes could indeed synthesize myristate as there would be a higher demand on 
myristate from the parasite than provided in the blood (Lee et al., 2007). Trypanosomes 
mainly synthesise fatty acids through an endoplasmic reticulum (ER) based elongase 
(ELOs) pathway instead of type I or type II fatty acid synthesis (Stephens et al., 2007). 
Type II fatty acid synthesis pathway does exist in the mitochondrion, but is not the main 
source of myristate (Lee et al., 2006). In bloodstream form trypanosomes myristate is the 
endpoint of fatty acid synthesis (Smith and Bütikofer, 2010), while procyclics produce 
stearate (Stephens et al., 2007). 
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Energy metabolism in trypanosomes has been well studied in both life cycle stages. It 
differs from its host’s, due to localisation of glycolytic enzymes in organelles called 
glycosomes (Opperdoes and Borst, 1977), reduced metabolic pathways and the regulation 
of glycolytic enzymes (Nwagwu and Opperdoes, 1982). Energy metabolism also differs 
between the two life stages of the parasite. Some of the features are described below.  
The most unusual aspect of the trypanosome energy metabolism is the 
compartmentalisation of the first nine glycolytic enzymes in the glycosomes. In 
bloodstream form 90% of the proteins found in the glycosomes are glycolytic enzymes 
(Aman et al., 1985). Although the glycosomes were named after presence of glycolytic 
enzymes, other metabolic pathways are also localised within those organelles. Pathways 
(other than glycolysis) described to be localised within the glycosomes include the pentose 
phosphate pathway (PPP), β-oxidation of fatty acids, purine salvage and biosynthetic 
pathways for pyrimidines, ether-lipids and squalenes, although activity varies between 
trypanosomatids (Michels et al., 2006). 
 
In bloodstream form trypanosomes, glycolysis is the only source of ATP production and 
pyruvate the endproduct of glycolysis (van Hellemond et al., 2005). In contrast, procyclic 
trypanosomes can use L-proline as energy source, which is more readily available in the 
midgut of the tsetse fly than glucose (Bursell, 1963) and, to a lesser extent, L-threonine 
(Bringaud et al., 2006); however, they do prefer D-glucose when available (Lamour et al., 
2005). But even when glucose is used in procyclics, the energy metabolism differs as is 
seen by the end products, which are succinate, acetate and alanine (Cazzulo, 1992). It has 
been shown in cultured trypanosomes that they are able to adapt very quickly to changes in 
nutrition offered and they can switch between L-proline metabolism and D-glucose 
metabolism within one hour (Coustou et al., 2008). 
 
The redox metabolism also differs from their mammalian host as trypanosomes rely on the 
thiol trypanothione, a metabolite unique to trypanosomes. Trypanothione is produced via 
the conjugation of two glutathione molecules with one spermidine (Fairlamb et al., 1985). 
The metabolites playing a role in the synthesis of trypanothione are putrescine, the 
precursor to spermidine, from L-ornithine and the formation of spermidine from 
decarboxylated S-adenosylmethionine. Enzymes involved in polyamine and trypanothione 
biosynthesis are essential for parasite growth in T. brucei (Willert and Phillips, 2012) and 
the identification of pathways involved have gained a lot of research interest due to their 
potential in drug discovery. The drug eflornithine for example, which is currently in use 
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against stage 2 HAT, is a suicide inhibitor of the enzyme ornithine decarboxylase, blocking 
the formation of putrescine from L-ornithine leading to the death of the parasites. 
Formation of decarboxylated S-adenosylmethionine from S-adenosylmethionine is 
regulated by the enzyme S-adenosylmethionine decarboxylase. The human S-
adenosylmethionine decarboxylase is stimulated by putrescine. However the trypanosome 
enzyme is allosterically activated by the formation with a catalytical dead paralogue, 
termed prozyme, and is not affected by putrecine (Willert et al., 2007). The appearance of 
inactive enzyme homologues (prozymes) has been observed in a variety of enzyme 
families during a genome search of metazoan species (Pils and Schultz, 2004). In 
trypanosomes so far three enzymes have been found where prozymes increase the function 
of enzymes, namely hexokinase (Chambers et al., 2008; Morris et al., 2006), 
deoxyhypusine syntethase (Nguyen et al., 2013) and the above mentioned S-
adenosylmethionine decarboxylase. 
 
1.4. Metabolomics 
Metabolomics is an emerging field of postgenomic biology that aims to identify and 
quantify small cellular metabolites (Mr < 1200) within a given biological sample.  
The ‘-omics’ technologies comprises genomics for identification of the genome, 
transcriptomics for studying gene expression, proteomics for the analysis of all proteins 
present in the cell and metabolomics. Transcriptomics, proteomics and metabolomics are 
considered more dynamic fields than genomics as they can vary in response to 
environmental conditions (van der Werf et al., 2005), with metabolomics being described 
as the closest representation to the phenotype. Originated as recently as the early 1990s, 
Metabolomics is considered the latest contribution to the ‘-omics’ technologies. The rising 
interest in metabolomics in recent years can be seen in the rise in the number of 
publications in the area. In 1999 three publications with the keyword 
metabonomic/metabolomic could be found, but this number reached 203 in 2004 (Dettmer 
et al., 2007). In a similar search using the medline trend website (Web resource at 
URL:http://dan.corlan.net/medline-trend.html) with the terms “Metabolomics” or 
“Metabonomics” a similar rise in publications could be found from the years 2000 to 2013 
(see Fig 1.4). 
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Figure 1.4: Medline trend created for publications using the term “Metabolomics” or ”Metabonomis”. 
Publication number was normalised against the total number of publications in that year. Trend was obtained 
from: Alexandru Dan Corlan. Medline trend: automated yearly statistics of PubMed results for any query, 
2004.  
 
However, the rising number of publications can also be explained as a ‘knock on effect’, as 
more technology and method development in the field of metabolomics are being made 
available, the more it becomes applicable to a wider range of research areas. Metabolomics 
is increasingly applied to investigate microbial, plant, environmental and mammalian 
systems (Brown et al., 2011). However, the wide range of chemical diversity and range of 
concentrations (dynamic range) of different metabolite classes makes it difficult to produce 
a single analytical platform. Metabolites represent a more diverse set of chemical diversity 
when compared to proteins (constituted by the 20 amino acids) and the nucleic acids and 
therefore provides wide variations in chemical and physical properties (Dunn and Ellis, 
2005). Consequently, it is necessary to use a variety of techniques for complete coverage 
of all cellular metabolites (Castle et al., 2006).  
 
1.4.1. Nuclear magnetic resonance spectroscopy (NMR spectroscopy)  
NMR was one of the first techniques to be used for a broad untargeted metabolite profiling 
since the 1970s (Beckonert et al., 2007). Many NMR-based applications for metabolomics 
have been published but NMR has been commonly utilized for biomarker discovery by 
investigating numerous diseases and toxic processes studying body fluids (Nicholson et al., 
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2002). The main benefits for using NMR include highly reproducible quantitation even 
across different instruments and simple sample preparation without the need for 
derivatization (Creek et al., 2012a). Limitation of NMR includes the relatively poor 
sensitivity compared to mass spectrometry (Creek et al., 2012a).  
 
1.4.2. Mass spectrometry (MS) 
MS is a well established analytical technique that measures the mass to charge ratio of 
charged particles and has been established as one of the most essential tools for 
metabolomic research (Baran et al., 2009). The principle of mass spectrometry consists of 
ionizing chemical compounds to create charged molecules (or fragments). These charged 
molecules can then be detected by analysing the mass to charge ratio. A MS instrument can 
be divided into three different parts; an ion source, a mass analyser, and a detector. As the 
“-omics” approaches require the analysis of complex mixtures, novel analytical methods / 
techniques had to be introduced. A variety of mass spectrometry based approaches are 
commonly used, such as mass spectrometry coupled to liquid chromatography (LC-MS), 
gas chromatography (GC-MS) and capillary electrophoresis (CE-MS) with different types 
of mass spectrometers (Barrett et al., 2010). 
 
1.4.2.1. Chromatography 
Direct injection of samples into the mass spectrometer (MS) has the advantage that no 
metabolites are lost during sample preparation. However, in complex samples and samples 
with high salt content ion suppression can occur, as well as adduct formation during the 
electrospray process (Dettmer et al., 2007). Combining chromatography with mass 
spectrometry can reduce ion suppression as complex samples are separated before entering 
the MS. Which chromatography system to use depends on the kind of molecules studied, 
the two most popular systems are Gas chromatography-MS (GC-MS) and Liquid 
chromatography-MS (LC-MS). 
 
Gas chromatography-MS is often described as the gold standard for metabolomics (Garcia 
and Barbas, 2011). Ion suppression of co-eluting compounds rarely occurs, compared to 
LC-MS (Koek et al., 2011). Other benefits of using GC-MS are the capacity for high 
quantitative accuracy and reproducibility of samples, as well as the use of ‘libraries’ to 
identify compounds by their mass spectra (Schauer et al., 2005). As samples have to travel 
through the column in gas form with temperatures around 350°C, compounds suitable for 
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the GC-MS platform are low molecular weight (<350Da), volatile and thermally stable 
metabolites (Dunn, 2008). However, compounds can be made volatile and thermally stable 
by chemical derivatisation, and here lies the drawback of GC-MS. Sample preparation can 
be complex and lead to multiple derivatisation products. Furthermore, sample stability is 
not guaranteed (Dunn and Ellis, 2005).  
 
Liquid chromatography-MS is the more prominent technology due to ability for greater 
coverage of the metabolome (Garcia et al., 2008) and is becoming increasingly popular for 
the use in metabolomics. Sample preparation is less complex than GC-MS as samples do 
not need to be derivatised. Samples go through the column in liquid phase and are 
separated according to their polarity. Reversed-phase LC-MS is well established in 
metabolomics. However, many polar or charged metabolites are not retained. Therefore, 
another form of LC, hydrophilic interaction liquid chromatography (HILIC) with the 
introduction of robust and reproducible stationary phases has recently gained popularity in 
metabolomics studies (Cubbon et al., 2010). More recently approaches to combine 
reversed phase colums with HILIC in a single run has been successfully performed and it 
was shown, with the example of beer samples, that a greater coverage of metabolites was 
achieved (Haggarty et al., 2015). 
 
1.4.2.2. Ionisation 
Soft ionisation techniques have been the milestone in applying mass spectrometry to 
biological studies, such as metabolomics and proteomics. Electron impact (EI) ionisation is 
mainly applied to GC-MS studies. The spectra obtained contain many fragments which can 
be used for compound identification as fragmentation patterns are very reproducible 
(Watson, 2010). Electrospray ionisation (ESI) is commonly coupled to LC-MS. Ions are 
formed by transferring the solvents through a capillary, which is held at high voltage. Ions 
enter the mass analyser after exiting the capillary and transferred from liquid into gas state. 
ESI can be performed in both positive and negative mode, which gives a wider coverage of 
the metabolome (Dettmer et al., 2007). 
 
1.4.2.3. Mass analysers 
The mass analyzer is used to sort the ions by their masses by applying electromagnetic 
fields. A detector measures the mass to charge ratio (m/z) of the ions and provides data for 
calculating the abundances of each ion present. 
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For the analysis of biomolecular samples, the Fourier transform ion cyclotron resonance 
mass spectrometry (FT-ICR-MS) and the Orbitrap are currently able to achieve high 
resolution and mass accuracy in the 1 ppm range (Breitling et al., 2006a). In FT-ICR-MS, 
trapping of ions is achieved by a strong magnetic field which confines the charged particles 
to a circular path. The Orbitrap, which was exclusively used in this study, is a powerful 
mass spectrometer that can examine a variety of types of chemical systems which makes it 
an appropriate analysing platform for studies such as proteomics and metabolomics. The 
Orbitrap was invented by Alexander Makarov as a new type of mass spectrometer and 
patented in 1999. It uses dynamic trapping of ions in an electrostatic field (Makarov, 
2000), more specific orbital trapping based on the Kingdon trap (Kingdon, 1923). The trap 
consists of an outer barrel like electrode and a central spindle like electrode along the axis. 
Ions are injected tangentially into the electric field between the electrodes and trapped. The 
electrostatic attraction to the inner electrode is balanced by centrifugal forces which makes 
the ions cycle around the central electrode in rings. Additionally, the ions also move back 
and forth along the z-axis of the central electrode. The main distinction of the Orbitrap is 
that the mass to charge ratio is derived from the frequency of the ion oscillations along the 
axis of the field which can then be determined using image current detection and fast FT 
algorithms (Makarov, 2000). The image current is detected on split outer electrodes and 
then amplified by a differential amplifier. Orbitraps have a high mass accuracy (1–2 ppm), 
a high resolving power (up to 200,000) and a high dynamic range (around 5000) (Hu et al., 
2005; Makarov et al., 2006). 
 
1.5. Applications for metabolomics 
The term metabolomics can be identified as the identification and quantification of all 
small molecules within a biological system (Dettmer et al., 2007). However, to date there 
is not a single analytical platform that can achieve this. The metabolome (which is 
identified as the complete set of all metabolites within an organism) represents a broad 
variety of compound classes and analytical platforms can be biased against one or more of 
them. Therefore, different approaches are in use to make the most of metabolomics 
technologies and depending on the research question asked. Below are the most common 
strategies used (Dettmer et al., 2007; Dunn, 2008; Dunn and Ellis, 2005). 
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Metabolite footprinting, also described as the exometabolome, is the analysis of the 
uptake of extracellular metabolites and the secretion of intracellular metabolites. The 
samples can be taken non-invasively. 
Metabolite fingerprinting, also defined as intracellular metabolome, provides a snapshot 
of the global metabolism. Aims to sort samples from different biological origin or status 
intro groups rather than get a good identification and quantification of metabolites. 
Metabolite profiling, aims for an untargeted analysis of the metabolome within a 
biological sample. To obtain a wide coverage of the metabolome multiple analytical 
platforms (or extraction methods) can be used. 
Metabonomics, aims to show quantitative changes to the metabolome in response to 
pathophysiological stimuli or genetic perturbations.  
Metabolome is the definition of the complete set of all metabolites present in an organism. 
Stable isotope labelling, combined with metabolomics has gained an enormous research 
interest over the last few years. With the use of 
13
C labelled compounds in metabolomics it 
is possible to track the carbon flux through a cell and get a much better inside of the 
metabolic pathways than with metabolomics alone. 
The distribution of labelled carbons gives an indication of what metabolic pathways are 
active, new metabolites (or pathways) can be discovered.  
 
The simplest way is to divide studies into two different approaches: targeted or untargeted. 
The targeted approach already requires knowledge about the metabolite(s) of interest and 
this approach is useful to gain knowledge of metabolite quantification or information about 
specific metabolic pathways. The untargeted approach is described as hypothesis 
generating (Creek et al., 2011). 
 
Although terminology of metabolomics techniques used varies between different research 
groups, metabolomics is increasingly applied to the study of microbial, plant, 
environmental and mammalian systems (Brown et al., 2011). Applications include 
biomarker discovery, studies of gene function and the effects of drug therapy and toxicity 
(Nicholson et al., 2002). 
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1.6. Metabolomics and enzyme function identification 
The full functional annotation of all genes (or gene products) within an organism displays a 
great challenge in the post-genomic era. Although the number of whole genome sequences 
available is rising, even in a well described organism like E. coli 40% of the genes have no 
confirmed function (Keseler et al., 2009). In other organisms the number is even higher. In 
the tritryps (T. brucei, T. cruzi and Leishmania major) this number reaches up to 70% 
combining the unknowns in all three species, although their genome sequences were 
published nearly 10 years ago (Choi and El-Sayed, 2012). With the data available from the 
whole genome sequencing projects, the potential function of a hypothetical protein can be 
determined by bioinformatics approaches, such as BLAST or Pfam domain searches. An 
alternative approach is the prediction of a protein’s function based on the structure. This 
method is well described by (Whisstock and Lesk, 2003)which gives an overview of 
automated structure-based function prediction. However, it has been shown in the past that 
these annotations can be incorrect. In a study, Barrett et al. found that the trypanosome 
enzyme Tb927.8.2020, which had been putatively annotated as an arginase, did not show 
classic arginase activity (Hai et al., 2015; Vincent et al., 2012).  
 
One of the tasks in functional genomics is to search for novel enzymes but also to provide 
functions for genes where bioinformatics can only give putative function. Metabolites can 
be used to assign or validate the function of enzyme activities as these are often the final 
downstream products or substrates of gene expression (Baran et al., 2009). Enzymatic 
reactions play an important role, not only in the regulation of all processes of life but also 
as biocatalysts in industrial processes or as targets in the discovery of new drugs (Liesener 
and Karst, 2005). 
  
Traditional approaches to establish enzyme activity include enzyme assays, but the main 
drawback to this technique is that the enzyme function has to be known (Liesener and 
Karst, 2005). Integrated ‘omics’ approaches can be used to facilitate the identification of 
unknown enzymes (Fridman and Pichersky, 2005), however, prior biochemical knowledge 
was still essential.  Mass spectrometry based analysis of small molecular metabolites has 
become a valuable method for the discovery and validation of functional assignments for 
enzymes (Baran et al., 2009).  
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1.6.1. Enzyme function identification by in vitro assay with recombinant protein 
A systematic method to discover novel enzymes based on an in vitro assay in combination 
with metabolite profiling was introduced by Saito et al. (2006). Proteins of interest were 
purified and used for an in vitro reaction with a complex metabolite mixture. Bacto yeast 
extract, Bacto malt extract and Nutrition Broth were tested as a suitable metabolite source 
for their ease of preparation and low cost while still containing a large variety of 
compounds. The advantages of using natural and complex metabolite mixtures also include 
the possibility for screening of unknown type of reactions and an environment closer to the 
physiological conditions than standard in vitro essays (Saito et al., 2006). After the reaction 
the mixture was purified and analysed by CE-MS. The metabolite profiles of the reaction 
mixture incubated in the presence and absence of the protein of interest were compared. 
The idea is that the compound whose level decreases following incubation with the protein 
can be considered a likely substrate for the enzyme, and a compound with increasing levels 
after incubation a likely product. The identification of those compounds can therefore 
directly report on the enzyme’s activity. This procedure should be effective for discovering 
novel activities of enzymes as well as identifying unknown enzymes in an unbiased 
manner. The results demonstrated that it was possible to monitor several known enzymatic 
reactions by observing the changes in substrates/products levels in a complex mixture of 
metabolites. This method was further applied to identify the unknown E. coli protein YihU 
as a novel hydroxybutyrate dehydrogenase, involved in an alternative succinic 
semialdehyde metabolism (Saito et al., 2009). In a similar approach, termed ‘activity based 
metabolomic profiling’, using LC-MS, the protein Rv1248 from Mycobacterium 
tuberculosis was identified as a 2-hydroxy-3-oxoadipate synthase (de Carvalho et al., 
2010). The same group later identified the gene product of Rv1692 from M. tuberculosis. 
Originally annotated as a nucleotide phosphatase, applying the activity based metabolomic 
profiling method, it was shown that the enzyme is in fact a D,L-glycerol 3-phosphate 
phosphatase (Larrouy-Maumus et al., 2013). That this approach is also applicable outside 
the research of microorganisms was shown by the identification of a methyltansferase in 
the plant Madagascar periwinkle (Catharanthus roseus). The identified S-
adenosylmethionine dependent N-methyltransferase plays a role in the biosynthesis of the 
anti cancer drug vindoline (Liscombe et al., 2010). 
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1.6.2. Metabolite profiling by disrupting enzyme activity 
Metabolite profiling on mutants, with a gene of interest either knocked out or knocked 
down by RNA interference (RNAi), can also determine the function of that gene when 
compared to wild-type (Saghatelian et al., 2004). The most ideal case shows one 
metabolite increasing (the substrate of that reaction) and one metabolite decreasing (the 
product of that reaction). However, unless the gene of interest is essential for that 
organism, visible changes to the dataset can be numerous or nonexistent. Organisms could 
have the ability to bypass the blocked reaction and changes in the dataset can be non- 
conclusive. In the case of RNA interference, a complete knock-down of the gene might not 
be achieved and therefore not show changes in substrate and product. Compared to the in 
vitro assay (1.6.1) results from genetic mutant assays can not only give information about 
the gene of interest and its function, but also if that gene is essential and if loss of function 
causes changes to the phenotype.  
 
1.6.3. Stable isotope labelling for pathway identification 
The use of stable isotope labelling combined with untargeted metabolomics has shown to 
improve the interpretation of data regarding pathway identification. Normally, untargeted 
metabolomics lacks the information that is needed to assign detected metabolites to 
pathways, as metabolites can participate in multiple pathways (Fan et al., 2012). The use of 
labelled compounds makes it possible to follow the fate of a single metabolite within the 
cell. For example, by adding uniformly labelled 
13
C glucose (U-
13
C glucose) to the culture 
medium, the carbon contribution from glucose into other metabolites can be traced and its 
flux can also be determined (Winder et al., 2011). The uses of stable isotope labelling for 
novel metabolite or pathway discovery has the advantage of being independent from 
genetic modifications or studies with recombinant protein, therefore making it a faster 
approach for pathway identification (Prosser et al., 2014). 
 
1.7. Trypanosome metabolomics 
Many applications for metabolomics analysis of trypanosomes have been developed in 
recent years. Early trypanosome metabolomics experiments were performed with NMR, 
for example the assessment of the end products of anaerobic glycolysis using U-
13
C 
labelled glucose (Mackenzie et al., 1983) and the tracing of polyphosphates in T. brucei, T. 
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cruzi and L. major (Moreno et al., 2000). The identification of the enzyme 
Acetyl:succinate CoA transferase and its role in carbohydrate metabolism in procyclics  
was performed using gene knock down and NMR (Rivière et al., 2004). 
 
Earlier studies on trypanosome metabolomics was performed using direct infusion and 
approximately 1,000 peaks were detected, with a high percentage of peaks associated to 
lipid compounds (Breitling et al., 2006b).The use of LC-MS with HILIC columns 
optimised the identification of polar compounds in trypanosome extracts (Kamleh et al., 
2008). Recently, LC-MS, using HILIC (or pHILIC) columns has emerged as the main 
analytical platform for trypanosome metabolomics used (in Glasgow) (Barrett et al., 2010). 
 
Development of a minimal media (CMM) for trypanosome growth has further advanced 
the metabolomics platform in Glasgow, as CMM reduces background noise on the LC-MS 
platform used while not affecting the ability of T. brucei’s growth (Creek et al., 2013). 
  
For the analysis of the metabolome it is crucial to quench the parasites metabolism as 
rapidly as possible before extracting metabolites. The first method to achieve this was to 
add boiling ethanol to trypanosomes (Kamleh et al., 2008). A drawback of this method was 
that trypanosomes were still in media at that point, making it necessary to distinguish 
between intra- and extracellular metabolites.  The development of new extraction methods 
has greatly improved the number of metabolites discovered and metabolite extraction for 
metabolomics is now achieved by rapidly chilling the cells in culture to 0°C by suspending 
them in a dry ice/ethanol bath. The medium can be removed by gently spinning the culture 
and washing steps before extracting the trypanosome metabolites from a cell pellet by 
adding a mix of chloroform:methanol:water (t’ Kindt et al., 2010; Robinson et al., 2007). 
 
Metabolomics studies lead to a better understanding of the metabolism of trypanosomes, 
the earlier understanding of the fatty acid synthesis metabolism could be revised and with 
metabolomic approaches it was shown that trypanosomes are indeed capable of fatty acid 
synthesis and that they use a unique mechanism to do so (Smith and Bütikofer, 2010; 
Stephens et al., 2007). Also, metabolomics approaches have been employed to investigate 
the energy metabolism in procyclic and bloodstream form trypanosomes (Coustou et al., 
2008; Ebikeme et al., 2010; Mazet et al., 2013; Rivière et al., 2004). Recently it was shown 
that intermediates from glucose enter many branches of the metabolism, by combining 
stable isotope labelling with metabolite profiling (Creek et al., 2015). 
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Another application for the uses of metabolomics in trypanosomes are mode of action 
(MOA) studies for drug discovery. The recent example of Eflornithine (an inhibitor of the 
enzyme ornithine decarboxylase), showed that by adding Eflornithine to cultured cells and 
comparing treated and non treated samples, L-ornithine increased significantly in drug 
treated cells, while levels of putrescine decreased significantly (Vincent et al., 2012).  
 
1.8. Secretome and Host Pathogen Interaction 
1.8.1. Secretory pathway in trypanosomes 
Despite trypanosomes being early divergent eukaryotes the classical secretory pathway in 
trypanosomes is similar to that of other eukaryotes and has been well studied for the endo- 
and exocytosis of VSGs. The organelles involved in the classical secretory pathway are 
typical eukaryotic organelles, including endoplasmic reticulum (ER), Golgi, endosomes 
and lysosome which are located nearby the posterior flagellar pocket (Silverman and 
Bangs, 2012). That trypanosomes use this secretion pathway was demonstrated for VSGs 
using immunogold labelling. VSGs could be traced in ER, golgi cisternae, trans-golgi 
network, transport vesicles, flagellar pocket and, ultimately, on the cell surface (Duszenko 
et al., 1988). The secretion of VSGs is linked to the modification of VSGs with the GPI-
anchor within the ER, as deletion of the GPI anchor leads to mis-sorting into lysosomes 
(Triggs and Bangs, 2003).  
 
Endocytosis is up regulated in bloodstream form trypanosomes (compared to procyclics) 
and important for recycling of VSGs and clearance of VSG recognising immunoglobulins 
(Engstler et al., 2007; Field and Carrington, 2004)(Field and Carrington, 2004). 
Endocytosis and exocytosis where thought to be restricted to the flagellar pocket, however, 
a recent study indicates that exocytosis might be possible through microvesicles (Geiger et 
al., 2010), a mechanism already described in T. cruzi (da Silveira et al., 1979). 
 
1.8.2. Secretome 
The term secretome describes a subset of the proteome, including all proteins actively 
secreted from the cell and the components of the cellular machinery used for protein 
secretion. The term (and this definition) was first used in a study that tried to predict all 
secreted proteins from Bacillus subtilis using computational methods (Tjalsma et al., 
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2000). Verifying these results with proteomic approaches showed that 50% of the secreted 
proteins were correctly identified (Antelmann et al., 2001). 
  
The secretome has been the focus on many studies of human pathogens to better 
understand the host-pathogen interaction (Ranganathan and Garg, 2009), as well as a 
research tool for biomarker discovery in cancer (Grønborg et al., 2006). The use of 
proteomic techniques for the identification of excreted/secreted proteins (ESPs) started in 
the1990s and became more popular from 2004 , with the first paper regarding the 
trypanosome excreted/secreted proteins (ESPs) or secretome published in 2008 
(Holzmuller et al., 2008). 
 
1.8.4. Host pathogen interaction 
Shedding of extracellular vesicles (EVs) was demonstrated for infective trypomastigotes of 
Trypanosoma cruzi. It was further shown that shedding occurred independent from 
proteins present in the culture medium, but in a time and temperature dependent process 
(Gonçalves et al., 1991). One major component of those EVs was Tc85, a trans-
sialidase/gp85 glycoprotein, which is involved in host cell adhesion and invasion (Alves 
and Colli, 2008). As T. cruzi, in contrast to T. brucei, has intracellular location in the 
mammalian host interaction with the host cell is necessary for infection.  
 
During second stage HAT T. brucei crosses the blood brain barrier (BBB) in a mechanism 
not yet fully understood. However, secreted proteases from the bloodstream form 
trypanosomes, in particular cysteine proteases Cathepsin B and Cathepsin L (‘Brucipain’), 
play a vital role in the pathogenesis of T. brucei. RNAi cell lines targeting those proteases 
have successfully stopped the lethal infection in mice (Abdulla et al., 2008). The proteases 
are important for the parasites to invade the mammalian tissue after infection (Huet et al., 
1992).  
 
Secreted/excreted proteins from the parasites have been described as being important 
factor for virulence and to avoid the host immune response (Geiger et al., 2010). Garzon et 
al. (2006) showed that excreted/secreted proteins can inhibit the maturation of dentritic 
cells and stop them from inducing a lymphocytic allogenic response.  
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1.8.5. Trypanosome secretome 
ESPs from pathogens can have a variety of functions, from protecting the cell from the 
host immune system, advancing the pathogenesis and to provide nutrients for cell survival.  
In the case of the protozoan parasite T. brucei the primary secretory cargo are 
glycosylphosphatidyl inositol anchored variable surface proteins (VSGs) which are 
essential for the parasite to evade the immune system (Bangs et al., 1996; Engstler et al., 
2004). Several metabolic enzymes have been described as being secreted from bloodstream 
form trypanosomes, such as enzymes belonging to the nucleic acid metabolism, in 
particular IAG nucleoside hydrolase, which has been detected in bloodstream form 
trypanosomes (Parkin, 1996). 
 
Bioinformatic approaches to identify ESPs exist, but are not always reliable. Proteins must 
have a transit peptide sequence to be secreted via the classical secretory pathway, therefore 
it is essential to know the secretory pathways used in a particular organism. A study on 
different strains of trypanosomes showed less than 20% of experimentally identified 
secreted proteins were predicted using bioinformatic approaches (Geiger et al., 2010). 
Endocytosis and exocytosis in trypanosomes occur through the flagellar pocket, but 
evidence has been found that trypanosomes possibly also use exocytosis of microvesicles 
to release proteins from cells (Geiger et al., 2010). 
 
Proteomic approaches have been shown to give good results for the analysis of secreted 
proteins in leishmania and trypanosomes. Gel based proteomic analysis, like difference gel 
electrophoreses (DiGE), is a two-dimensional gel electrophoresis (2-DE) approach that 
allows for good separation of complex protein mixtures (O’Farrell, 1975). Proteins are first 
separated according to their charge (isoelectric focusing), followed by their size on a 
polyacrylamide gel. Proteins of interest can be selected from the gel, digested with trypsin 
and analysed using peptide mass fingerprinting. This approach, combined with fluorescent 
dyes is a useful tool for comparing two different sets of proteomes. A gel free approach 
also exists, where complex protein mixtures are digested into peptides and analysed with 
LC-MS/MS.  
  
25 
 
1.9. Aims 
Human African trypanosomiasis is a neglected tropical disease that affects mainly the 
poorest regions in Africa. The disease is fatal when left untreated and drugs currently in 
use are old and some have undesirable side effects. 
 
The causative agent of HAT is the parasitic protozoan T. brucei. The genome of this 
parasite has been sequenced and published. However, an estimated 40 % of the genes still 
have no assigned function. 
 
This project focuses on metabolomic and proteomic approaches to determine the function 
of unknown metabolic enzymes and pathways in trypanosomes with three approaches 
being investigated: 
 
 High throughput approach for enzyme function identification in an untargeted 
approach. Putatively identified metabolic enzymes from T. brucei strain 427, as 
identified from the trypanosome database TritrypDB, were used in this study.  
After the recent success stories of an unbiased, untargeted enzyme assay (Saito et 
al., 2009; DeCavalho et al., 2010) this approach was tested for its uses of a high 
throughput approach applicable to trypanosome genes. 
 
 The use of stable isotope labelling combined with metabolomic techniques for the 
study of amino acid metabolism in trypanosomes, specifically the pathways 
involving L-methionine, L-proline and L-arginine in bloodstream form 
trypanosomes. 
 
 Identification of secreted/excreted proteins from two different T. brucei strains, 
namely 427 and GVR 35, using proteomic approaches. 
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Chapter 2 
Methods 
2.1. Cell culture 
2.1.1. Cell culture of T. b. brucei 
T. b. brucei bloodstream form (strain 427) were cultured in HMI-9 medium (Gibco) 
(Hirumi and Hirumi, 1989) supplemented with 10% FBS Gold (PAA) or tetracycline-free 
FBS (Gibco), unless stated otherwise. Trypanosomes strain GVR35 were originally 
cultured in modified HMI-9 (from P. Voorheis; Appendix A,Table A1) supplemented with 
20% FBS Gold or tetracycline-free FBS and 20% Serum plus (SAFC bioscience). For 
metabolomic and proteomic analyses, parasites were cultured in Creek’s ‘Minimal’ Media, 
CMM ((Creek et al., 2013); Appendix A, Table A2) with 10% FBS Gold. The 2T1 cell line 
(Alsford and Horn, 2008) was cultured in HMI-9 medium with 10% tetracycline-free FBS 
and maintained in 2 µg ml 
-1 
puromycin and 2.5 µg ml 
-1
 phleomycin selection until 
transfection, when antibiotic selection was changed to 5 µg ml 
-1
 hygromycin and 2.5 µg 
ml 
-1
 phleomycin after 24 h to select for successfully transfected parasites.  
 
For continuous growth, cell densities were kept between 5 x 10
4
 and 2 x 10
6
 cells ml
-1
. The 
cell density was checked every 48 hours using an improved Neubauer haemocytometer. 
For growth curves, cells were counted every 24 hours and cell counts performed in 
triplicate. 
 
Stabilates of bloodstream form trypanosomes were routinely prepared by mixing cells in 
mid-log phase 1:1 (v/v) with a freezing mix containing 80% culture medium and 20% 
glycerol. Samples were stored overnight at -80°C, before being transferred to liquid 
nitrogen for long term storage.  
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2.2. Molecular Methods  
2.2.1. DNA isolation 
Genomic DNA (gDNA) was extracted using the DNeasy Blood & Tissue Kit (Qiagen). 
Bloodstream form trypanosomes (strain 427) were grown to mid-log phase. 5 x 10
6
 cells 
were harvested by centrifugation for 5 min at 1,800 rpm. The resulting cell pellet was 
resuspended in 200 µl of 1 x PBS, and DNA was extracted following manufacturer’s 
instruction.
 
 
2.2.2. RNA isolation 
RNA was extracted from bloodstream form trypanosomes using the RNeasy Mini Kit 
(Qiagen). Mid-log phase parasites (5 x 10
7
 cells) were harvested by centrifugation for 10 
min at 1,300g. The pellet was resuspended in 1 ml Trizol (Invitrogen) and samples stored 
at -80°C until RNA isolation. 
 
For RNA isolation, to 1 ml of cells in Trizol 200 µl of chloroform was added and mixed 
thoroughly. After centrifuging at 12,000g for 15 min (4°C), the mixture separated into a 
lower red phenol – chloroform phase, an interphase, and an upper colourless aqueous 
phase. The upper colourless aqueous phase was removed and the RNeasy Mini Kit was 
used from this step, according to manufacturer’s instruction. After RNA extraction, 
samples were treated with DNase (Finnzymes). RNA concentration was measured using a 
Nanodrop 1000 spectrophotometer (Thermo Scientific), NanoDrop 1000 software (version 
3.7.0) and the method RNA-40. 
 
2.2.3. Polymerase chain reaction 
DNA amplification by polymerase chain reaction (PCR) was used to produce desired 
regions of DNA for molecular cloning, using appropriately designed primers, or to screen 
for successful transformations using vector specific primers. All oligonucleotides used 
where obtained from Eurofins MWG Operon (Ebersberg, Germany), and are listed in 
Appendix B, Table B1. 
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The standard PCR reaction used for colony screening was performed in 10 µl volume 
reactions using GoTaq DNA polymerase (Promega) and vector specific primers (T7 
promoter (forward) and HIS tag (reverse)). 
 
Cycling conditions: 
1 – Polymerase activation 94°C for 5 min 
2 – Denaturation  94°C for 30 s 
3 – Annealing   42°C for 30 s 
4 – Extension   68°C for 1 min 
5 – Repeat step 2-4  30 cycles 
6 – Final extension  68°C for 5 min 
PCR reactions for cloning were performed in 50 µl volume using either KOD HotStart 
proofreading polymerase (Novagen/Merck) or Phusion HiFi proofreading polymerase 
(NEB). Conditions were applied as by manufacturers' instruction.  
 
Cycling conditions (KOD HotStart proofreading polymerase): 
1 – Polymerase activation 95°C for 2 min 
2 – Denaturation  95°C for 20 s 
3 – Annealing   54.2°C for 10 s 
4 – Extension   68°C for 30 s (<1,500bp), 50 s (>1,500bp) 
5 – Repeat step 2-4  30 cycles 
6 – Final extension  70°C for 20 s 
 
Cycling conditions (Phusion) 
1 – Polymerase activation 98°C for 3 min 
2 – Denaturation  98°C for 30 s 
3 – Annealing   75°C for 30 s 
4 – Extension   72°C for 30 s 
5 – Repeat step 2-4  35 cycles 
6 – Final extension  72°C for 10 min 
 
2.2.4. Reverse transcription 
To determine the knockdown efficiency of tetracycline induced RNAi lines, reverse 
transcription coupled to real-time PCR (2.2.5) was applied. For reverse transcription 
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reaction, 1 µg of RNA sample was mixed with 250 ng random primers (Invitrogen), 1 µl of 
dNTPs (10 mM) and dH2O to a final volume of 14 µl. To remove secondary structures, the 
sample mix was heated to 65°C for 5 min and immediately placed on ice. To synthesise 
cDNA 6 µl RT-mix (containing 5x First-Strand Buffer, 0.1 M DTT and SuperScript III 
reverse transcriptase (Invitrogen)) was added to the sample and incubated for 25 min at 
25°C, and then for a further 60 min at 50°C. The transcriptase was inactivated for 15 min 
at 70°C. Finally, complementary RNA was removed by adding E. coli RNaseH (2U) for 20 
min at 37°C. Samples were prepared in duplicate, with one sample set containing dH2O 
instead of SuperScript III RT as negative control.  
 
2.2.5. Real-time PCR 
Complementary DNA (cDNA) obtained from reverse transcription reaction (2.2.4) of 
tetracycline induced and uninduced RNAi lines were used as template DNA. SYBR® 
Green PCR Mastermix (Applied Bioscience) and 96-well plates were used for relative 
quantitative PCR. Sample setup included three replicates of each sample (+/- reverse 
transcription reaction) for the transcript of interest. The constitutively expressed GPI-8 
transcript was chosen for comparison (Lillico et al., 2003) and water controls were used to 
check for contamination. Amplification of cDNA (see 2.2.4) was performed using Applied 
Biosystems Prism 7500 Real Time PCR system, following the ‘ddCT’ program for 
absolute quantification and marker set to SYBR. Raw data was analysed using Applied 
Biosystems 7500 SDS Real-Time PCR systems software.   
Specific real-time PCR primers for target genes were designed using primer express 
software from Applied Biosystems. Primers should amplify a region of the gene in the 
range of 50 to 150 bp.  Primer efficiency was tested and an ideal primer should have an 
efficiency of > 90% (Table 2.1) 
 
Gene ID Forward primer Reverse primer Primer 
efficiency 
Tb927.7.5680 GTGTGCGTGATCGCGAAA 
 
TGTGCCAATGCGTGATACG 
 
98.62% 
Tb427tmp.02.3040 TGTTGGAGCCGCTATTCGA 
 
TTCACGAGAATGAAAAGCTCAAAG 
 
96.06% 
Tb427.05.3820 GCCACTGCACTGAAGGAGAAG 
 
TGCGACCCTCAAGAAAACGT 
 
115.08% 
Table 2.1: Real-time PCR primers and their efficiency for the use in determining the knockdown effect 
of induced RNAi lines. 
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Data was obtained using Applied Biosystems 7500 Real-Time system software and relative 
abundance of RNA was calculated against control transcript GPI-8. 
 
2.2.6. Plasmid generation 
2.2.6.1. Plasmids for recombinant overexpression 
A ligation independent cloning kit (pET 30 Xa/LIC, Novagen) was used to obtain the 
expression vectors for all recombinant proteins used in this study, unless stated otherwise. 
Constructs used are listed in Table 2.2 (a) and 2.2 (b). Primers were specifically designed 
for ligation independent cloning (see Appendix, Table B1) as the cloned DNA needs a 
vector specific overhang which can be created by treating the obtained PCR product with 
T4 DNA polymerase, following the manufacturer’s instructions. 
 
The annealing reaction typically contained 1 µl of Xa/LIC vector and 2 µl (0.02 pmol) of 
insert DNA. The reaction volume was 4 µl and included 1 µl of 25 mM EDTA. 
 
Gene ID Gene name Plasmid ID 
 
Tb427.01.1130 Glycerol-3-phosphate dehydrogenase (FAD-
dependant) 
 
pMB-G190 
Tb427.06.4920 S-adenosylmethionine synthetase (putative) 
 
pMB-G191 
Tb427.08.3800 Nucleoside phosphatise (putative) 
 
pMB-G192 
Tb427.10.13130 UTP-glucose-1-phosphate  
uridyltransferase 2 (putative) 
 
pMB-G193 
Tb427.10.13430 Citrate synthase (putative) 
 
pMB-G194 
Tb427tmp.02.0530 Phosphoribosylpyrophosphate synthase (putative) 
 
pMB-G195 
Tb427tmp.02.3040 Aldo/keto reductase 
 
pMB-G196 
Tb427.05.3820 Aspartate carbamoyltransferase (putative) 
 
pMB-G197 
Tb427.10.2010 Hexokinase I pMB-G198 
 
Table 2.2 (a): Plasmids created for recombinant protein over expression. Proteins were used for the high 
throughput enzyme identification approach. 
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Gene ID Gene name Plasmid ID 
 
Tb09.160.0810 Kynureninase (putative) 
 
pMB-G157 
Tb927.10.2750 Deoxyhypusine synthase (putative) 
 
pMB-G158 
Tb927.7.5680 Deoxyribose-phosphate aldolase (putative) 
 
pMB-G159 
Tb927.5.287b Galactokinase, Pseudogene 
 
pMB-G160 
Tb927.2.3080 Fatty acid desaturase (putative) 
 
pMB-G161 
Tb11.01.6500 NAD+ synthase (putative) 
 
pMB-G162 
Tb927.8.2020 Arginase/agmatinase-like protein pMB-G131 
 
Table 2.2 (b): Plasmids created for recombinant protein over expression. Proteins were used in this study 
either for the high throughput enzyme identification approach or targeted investigation. Plasmids were 
created by B. Nijgal, with the exception of pMB-G131, which was created by E. Kerkhoven. Tb927.5.287b 
was annotated as Galactokinase, pseudogene. The gene sequence shows several stop codons, however, 
protein is produced by E. coli when overexpressed. 
2.2.6.2. RNA interference constructs 
Target sequences and oligonucleotides for cloning were designed using the program 
TrypanoFAN RNAit (Redmond et al., 2003) and oligonucleotides are listed in Appendix 
B, Table B2. Target sequence was amplified from T. b. brucei strain 427 gDNA using 
Phusion high fidelity polymerase and cloned into plasmid pGL2084 (Jones et al., 2014) in 
a BP recombinase (Invitrogen) reaction following manufacturer’s instructions. Resulting 
plasmids were transformed using DH5α max efficiency cells (Invitrogen), purified and 
digested with AscI (NEB) prior to transfection.  
 
2.2.7. Plasmid Purification 
The pET30 Xa/LIC was transformed into NovaBlue GigaSingles competent cells 
(Novagen) and grown on LB (Luria Broth, Sigma) agar plates supplemented with 30 µg/ml 
kanamycin (KAN). Up to five colonies were selected and screened by PCR for presence of 
the insert. A 5 ml overnight culture from a single colony, that tested positively for presence 
of the insert, was set up (LB medium + 30 µg/ml KAN) and the plasmid isolated using 
QIAprep Miniprep Kit (Qiagen GmbH, Hilden, Germany). The yield of plasmid was 
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assessed using Nanodrop 1000 Spectrophotometer (Thermo Scientific), using the 
NanoDrop 1000 software, version 3.7.0 and the method DNA-50. 
 
2.2.8. Transformation 
2.2.8.1. Competent cells 
Competent cell lines were produced chemically. E. coli cells were streaked out on LB agar 
plate containing appropriate antibiotic (chloramphenicol for pLysS lines) and incubated 
overnight at 37°C. A single colony was inoculated in 5 ml LB broth (with appropriate 
antibiotic if required) and incubated overnight at 37°C. Overnight cultures were diluted 
1:1000 in LB broth to a final volume of 200 ml and grown at 37°C to OD600 0.6. The 
culture was divided into 50 ml falcon tubes, incubated on ice for 15 min, and centrifuged 
for 15 min, 2,000 rpm, at 4°C.  The resulting cell pellets were resuspended in 16 ml RF1 
buffer (Table 2.3), incubated on ice for 15 min, and centrifuged for 15 min at 1800 rpm, at 
4°C.  The cell pellets were pooled by resuspending in 4 ml of RF2 buffer (Table 2.3), 
incubated for 1 h on ice, and divided into 200 µl aliquots on dry ice. Aliquots were then 
stored at -80°C. 
RF1 buffer RF2 buffer 
    
100 mM rubidium chloride 10 mM MOPS pH 6.8 
50 mM MnCl2.4H2O 10 mM rubidium chloride 
30 mM potassium acetate 75 mM calcium chloride 
10 mM calcium chloride 15% glycerol 
15% glycerol   
    
pH 5.8 pH 6.8 
  
Table 2.3: RF1 and RF2 buffers for chemically competent cells 
 
2.2.8.2. Bacterial transformation 
NovaBlue GigaSingles competent cells (Merck Bioscience, UK) were used for cloning. 
For over-expression, several E.coli strains were used, depending on the protein (see 2.3.1). 
E. coli BL21 (DE3) (Merck Bioscience, UK) and Rosetta (DE3) pLysS were used for the 
majority of proteins.  
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For bacterial transformations 1-10 ng of plasmid DNA was used to transform 20 μl of 
competent cells. The mixture was incubated on ice for 5 min. The cells were heat shocked 
for 30 s at 42°C, and then chilled on ice for 2 min. A 250 µl aliquot of pre-warmed SOC 
medium was added to the mixture, and the cells were incubated for 60 min at 37°C with 
shaking. Typically, 150 μl of transformed bacteria were spread evenly over the surface of 
an LB agar plate containing the appropriate antibiotic, and incubated at 37°C overnight to 
select for transformed cells. 
 
2.1.4. Glycerol stocks 
Transformed E. coli stocks were prepared by adding glycerol 1:1 (v/v) to the E. coli culture 
at OD600 0.6 -1.2. Glycerol stocks were stored at -80°C. 
 
2.2.8.3. Transfection of parasites 
T. brucei strain 2T1 was used for transfection (Burkard et al., 2007). Briefly, 4 x 10
7
 cells 
from a mid-log culture were resuspended in 100 µl transfection buffer (90 mM sodium 
phosphate, 5 mM potassium chloride, 0.15 mM calcium chloride and 50 mM HEPES, pH 
7.3 (Schumann Burkard et al., 2011)) and 10 µg linearised DNA (in sterile dH2O) were 
added. Cells were electroporated in 2 mm gap cuvettes (Biorad) using the Amaxa 
Nucleofector II (Lonza, Germany) and the program X-001. Cells were diluted 1:20 or 1:40 
in HMI-9, and seeded in 24-well plates. Appropriate antibiotics were added 12 hours post-
transfection. To obtain stable clones a serial dilution on a 96-well plate was performed and 
clones selected and tested for the correct selection markers (Alsford and Horn, 2008). 
 
2.3. Protein methods 
2.3.1. Overexpression 
For protein overexpression different strains of E.coli (all derived from BL21 (DE3)) were 
used. In general E.coli BL21 (DE3) and Rosetta (DE3) pLysS were used for most proteins. 
However, if protein overexpression failed, E. coli C41 (DE3) pLysS or C43 (DE3) cells 
were used, due to their reported ability to overexpress toxic or membrane bound proteins 
(Dumon-Seignovert et al., 2004). The Rosetta (DE3) pLysS, C41 (DE3) pLysS and C43 
(DE3) were kindly provided by Nathaniel Jones, from the University of Glasgow.  Cells 
were grown in LB medium at 37°C, unless stated otherwise. 
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Large scale overexpression was performed by inoculating 1 litre of LB (plus appropriate 
antibiotic) with an overnight culture, at 37°C in an orbital shaker, until an OD600 between 
0.6 and 1.2 was reached. To induce overexpression, IPTG was added to a final 
concentration of 1 mM and cultures were incubated overnight at 18°C. Cells were 
harvested by centrifugation and the pellet was stored at -20°C if not used immediately. For 
small scale overexpression 70 ml of LB (plus appropriate antibiotic) were used and treated 
as above. 
 
2.3.2. Protein purification 
For small scale purifications, Ni-NTA Spin Columns (Qiagen GmbH, Hilden, Germany) 
were used, and manufacturer's instructions were followed. Large scale purifications were 
performed with immobilised metal affinity chromatography (IMAC) using a Poros MC20 
column, stripped with 50 mM EDTA and 1 M NaCl (pH 8.0) and recharged with 0.1 M 
nickel sulfate prior to every run. Cells were lysed using a bacterial protein extraction 
solvent (B-Per, Thermo Scientific) and purified under native conditions with SB buffer (20 
mM phosphate buffer plus 500 mM NaCl, pH 7.5) and increasing concentrations of 
imidazole (50 mM for the washing step to remove non-specific binding and 500 mM to 
elute the his-tagged protein of interest). 
 
2.3.3. SDS-PAGE 
Samples for SDS-PAGE were boiled in SDS buffer (50 mM Tris-HCl, pH 6.8; 2% SDS; 
10% glycerol; 1% β-mercaptoethanol; 12.5 mM EDTA and 0.02% bromophenol blue) for 
10 min at 95°C. Up to 20 µl protein solution was separated on NuPAGE 4-12% Bis-Tris 
Gel (Novex) in 1x NuPAGE MES SDS running buffer (Novex) at 125V. 
 
2.3.4. Western blotting 
Samples were run on SDS-PAGE (section 2.3.3) and transferred to a nitrocellulose 
membrane (Hybond-ECL) at 100 mA, for 1-2 h, at 4°C. Membranes were blocked using 
phosphate buffered saline/0.1% tween (PBStween) plus 5% milk powder for 1 h at room 
temperature, and probed with primary antibody RAD51 (1:1,000) for 1 h. Membranes were 
washed with PBS/tween (0.1%) three times for 10 min, incubated with secondary antibody 
anti-Rabbit (1:5,000) for 1 h, and washed as described. 1 ml of Piece ECL Western blotting 
substrate (Thermo Scientific) was added and left for 5 min before the blot was analysed.  
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2.3.5. Bradford assay 
Protein concentrations were determined by Bradford assay using the Bio-Rad protein assay 
(Bio-Rad Laboratories). 50 µl of sample were mixed with 1 ml of Bradford reagent (in 1:5 
dilution with dH2O) in a 1 ml disposable cuvette. A standard curve was prepared with 
bovine serum albumin (BSA, Sigma-Aldrich), where 50 µl of BSA standards were also 
mixed with 1 ml Bradford reagent, with concentrations from 0.5 mg/ml – 0.1 mg/ml, and 
dH2O as blank. The solutions were incubated for 5 min at room temperature to allow for 
the colour of the dye, responding to the concentration of the protein, to change. The 
absorbance (OD595) was then determined using an Eppendorf spectrophotometer 
(Eppendorf, Germany). Experimental OD595 were plotted against concentrations of 
standards using an Excel spreadsheet template kindly provided by Alan Scott (Glasgow 
Polyomics). 
 
2.3.6. Sample preparation for proteomics 
The secretome was prepared using the method described by Holzmuller et al. (2008) and 
Grébaut et al. (2009). Trypanosomes were incubated at 2x10
8
 parasites/ml for 2 hours at 
37°C in serum free modified HMI-9 (Voorheis, Table A1). The supernatant was separated 
from trypanosomes by centrifugation (1,000g, 10 min, 4°C) and filtered using a 0.22 µm 
low-binding protein filter. A mixture of protease inhibitors (Protease inhibitors complete 
Mini (Roche)) were added to the samples prior to storage at -80°C. Protein concentrations 
were measured using the Bradford assay and proteins were precipitated to concentrate the 
protein solutions for DiGE analysis, but also to remove protease inhibitors added to the 
sample sets after secretome preparation. 
 
2.3.7. Protein precipitation 
Protein precipitations for secretome sample analysis were performed by mixing the cell-
free spent media with 100% acetone (1:4 v/v) and incubating overnight at -20°C, followed 
by 2 washes with 80% acetone at 4°C and 13,000 rpm for 10 min. Pellet was resuspended 
in DiGE lysis buffer (Appendix C) and stored at -80°C.  
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2.3.8. DiGE 
Protein samples for DiGE analysis were labelled with cyanine dyes at an alkaline pH. T. b. 
brucei strain 427 was labelled with Cy5 and strain GVR 35 with Cy3. 50 μg of protein 
sample in 83.3 µl (GVR35) or 71.4 µl (427) DiGE lysis buffer were mixed with 400 pmol 
CyDye and incubated in the dark for 30 min on ice. The labelling reaction was quenched 
by adding 1 μl of 10 mM lysine and by incubating it for an additional 10 min. Samples 
were mixed, adjusted to 460 µl with DiGE rehydration buffer (Appendix C), applied to an 
immobilised pH gradient iso-electric focusing strip, IEF, (pH 4.0-7.0, linear range, 24cm) 
and run overnight according to protocol #9 (see Table 2.4). 
 
Step 1 30V       step ‘n’ hold    10h 
2 300V     step ‘n’ hold     2h 
3 600V           gradient      2h 
4 1000V         gradient      2h 
5 8000V         gradient      2h 
6 8000V     step ‘n’ hold   9h 
7 1000V     step ‘n’ hold 
Table 2.4: Protocol #9 for IEF 
 
Following IEF, Strips were dipped into 0.1% SDS solution and incubated in 10 ml strip 
equilibration buffer (SEB) + DTT (10 mg/ml) for 15 mins, and for a further 15 mins in 10 
ml SEB + iodoacetamide (25 mg/ml). The equilibrated IEF strips were placed on top of a 
12% SDS-polyacrylamide gel and sealed with 0.5% agarose NA in 1x running buffer 
(Table S5) containing a trace of bromophenol blue to act as a dye front. Gels were run at 
1W per gel overnight in an Ettan DALT II system for 2-D gel electrophoresis (Amersham 
Bioscience). This was done with the help of Alan Scott (Glasgow Polyomics). 
 
2.3.9. Gel imaging and image analysis 
The 2-D DiGE gel was scanned using a Typhoon 9400, following manufacturer’s 
instructions. Wavelength was set to 532 nm (Cy3) and 633 nm (Cy5) for two sequential 
scans and the scanner was set to high resolution scan (100 µm pixel). 
Spot detection was performed using DeCycler 2D software, set for 1,000 spots recognition. 
Protein spots with a minimum of 2-fold difference between strain GVR 35 and strain 427 
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were picked for analysis. The preparatory gels were stained with Colloidal Coomassie, and 
images were matched with DiGE image. Protein spots of interest were manually excised 
from the preparatory gel in a laminar flow hood. Gel pieces were washed, first with 250 µl 
100 mM ammonium bicarbonate (ABC) (twice for 30 min), followed by washes with 200 
µl 50% acetonitrile (ACN) / 100 mM ABC for 45 min (wash was repeated until gel pieces 
were destained). 50 µl of ACN was added to gel pieces and left for 10 min before samples 
were dried in speed vac. Dried gel pieces were re-hydrated with 10 µl trypsin (0.02µg/µl in 
25 mM ABC) and 20 µl 25 mM ABC was used to cover the gel pieces for overnight 
incubation. Digested proteins were dried and analysed by LC-MS/MS. Separation was 
achieved using an UltiMate 3000 Rapid Separation LC system (Dionex, Thermo Scientific) 
coupled to electrospray ionization tandem mass spectrometry (AmaZon ETD ion trap mass 
spectrometer; Bruker Daltonics). Raw MS/MS data were submitted to Mascot server and 
searched against Trypanosoma brucei database TriTrypDB (version 5.0).  
 
2.3.10. Filter aided sample preparation for trypsin digest (FASP) 
To analyse the whole secretome from T. b. brucei strain GVR 35 and strain 427, samples 
were prepared with FASP (Filter Aided Sample Preparation method) using an Ultracel 
YM-10 filter (Millipore). 
 
20 µl of strain 427 sample (14 µg protein) and 25 µl of strain GVR 35 (15 µg protein) were 
used for trypsin digest. Sample volume was made up to 30 µl by adding SDT buffer (4% 
SDS, 100 mM Tris-HCl pH 7.6 and 0.1 M DTT). Samples were mixed with 200 µl of UA 
solution (8 M urea in 0.1 M Tris-HCl buffer pH 8.5), loaded into the filtration device and 
centrifuged for 40 min at 13,000 rpm. An additional 200 µl UA solution was added to the 
filter and centrifugation repeated. 100 µl of 50 mM iodoacetamide in UA solution was 
added to the filter and incubated at room temperature for 5 min, before being centrifuged 
for 30 min at 13,000 rpm. 120 µl of a solution of ammonium bicarbonate containing 0.02 
µg/ml of trypsin were added to the filter and samples were incubated overnight at room 
temperature. Following digestion, peptides were collected by centrifugation of the filter 
unit for 40 min at 13,000 rpm. Samples were acidified using trifluoroacetic acid (FA), 
desalted and dried down for analysis in Concentrator 5301 by LC-MS/MS (UltiMate 300 
Rapid Separation LC System coupled to AmaZon ETD ion trap mass spectrometer). Raw 
MS/MS data were submitted to Mascot server and searched against T. brucei database 
TriTrypDB (version 5.0).  
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2.3.11. Dimethyl-labelling for proteomics 
Protein samples were treated as previously stated (2.3.10) and resulting peptides were 
resuspended in 100 mM triethyl ammonium bicarbonate (TEAB, Sigma-Aldrich). The 
GVR 35 strain sample was light-labelled with 4% formaldehyde (Sigma-Aldrich) and 600 
mM sodium cyanoborohydride (Sigma-Aldrich), whereas strain 427 sample was heavy-
labelled with 4% deuterated formaldehyde (Cambridge Isotope) and 600 mM sodium 
cyanoborohydride (Sigma-Aldrich). Samples were incubated for 1 h at room temperature 
after which the reaction was stopped using 1% ammonium hydroxide (Sigma-Aldrich). 
Labelled samples were acidified with 5% FA, dried in Concentrator 5301 and analysed by 
LC-MS/MS (2.3.10). The raw data was analysed with Mascot Distiller (Version 2.5.1.0). 
The Mascot search engine set against T. brucei protein database from TritrypDB. The 
settings were: Fixed modification was set to Carbamidomethyl (C), while Oxidation (M) 
was set as a variable modification. For protein identification, peptide and fragment mass 
tolerances were set to ± 0.3 Da allowing for two missed cleavages. 
 
2.4. Metabolite profiling 
2.4.1. In vitro investigation of unknown enzymes sample setup 
Commercial yeast extract powder (Foremedium Ltd., Hunstanton, England, UK) was used 
as metabolite source. 1-2 mg of yeast extract per sample was used, and metabolites were 
extracted using Chloroform/Methanol/Water (ratio1:3:1 v/v/v) containing 1 µM internal 
standards (theophylline, 5-fluorouridine, Cl-phenyl cAMP, N-methyl glutamine, 
canavanine and piperazine). Samples were dried using a speed-vac and dried extracted 
metabolites were resuspended in 100 µl 10 mM MOPS buffer plus 5 mM MgCl2 and 
pooled to provide an even metabolite source for control / treatment. Enzyme cofactors 
obtained from Sigma are listed in Table 2.5. The final concentration for each cofactor was 
0.1 mM. Two sets of cofactor mixes were prepared fresh as supplements to the metabolite 
mix. 
 
Cofactor 1 NAD+ NADP+ ADP GDP CoA FMN FAD+ PP TPP 
Cofactor 2 NADH NADPH ATP GTP Acetyl CoA FMN FAD+ PP TPP 
Table 2.5: The two sets of cofactors mixtures used for in vitro assay for enzyme function identification 
at a working concentration of 1 mM (see S1 for abbreviations). 
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Reactions were performed in 10 mM MOPS buffer plus 5 mM MgCl2 and included the 
metabolite mix, cofactors for the control sample and additionally purified enzyme in the 
treatment sample. The mix was incubated at 37°C for 30 min and the reaction was 
quenched with 400 µl acetonitrile. A blank sample (10 mM MOPS buffer plus 5 mM 
MgCl2) was similarly processed in parallel each time. Each sample included: the 
metabolite mix, the cofactor 1 (or 2) mix and the enzyme. Samples without the enzyme and 
blank samples were also prepared (Table 2.6). 
 
Table 2.6: Sample preparation for in vitro investigation.  
 
2.4.2. Intracellular metabolite extraction from parasites 
Trypanosomes were grown to mid-log phase and a sample volume equivalent to 5 x 10
7
 
cells was rapidly cooled to 4°C by submerging the 50 ml falcon tube into a dry ice/ethanol 
bath. Samples were kept on ice (or 4°C) from this step onwards. Samples were centrifuged 
at 1,250g for 10 min, and most supernatant, except 1 ml, was removed. The pellet was 
resuspended in the remaining 1 ml of medium. This was transferred to an Eppendorf tube 
and briefly centrifuged to completely remove the supernatant. The cell pellet was washed 
in cold 1xPBS and metabolites extracted by resuspending in 100 µl 
chloroform:methanol:water (ratio1:3:1 v/v/v) with internal standards (2.4.1) and by 
vigorously shaking for 1 h at 4°C.  Samples were centrifuged at 16,000g for 10 min and the 
supernatant collected and stored at -80°C under argon. 
 
2.4.3. 
13
C – labelled tracking 
T. b. brucei strain 427 was grown in CMM + 10% FBS Gold (PAA, Piscataway, NJ) for U- 
13
C-labelled tracking. For L-methionine studies, 50% of U-
13
C L-methionine (50 µM L-
methionine and 50 µM U-
13
C L-methionine) was added to the parasite culture medium 
(starting density of 2 x 10
4
 cells ml
-1
). For L-proline and L-arginine, 100% labelled 
Metabolite mix Cofactor mix 1 Cofactor mix 2 Enzyme ACN Enzyme
Sample 1 -E 86 µl 10 µl 4 µl 400 µl
Sample 1 - C 86 µl 10 µl 400 µl 4 µl
Sample 2 -E 86 µl 10 µl 4 µl 400 µl
Sample 2 - C 86 µl 10 µl 400 µl 4 µl
Blank - Mops 400 µl
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compound was used at a concentration of 200 µM. Cells were incubated at 37°C for 48 h, 
and metabolites extracted as previously described (2.4.2). Samples were prepared in 
triplicate and for every labelled setup a control with the equal concentration of unlabelled 
compound was set up, also in triplicate. Fresh medium and spent medium controls were 
also collected and 5 µl were added to 100 µl extraction solvent (CMW 1:3:1) prior to 
analysis. 
Labelled compounds were obtained from Cambridge Isotope Laboratory, Inc.: 
L-methionine, 
13
C5, enrichment 99%, cat: CLM-893-H-0.1 
L-proline, 
13
C5, enrichment 99%, cat: CLM-2260-H 
L-arginine, 
13
C6, enrichment 99%, cat: CLM-2265-H-0.1 
 
2.4.4. Standards 
Internal standards were added to the extraction solvent as previously described (2.4.1): 
during the analysis the stability of the samples can be tracked by comparing the total ion 
current (TIC) profile of samples and internal standard. With each experiment a set of 
authentic standards was run prior to the sample set (Appendix D, Table D1). The authentic 
standards are used for metabolite identification and retention time prediction in IDEOM as 
described by Creek et al. (2011).  
 
2.4.5. Liquid chromatography-mass spectrometry 
The sample platform chosen for this project was liquid chromatography coupled with mass 
spectrometry. All samples were separated with high performance liquid chromatography 
(HPLC) on either ZIC-HILIC (Hydrophilic Interaction Liquid Chromatography column, 
Merck) or ZIC-pHILIC (polymer based - Hydrophilic Interaction Liquid Chromatography 
column, Merck) prior to mass detection on an Exactive Orbitrap mass spectrometer 
(Thermo Fisher). Analysis was performed in positive and negative mode, using 10 µl 
injection volume and a flow rate of 100 µl/min. For HPLC gradient, ZIC-HILIC solvent A 
was 0.1% formic acid in water and solvent B was 0.08% formic acid in acetonitrile.  ZIC-
pHILIC solvent A was 20 mM ammonium carbonate in H2O, and solvent B was 100% 
acetonitrile. 
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2.4.6. Data analysis 
The analysis was performed using IDEOM software (Creek et al., 2012b). IDEOM uses the 
software MZmatch (Scheltema et al., 2011) and the statistical platform R to analyse the 
raw data. First, the raw data is converted to mzXML files using the software msconvert. 
The program XCMS can use the mzXML files to identify peaks and convert the data into 
peakML files. MZmatch uses peakML files to group peaks across replicate samples, filter 
peaks by removing groups with high variability in peak intensity, and annotate related 
peaks. Those MZmatch files will be used by IDEOM to run an automated identification 
procedure based on exact mass and retention time. Furthermore, IDEOM assigns 
confidence levels to the identifications, relying on authentic standards run within each 
experiment. 
 
mzXML files can also be used for analysis of metabolite tracking with uniformly 
13
C-
labelled compounds. The open source software mzMatchISO (Chokkathukalam et al., 
2013) works within MZmatch.R. The labelled compounds have the same retention time as 
their unlabelled counterparts, but differ in the mass of the heavy/light carbons when 
labelling occurs. To assign the detected mass shift, it requires a tab-delimited text input file 
containing the compounds of interest to be matched against the dataset, to search for the 
labelled compounds and their labelling pattern. The output file is in pdf format, showing 
the detected labelling pattern and peak shapes. 
 
2.5. Enzyme assays 
2.5.1. Hexokinase 
Hexokinase (Sigma) activity was assayed in a coupled reaction with glucose-6-phosphate 
dehydrogenase (Figure 2.1). The reaction mix included 50 mM Tris-HCl, pH 8.0, 13.3 mM 
magnesium chloride, 670 mM glucose, 16.5 mM ATP, 6.8 mM NADP
+
 and 1 IU glucose-
6-phosphate dehydrogenase. The reaction mix was run at 25°C for 6 min on a UV-VIS 
spectrophotometer (UV-2550, Shimadzu) before hexokinase was added and changes in 
absorbance (A340) measured over time.  
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Figure 2.1: Coupled enzyme assay for hexokinase. The phosphorylation of D-glucose was measured by 
production of NADPH at 340 nm. 
 
2.5.2. Glucose dehydrogenase 
Glucose dehydrogenase (Figure 2.2) was ordered from Sigma and made up to 1 U/mg with 
10 mM Tris-HCl buffer (pH 7.2). Activity was tested using a UV-VIS spectrophotometer 
(UV-2550, Shimadzu) the reaction mix included: 100 mM Tris-HCl buffer, 1 M glucose 
and 20 mM NAD
+
.  
Reaction mix was run on the spectrophotometer at 25°C for 5 min before glucose 
dehydrogenase was added. Changes in absorbance (A340) were measured over time. 
 
Figure 2.2: Reaction catalysed by glucose dehydrogenase. The formation of NADH was measured at 340 
nm. 
 
2.5.3. NAD
+
 synthase 
NAD
+
 synthase activity was assayed in a coupled reaction assay (Figure 2.3). In the first 
reaction NAD
+
 was synthesised by either (1) reaction mix containing  2 mM ATP, 5 mM 
magnesium chloride, 50 mM Tris-HCl, 56 mM potassium chloride, 1 mM deamido-NAD
+
, 
20 mM L-glutamine and 0.2 mg/ml BSA, pH 8.0 (Wojcik et al., 2006), or (2) reaction mix 
including 2 mM ATP, 2 mM ammonium chloride, 20 mM magnesium chloride, 2 mM 
potassium chloride, 1 mM deamido-NAD
+
 and 0.2 mg/ml BSA (Ozment et al., 1999).  
In both cases the reaction volume was 100 µl. 
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Reaction mix was incubated for 1 h at 37°C with recombinant protein and the reaction 
stopped by boiling the mix for 3 min and immediately cooling it down on ice. Reactions 
were spun down for 10 min at 12,000 rpm (4°C) and 90 µl were used for further analyses.  
 
To determine if the putative NAD
+
 synthase had produced NAD
+
, 90 µl of reaction mix 
obtained from the first assay were used instead of NAD
+
 in a glucose dehydrogenase assay 
(2.5.2). 
 
Figure 2.3: Coupled enzyme assays for NAD
+
 synthase. (1) Glutamine dependend NAD
+
 synthase assay 
(Wojcik et al., 2006) and (2) Ammonia dependent NAD
+
 synthase assay (Ozment et al., 1999).    In both 
assays the formation of NADH from NAD
+
 was measured at 340nm. 
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Chapter 3 
 
3.1. Introduction 
In this chapter the use of metabolomics for enzyme function identification will be explored 
and discussed. Although bioinformatics studies can help to identify the function of a 
protein, using tools such as BLAST alignments and domain searches, having experimental 
proof is required and important when studying the metabolism of any organism.   
 
Enzymes used for this study were chosen randomly from a list of putative enzyme that was 
obtained from the trypanosome database TritrypDB. The only objective for the chosen 
‘enzymes’ was that they should have a predicted metabolic function, relatively small size, 
so the cloning and over-expression would not cause too many difficulties, and that their 
function had not been determined before using recombinant or purified protein. The goal 
was to set up a workflow that would allow a high throughput approach to screen putative 
trypanosome proteins for enzymatic reactions. Certain compromises had to be made to 
make this approach fast with relatively low costs. The choice for a good over expression 
system was one of the compromises. E. coli is a well established organism to over express 
proteins; however, the lack of post translational modifications could cause problems for the 
functionality of the enzymes. Other over expression systems, for example trypanosomatid 
expression systems (Tetaud et al., 2002), would therefore be more suitable. However, high 
cost of culture media and lower levels of over expression was seen as too big a 
disadvantage compared to E. coli. Several E. coli strains were tested in this study. 
Originally, BL21 (DE3) were used (E. Kerkhoven, thesis), but Rosetta (DE3) cells showed 
higher yield and allowed for a higher number of expressed proteins and from 21 proteins 
originally selected for the screen, seven could be analysed. 
 
The metabolite basis of this assay was a commercially available yeast extract. 
Trypanosome extract would have been preferred, but as with the expression system, the 
cost of media and the low density of cells in culture (compared to yeast or E. coli) made 
other metabolite sources better suited.  E. coli extract, marmite and several stock cubes 
were also tested for their use, but the commercial yeast extract seemed the better choice for 
this screening method. 
(1) Yeast extract was commercially obtained at a high quantity, meaning the standard 
condition was highly controlled for all experiments.  
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(2) Yeast extract was treated to remove all proteins; therefore it was certain that the only 
protein added to that mix was the intended purified enzyme. 
(3) Yeast extract provided a high number of detected metabolites on both ZIC-HILIC and 
ZIC-pHILIC while being fast and easily prepared (compared to E. coli extract). 
 
3.1.1. In vitro assay combined with metabolite profiling 
Using the screening method developed by Saito et al. (2006), seven (out of 21) putative 
identified enzymes from T.b.brucei (see Table 3.1) were tested for their function using 
metabolite profiling by Liquid Chromatography – Mass Spectrometry (LC-MS).  The 
enzymatic activity is determined by monitoring the changes in metabolite levels between 
control (no enzyme) and treatment (incubated with enzyme) samples.  
 
Yeast extract was used as the metabolite source and to ensure that possible essential 
cofactors needed for enzymatic reactions were present, mixes of most common cofactors 
(as listed in method 2.4.1) were added to every reaction mix. As described, two cofactor 
mixes were prepared and samples were set up in two batches each containing a different 
cofactor mix. 
 
Table 3.1: Identification of putative identified enzymes used in high throughput approach 
 
Ideally, decreasing level of a specific metabolite indicates the substrate of an enzymatic 
reaction, while an increasing level indicates the product of that reaction. However, due to 
the ability of mass spectrometry to simultaneously identify a large number of metabolites 
(the LC-MS approach of this study routinely detects around one thousand metabolites per 
experiment), changes in several, unrelated, metabolites will be detected. This is due to 
sample variation between either a set of controls or even between conditions. To keep 
those changes to a minimum, samples were run in triplicate. 
Gene ID Gene name Plasmid ID
Tb927.10.2750 Deoxhypusine synthase, putative pMB-G158
Tb927.7.5680 Deoxyribose-phosphate aldolase, putative pMB-G159
Tb11.01.6500 NAD synthase, putative pMB-G162
Tb427.06.4920 S-adenosylmethionine synthetase, putative (METK1) pMB-G191
Tb427.10.13430 citrate synthase, putative pMB-G194
Tb427tmp.02.3040 aldo/keto reductase, putative pMB-G196
Tb427.05.3820 aspartate carbamoyltransferase, putative pMB-G197
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To validate the enzyme assay two commercially available enzymes were tested using this 
approach.  The enzymes chosen were glucose dehydrogenase and hexokinase (both 
Sigma).  
 
3.1.2. RNA interference 
To further assess potential function of the proteins, when the in vitro assay approached 
failed, and to establish if the protein is essential to bloodstream form trypanosomes, RNA 
interference (RNAi) lines were created. T. brucei strain 2T1 were transfected with plasmid 
pGL2084 (Jones et al., 2014) containing a fraction of the gene of interest in a stem loop 
construct (Alsford and Horn, 2008) and RNAi was induced with either 1 µg ml
-1
 or 5 µg 
ml
-1
 tetracycline. To determine whether protein was essential or not, growth curves were 
made by counting uninduced and induced cells every 24 h. To establish a possible function 
of the protein, metabolite profiling on extracted metabolites from induced cultures were 
compared to the metabolite set of uninduced cultures. 
 
RNAi lines were created for four putative identified enzymes: deoxyribose-phosphate 
aldolase, NAD
+
 synthase, also alpha/keto reductase and aspartate carbamoyltransferase. 
With the exception of NAD
+
 synthase, which did not obtain puromycin sensitivity and was 
therefore not further analysed, all cell lines showed the correct selection markers and 
knock down effect was assessed using reverse transcription RT-PCR.  
 
Using metabolite profiling on RNAi lines, ideally, a decreasing metabolite (comparing 
induced cell line to uninduced cell line) should indicate the product of an enzymatic 
reaction, while an increasing metabolite should indicate the substrate of that reaction. 
However, as the whole cell metabolome is analysed, blocking one enzyme in the system 
could have a knock on effect on other reactions, therefore making it difficult to see the 
primary reaction. 
  
47 
 
3.2. Results 
3.2.1. Validation of in vitro method 
3.2.1.1. In vitro investigation of glucose dehydrogenase by metabolite profiling  
 
Glucose dehydrogenase is an enzyme belonging to the family of oxidoreductases and acts 
on the CH-OH group of the donor molecule. It catalyses the following reaction: 
Glucose + acceptor        D-Glucono-1,5- lactone + reduced acceptor 
The acceptor can be FAD, NAD(P) or pyrroloquinoline quinine (PQQ) and depending on 
the cofactor use the enzyme is categorized into EC group 1.1.1, 1.1.99 or 1.1.5 respectively 
(Ferri et al., 2011). Glucose dehydrogenase used here was obtained from Sigma and was 
isolated from Pseudomonas sp. with the EC 1.1.1.47, suggesting NAD
+
 and NADP
+
 the 
cofactors used by this enzyme according to BRENDA.  
 
Data analysed using IDEOM showed five metabolites significantly increased (Figure 2.1, 
a) in both samplesets. This would suggest either that NAD(P)
+
 was either already present 
in the yeast extract or the use of a different cofactor present in both sampleset (for example 
FAD). From the putatatively identified metabolites, only D-glucono-1,5-lactone was a 
basepeak. The related peak function from mzMatch assigned the putatatively identified 
metabolites 2,5-Dioxopentanoate, Vicianose and 2-O-alpha-L-Rhamnopyranosyl-D-
glucopyranose to the D-glucono-1,5-lactone basepeak. The very similar retention times and 
of all four metabolites makes it likely that the changes are related or even that the peaks 
resemble the same metabolite, with differences in mass caused by fragmentation or 
complex formation. 2,5-Dioxopentanoate seems to be a fragment of D-glucono-1,5-lactone 
as the peak intensity pattern of every individual replicate is identical. Furthermore, the two 
metabolites 2-Dehydro-3-deoxy-D-gluconate and citraconate show the same pattern. 
Interestingly, 2-Dehydro-3-deoxy-D-gluconate has the same mass as D-glucono-1,5-
lactone, as have citraconate and 2,5-Dioxopentanoate. However, the retention times are 
different. A possible explanation for this is that D-glucono-1,5-lactone comes of the 
column at two different times, as sometimes seen with D-glucose. However, as D-glucono-
1,5-lactone is not in the authentic standard list, there is no proof for this. Only one 
metabolite was decreased significantly in this dataset. It was putatatively identified as 2-C-
Methyl-D-erythritol 4-phosphate. However, closer investigation revealed that this is most 
likely an adduct of D-glucose, as the retention time of 14.65 min matches the authentic 
standard. 
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As this assay was performed with a known enzyme, the decrease in glucose levels (Figure 
3.1, b) and the increase of D-glucono-1,5-lactone (Figure 3.1., c) can be seen as 
confirmation for the validation of this assay. However, it also highlights the problematic of 
using complex datasets, such as metabolomics, to identify enzyme functions.  
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Figure 3.1: Significant changes in the metabolomics dataset of glucose dehydrogenase assay. Assay was 
set up as described in 2.4.1. and analysed with IDEOM.  (a) Screenshot of IDEOM spreadsheet showing the 
most significantly increased metabolites in the dataset (highlighted in red) compared to a no enzyme control. 
(b) peak intensity of the substrate and (c) peak intensity of the product of glucose dehydrogenase. 
Abbreviations: Cf1_C: Cofactor 1, Control (no enzyme); Cf1_E: Cofactor 1, Treatment (with enzyme); 
Cf2_C: Cofactor 2, Control and Cf2_E: Cofactor 2, Treatment. 
 
3.2.1.2. In vitro investigation of hexokinase by metabolite profiling  
 
Hexokinase is the starting enzyme of the glycolysis and catalyses the following reaction: 
Glucose + ATP        Glucose 6-phosphate + ADP 
Previous datasets on commercial enzymes (data not shown) showed many changes, 
specifically many metabolites decreasing in the treatment samples (most of them peptides), 
making an analysis difficult. The enzymes used for those assays had been already in use in 
our lab for a while, so enzymes were ordered fresh and assays were repeated. However, 
due to the changes mentioned above observed only in enzyme treated samplesets, a second 
extraction step was added to the workflow to test if those changes might disappear. For the 
hexokinase assay results shown here, four replicates for each condition were prepared and 
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two of the replicates were vortexted in the cold room (4°C) for 30 min after the enzymatic 
reaction was quenched with acetonitrile (ACN). Data analysis comparing those two 
conditions showed overall fewer ‘missing’ metabolites in both conditions. However, peak 
intensities were increased in samples with the added extraction step.  
 
Unlike the results of glucose dehydrogenase, as shown above, this dataset did not show the 
distinction in changes between the product and the substrate, which could be attributed to 
the high levels glucose in the sample mix and the fact that ATP was not detected. As ATP 
was added to the sample set 2, the explanation for no peak being detected in IDEOM might 
be that due to low intensity that peak was filtered out by IDEOM. However the product of 
the reaction, glucose 6-phosphate is only detected in enzyme treated cofactor mix 2 (Figure 
3.2 (b) and (d)). Also important, the enzyme treated cofactor 2 sample shows high levels of 
ADP, which is not present in cofactor 2 control sample (Figure 3.2 (a) and (c)). These 
results conclude that the added enzyme is indeed a hexokinase, as both products can be 
detected in the dataset.  
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Figure 3.2: Significant changes in the metabolomics dataset of hexokinase assay. Assay was set up as 
described in 2.4.1. and analysed with IDEOM. Most significant changes in the hexokinase dataset were ADP 
and glucose-6-phosphate (G6P) increased in the sample set 2. Sample set 2 had ATP added, which is required 
for hexokinase activity. Metabolite levels shown on the right (ADP or G6P) are the peak intensities from the 
control sample without ATP. (a) and (b) shows peak intensities of compounds without second extraction step, 
while (c) and (d) were incubated for 30 min at 4°C after enzymatic reaction was quenched.   
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3.2.2. Cofactor stability 
 
As cofactors were not consistently detected using IDEOM for data analysis and cofactors 
present in the authentic standard mixes reliably failed to be detected, a study was done to 
investigate the stability of the cofactor stock solutions (stored at -20°C). The two cofactor 
mixes were made fresh and an aliquot was taken for metabolite extraction and immediate 
analysis by LC-MS. The remaining samples were stored at -20°C and reanalysed every 
week for 4 weeks. 
 (a) (b) 
Figure 3.3: Decreasing levels of detected cofactors from cofactor mix 1 (a) and 2 (b) over a time course 
of four weeks. Samples were tested fresh at Day 1 and re-tested after 8,15,23 and 29 days. Analysis was 
performed by normalising the identified metabolite against an internal standard (N-methyl glutamine) using 
IDEOM. 
 
Figure 3.3 shows the detected levels of the cofactors decreasing dramatically from day 1 to 
day 8. If the cofactor mixtures degrade at -20°C or if the freeze/thaw cycles have an impact 
on the compounds being detected is not clear. However, this clearly indicates that cofactor 
mixes must be freshly prepared for the use in the in vitro enzyme assay. The stability test 
shows that the cofactors used can be detected (except for PP and TPP) on the LC-MS 
platform using ZIC-pHILIC columns. However, why are they not as easily detected in the 
IDEOM spreadsheets for the in vitro assays?  
 
One possible explanation is that the cofactor mixes used only contain 1mM of each 
cofactor, while the cofactor stability used the stock solution of 10mM. At the end of each 
enzyme assay incubation the sample was further diluted which would make the cofactor 
concentration in the analysed sample even lower. Figure 3.4 shows the differences in peak 
intensities of ATP, when run at 10mM and 1mM. It also seems plausible that in complex 
mixtures IDEOM filters the cofactor peaks out as they might appear under the threshold 
limit.  
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Figure 3.4: Peak intensities of ATP, 10mM and 1mM at day 1 of the time course. 
 
The cofactors, as listed in Methods section (or Table 3.2), are present in the standard mixes 
that are analysed with every MS run. However, in complex mixtures they are only rarely 
detected and it would be beneficial to have an idea of the retention time and also how 
reliable the detection of these compounds is. Table 3.2 shows the mass and retention time 
detected for each cofactor over a time course of four weeks. As this experiment was 
targeted (only one cofactor per sample) and as mentioned above cofactors in the standards 
are only rarely detected the confidence of the peak identification was judged by detected 
mass, retention time similar to the expected one and peak intensities. ATP and ADP were 
consistently detected over 4 weeks, but also traces of ADP and AMP were detected in the 
ATP sample, and ATP and AMP in the ADP sample. Although these findings are not 
necessarily surprising it is important to keep in mind when using different cofactor mixes 
for enzyme assays.  GDP, GTP, NAD and NADH were consistently detected, except for 
the last time point where GTP and NAD were not. NADP could not be detected in an early 
time point in the IDEOM spreadsheet (Day 7), which was surprising as the following time 
points showed clear levels of NADP in the sample. Coenzyme A, acetyl-coenzyme A, 
FAD and FMN were consistent in mass and retention time. Only PP and TPP were 
inconsistently detected and those compounds might be not suitable for pHILIC separation. 
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Table 3.2: Detected mass and retention time from each cofactor during a timecourse of four weeks. 
Timepoint 1: Day 1 (when cofactor stocks were prepared), Timepoint 2: Day 8, Timepoint 3: Day 15, 
Timepoint 4: Day 23, Timepoint 5: Day 29. 
 
 
Table 3.3: Monoisotopic molecular weight of the cofactors used in this study, taken from metacyc.org 
  
1 2 3 4 5
Mass RT Mass RT Mass RT Mass RT Mass RT
ATP 506.995 18.949 506.995 18.933 506.995 18.792 506.995 18.971 506.995 19.268
ADP 427.03 17.388 427.03 17.394 427.03 17.34 427.03 17.787 427.03 18.065
GTP 522.99 21.843 522.99 21.851 522.99 21.669 522.99 21.949
GDP 443.024 20.205 443.024 20.269 443.024 20.188 443.024 20.531 443.024 20.78
NAD 663.109 16.076 663.109 16.108 663.109 15.92 663.109 15.98
NADH 665.125 15.316 665.125 15.263 665.125 15.169 665.125 15.24 665.125 15.43
NADP 743.075 18.772 743.075 18.673 743.075 18.748 743.075 18.914
NADPH 745.091 19.079 372.545 19.093 372.546 18.922 372.545 18.954 745.091 19.195
CoA 767.115 15.544 383.558 15.595 767.115 15.357 767.115 15.482 767.115 15.778
Acetyl-CoA 809.126 14.226 809.126 14.233 809.126 14.014 809.126 14.09 809.126 14.275
FAD 785.157 13.159 785.157 13.217 785.157 12.975 785.157 12.978 785.157 13.109
FMN 456.105 13.128 456.105 13.167 456.105 12.941 456.105 12.962 456.105 13.121
PP 247.025 21.124 247.025 21.288
TPP 424.037 17.102 424.037 17.449
Monoisotopic molecular weight
Acetyl-CoA 809.126
ADP 427.029
ATP 506.996
CoA 767.115
FAD 785.157
FMN 456.105
GDP 443.024
GTP 522.991
NAD  664.117
NADH  665.125
NADP 744.083
NADPH 745.091
PP 247.025
TPP 425.045
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3.2.3. Results putative enzymes 
 
From 21 genes originally selected from TritrypDB, 16 were successfully amplified using 
PCR. Those PCR products were treated with T4 DNA polymerase and annealed into pET 
30 Xa/LIC over expression vector, except for gene Tb927.8.2020, which was cloned into 
pET28 vector (Kerkhoven, PhD thesis, 2012). Five PCR products did not get the DNA 
amount needed for T4 DNA polymerase treatment and these were not included in further 
experiments (for all gene ID, see Table 3.4). 
Plasmid DNA of the cloned constructs were transformed into E. coli BL21(DE3) for 
overexpression, followed by small scale protein purification using nickel affinity columns 
(Ni-NTA Spin Columns (Qiagen)) for initial over-expression screen. 
Clones pMB-G161, pMB-G192, pMB-pMB-G195 did not over-express in BL21(DE3) or 
Rosetta (DE3) pLysS.  
Over-expression of clones pMB-G157, pMB-G190, pMB-G193 and pMB-G198 was 
achieved in Rosetta (DE3) pLysS, however, protein was not detected in soluble fraction 
and therefore those proteins were not used for further analyses. 
Clone pMB-G160 is unnotated as a pseudo-gene in TriTrypDB, meaning that additional 
stop codons were found. Protein over-expression showed a much smaller protein than 
originally expected and this was not analysed further. For the nine proteins remaining, 
higher yield was achieved in E. coli Rosetta pLysS and were therefore used for the in vitro 
assay (Figure 3.5)    
 
Figure 3.5: Whole cell extract of Rosetta (DE3) pLysS pre (-) and post (+) induction with IPTG (1mM 
final). Expected recombinant protein sizes were G157: 53kDa, G158: 55kDa, G159: 35kDa, G160: 55kDa 
(Pseudogene), G162: 38kDa, G190: 71kDa, G191: 49kDa, G193: 59kDa, G194: 59kDa, G196: 40kDa, 
G197: 41kDa and overexpressed proteins are indicated with an arrow. 
 
Originally, over expressed proteins were purified using Ni-NTA Spin Columns (Qiagen). 
However, the resulting eluates showed high contamination with other proteins. Proteomic 
analysis of one set of purified proteins contained from the spin columns even showed 
enzymes from E. coli and changes to the metabolomics dataset could be traced to one of 
them. Therefore, protein purification was changed to use HPLC with a Poros MC20 
column (2.3.2).  
54 
 
Gene ID Gene name (putative) 
Plasmid 
ID PCR for cloning Protein over expression 
Metabolomics 
assay 
Tb927.8.2020 Arginase/agmatinase-like protein pMB-G131 
E. Kerkhoven, PhD thesis, 
2012 High levels overexpression see 3.2.3.8 
Tb09.160.0810 Kynureninase pMB-G157 performed by B. Nijgal Not soluable n.a. 
Tb927.10.2750 Deoxyhypusine synthase pMB-G158 performed by B. Nijgal High levels overexpression see 3.2.3.3 
Tb927.7.5680 Deoxyribose-phosphate aldolase pMB-G159 performed by B. Nijgal High levels overexpression see 3.2.3.4 
Tb927.5.287b Galactokinase, Pseudogene pMB-G160 performed by B. Nijgal smaller size than expected n.a. 
Tb927.2.3080 Fatty acid desaturase pMB-G161 performed by B. Nijgal No over expression n.a. 
Tb11.01.6500 NAD
+
 synthase pMB-G162 performed by B. Nijgal High levels overexpression see 3.2.3.5 
Tb427.01.1130 Glycerol-3-phosphate dehydrogenase pMB-G190 0.2 pmol No over expression n.a. 
Tb427.06.4920 S-adenosylmethionine synthetase pMB-G191 0.2 pmol High levels overexpression see 3.2.3.1 
Tb427.07.4390 Threonine synthase n.a. No positive PCR n.a. n.a. 
Tb427.08.3800 Nucleoside phosphatase pMB-G192 0.2 pmol No over expression n.a. 
Tb427.10.12980 Methyltransferase n.a. No positive PCR n.a. n.a. 
Tb427.10.13130 UTP-glucose-1-phosphate uridylyltransferase pMB-G193 0.2 pmol Not soluable n.a. 
Tb427.10.12430 Citrate synthase pMB-G194 0.2 pmol High levels overexpression see 3.2.3.2 
Tb427tmp.01.3640 Acyl-CoA dehydrogenase n.a. No positive PCR n.a. n.a. 
Tb427tmp.02.0530 phosphoribosylpyrophosphate synthetase pMB-G195 0.2 pmol Not soluable n.a. 
Tb427tmp.02.3040 Aldo/keto reductase pMB-G196 0.2 pmol High levels overexpression see 3.2.3.6 
Tb427.10.2490 Glucose-6-phosphate 1-dehydrogenase n.a. No positive PCR n.a. n.a. 
Tb427.05.3820 Aspartate carbamoyltransferase pMB-G197 0.2 pmol High levels overexpression see 3.2.3.7 
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Gene ID Gene name (putative) 
Plasmid 
ID PCR for cloning Protein over expression 
Metabolomics 
assay 
Tb427.10.2010 Hexokinase pMB-G198 0.2 pmol Not soluable n.a. 
Tb427.05.4560 Guanine deaminase n.a. No positive PCR n.a. n.a. 
      
Table 3.4: Trypanosome genes selected for in vitro enzyme identification assay. Gene ID represents the identification number given by TritrypDB. All genes chosen represented 
putative identified enzymes, except for glycerol-3-phosphate dehydrogenase, glucose-6-phosphate 1-dehydrogenase and hexokinase which were already descript to be present in 
trypanosomes, but were chosen as positive controls. Plasmid ID shows the identification number in our lab, when applicable. For Plasmid ID n.a. (not applicable) no plasmid was 
created due to failed PCR. PCR for cloning shows the concentration (in pmol) of DNA used for T4 DNA polymerase treatment, when performed during this project. When already 
created plasmids were used for protein over expression the person who created the original plasmid is named. Protein over expression indicates if the over expression was successful 
and Metabolomics assay refers to the appropriate chapter in this thesis.       
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3.2.3.1. S-adenosylmethionine synthetase, putative (G191) 
 
The enzyme S-adenosylmethionine synthetase catalyses the formation of S-
adenosylmethionine (AdoMet) from methionine and ATP, and is the starting enzyme in the 
methionine cycle (Figure 3.6).  
 
Figure 3.6: First step in the methionine cycle, adapted from Metacyc (http://metacyc.org). 1  S-
adenosylmethionine synthetase (EC 2.5.1.6) catalyses the first step from L-methionine to S-adenosyl-L-
methionine, using ATP as the adenosyl-group donor, leaving diphosphate and phosphate. Trypanosome 
genome shows nine genes coding for S-adenosylmethionine synthase. 
 
S-adenosylmethionine is the key branch point in cell metabolism. Most of the intracellular 
methionine is converted into S-adenosylmethionine (Nozaki et al., 2005) and there are 
three known downstream reactions for AdoMet:  
 
(1) AdoMet acts as the methyl group donor for most cellular methyltransferase reactions, 
in fact all biological methylation reactions with the exception of the methylation of 
homocysteine (Stipanuk, 2004). 
(2) AdoMet can also be used for the formation of polyamines via decarboxylated AdoMet. 
It serves, in trypanosomes, as the aminopropyl group donor in the synthesis of polyamines, 
including Spermidine (Reguera et al., 2007). 
(3) AdoMet can be recycled back to Methionine, via S-adenosyl homocysteine and 
homocysteine, a process known as the methionine cycle. 
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Activity of the reaction has been measured in cell extract of T. brucei and two isoforms of 
the enzyme are present in the bloodstream form (Bacchi and Yarlett, 1993).  TritrypDB 
shows nine copies of a putatively annotated gene in T. brucei (Tb427.06.4840 / 4850 / 
4860 / 4870/ 4880/ 4890/4900/ 4910/ 4920), but no experimental data with recombinant 
protein exists to confirm the correct annotation. 
 
A gene encoding for S-adenosylmethionine synthetase was cloned from T. b. brucei strain 
427 using the ligase independent cloning system pET30 Xa/LIC with primers specifically 
designed to create an overhang compatible with this system. 
Primers GGTATTGAGGGTCGCATGTCCGTGCGCCAG (MB0729, fwd)   and 
AGAGGAGAGTTAGAGCCCTACTGCACGTCACTAAGACC (MB0730, rev) were 
designed to produce the desired insert (introduced overhang is underlined).  
 
The activity of recombinant S-adenosylmethionine synthetase was investigated using an in 
vitro assay combined with metabolite profiling. The recombinant protein was purified 
using an Immobilised Metal ion Affinity Chromatography (IMAC) protocol (Figure 3.7). 
(a)          (b)  
Figure 3.7: Purification of recombinant putative S-adenosylmethionine synthetase (SAM synthetase). 
SAM synthetase was heterologously expressed and purified using immobilised metal affinity 
chromatography (IMAC).  (a) Purification profile using IMAC, with the protein of interest being eluted with 
500mM imidazole. (b) Protein verification by SDS-PAGE. 
 
The raw data was analysed using IDEOM (2.4.6). A heatmap was created in IDEOM using 
all identified basepeaks (Figure 3.8 (a)) and shows a minority of metabolites changing 
between the sample sets. Principal component analysis (PCA) of the dataset shows a less 
defined separation between control and treatment samples (Figure 3.8 (b)). The dataset 
showed a significant increase in S-adenosylmethionine in the sample set containing ATP 
(Figure 3.9 (a)). A low increase was also detected in the enzyme treated sample set 
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containing ADP (Figure 3.9 (a)). Whether that is because the commercially available ADP 
from Sigma was contaminated with ATP or because low levels of S-adenosylmethionine 
were present in the yeast extract is unknown. 
(a) (b) 
 
Figure 3.8: Heatmap and principal component analysis (PCA) of metabolomics dataset from SAM 
synthetase assay. (a) Heatmap created with the statistical software R in IDEOM from all identified 
metabolites with a confidence level between 5 and 10. The total number of detected metabolites was 1324. 
(b) PCA analysis of the same dataset. Abbreviations: Co1_C control sample of cofactor 1 metabolite mix, 
Co1_E enzyme treated sample of cofactor 1 metabolite mix. Co2_C / Co2_E cofactor 2 metabolite mix 
control (C) and enzyme treated (E) sample. In the heatmap the last digits representing the replicate number 
(1-3). Heatmap colours are represented in a gradient from dark blue (metabolite not present or significantly 
decreased, green (decreased, not significant), yellow (unchanged) and red (significantly increased).  
(a) (b) 
Figure 3.9: Peak intensity of S-adenosylmethionine and L-methionine. Assay was set up as described in 
2.4.1. and analysed with IDEOM. (a) S-adenosylmethionine (the product of s-adenosylmethionine 
synthetase) and (b) L-methionine (the substrate of the reaction). Comparing the intensities of those two 
metabolites, it shows that L-methionine is highly abundant in the yeast extract which probably explains why 
the levels of L-methionine do not decrease in this experiment. 
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Unfortunately, no decrease in L-methionine levels was detected, however, as seen in 
Figure 3.9 (b), L-methionine was highly abundant in the yeast extract and it seems that the 
high levels of that compound masked the decreasing levels in the enzyme treated sample 
set containing ATP.  
 
3.2.3.2. Citrate synthase, putative (G194) 
 
Gene Tb427.10.13430 has been putatively identified as citrate synthase, which is the first 
enzyme in the citric acid cycle and synthesizes citrate from acetyl-CoA and oxaloacetate 
(Figure 3.10). 
 
 
Figure 3.10: Reaction catalysed by Citrate synthase. Citrate and Coenzyme A are being produced from 
acetyl-CoA, oxaloacetate and water. Adapted from Metacyc.org. 
 
Gene Tb427.10.13430 was cloned from T. brucei strain 427 using the ligase independent 
cloning system pET30 Xa/LIC with primers specifically designed to create an overhang 
compatible with this system. 
Primers GGTATTGAGGGTCGCATGTGCATGCGTGCTCG (MB0739, fwd)   and 
AGAGGAGAGTTAGAGCCCTACGCTATGTTGTACTTTGTG (MB0740, rev) were 
designed to produce the desired insert (introduced overhang is underlined). Protein was 
heterologously expressed in E. coli Rosetta (DE3) pLysS and purified using IMAC 
protocol described in method section (Chapter 2.3.2). 
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The in vitro assay combined with metabolite profiling showed very few changes in the 
metabolite mix between control and treatment samples. Heatmap and PCA analysis (Figure 
3.11) show no pattern that would show sample separation from treatment vs control; 
however, a few changes indicated that there might be a reaction in the cofactor 2 treatment 
samples. The citrate synthase reaction, as shown in Figure 3.9., was not evident in this 
dataset. Due to the large sample variation (Figure 3.12 (b)), it is difficult to detect any 
possible changes in levels of citrate, but also the levels of acetyl CoA do not seem to 
change significantly between control and treatment samples (Figure 3.12 (a)). 
 
(a)        (b) 
 
Figure 3.11: Heatmap and principal component analysis (PCA) of metabolomics dataset from citrate 
synthase assay. (a) Heatmap created with the statistical software R in IDEOM from all identified metabolites 
with a confidence level between 5 and 10. The total number of detected metabolites was 1310. 
Abbreviations: Co1 cofactor 1  metabolite mix, Co2 cofactor 2  metabolite mix  with control (C) and enzyme 
treated (E) sample for each set and the last digits representing the replicate number (1-3). (b) PCA analysis 
created by the statistical software R using IDEOM, shows no clustering of sample sets (treatment vs control). 
Heatmap colours are represented in a gradient from dark blue (metabolite not present or significantly 
decreased, green (decreased, not significant), yellow (unchanged) and red (significantly increased).  
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Figure 3.12: Peak intensities of metabolites predicted to change in the dataset according to putative 
annotation of enzyme. However, as seen in (a) levels of Acetyl-CoA (in samples containing cofactor 2 mix) 
do not seem to change significantly when sample mix is treated with enzyme compared to control sample and 
citrate levels are similar between control and treatment samples (b). 
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Figure 3.12 c: Peak intensity of significantly increased metabolite in G194 dataset putatively annotated 
as 2S-amino-tridecanoic acid. Changes in yeast extract with cofactor 1 mix, untreated (Control), treated 
(Treatment) with enzyme are represented on the left and changes in yeast extract with cofactor 2 mix, 
untreated, treated, are shown on the right. Structure of this compound is shown next to the changes. 
 
The most significant change in this dataset was a compound with the mass of 229.20 and a 
retention time of 4.31 min, which has been putatively identified as 2S-Amino-tridecanoic 
acid (basepeak) with a confidence of 7 (Figure 3.12 (c)). However, 5 isomers are assigned 
to this compound (Table 3.5); with 2S-Amino-tridecanoic acid showing a retention time 
62 
 
(rt) closest to the predicted rt. This metabolite was only detected in the enzyme treated 
samples, with higher change detected in the cofactor 2 treated sample set (Figure 3.12 (c)).  
Isomers 
ppm 
error predicted RT error 
2S-Amino-tridecanoic acid 0.72 -7.70% 
[FA amino(13:0)] 13-amino-tridecanoic acid 0.72 -28.10% 
[FA amino(13:0)] 2R-aminotridecanoic acid 0.72 -7.90% 
[FA amino(13:0)] 2-amino-tridecanoic acid 0.72 -7.90% 
Capryloylcholine 0.72 -49.40% 
   Table 3.5: Isomers of detected compound showing significant increase in treatment samples. Putative 
identification was 2S-Amino-tridecanoic acid, which showed the lowest retention time error to the predicted 
retention time.     
 
2S-Amino-tridaconic acid is an amino fatty acid belonging to the 13C-carbon saturated 
fatty acids. Searches in metacyc.org, KEGG and PubMed have not indicated the possible 
existence of a pathway containing this metabolite in trypanosomes. Therefore, it is possible 
to give a possible function for this protein on this one significant increase found in the 
dataset. 
 
3.2.3.3. Deoxyhypusine synthase, putative (G158) 
 
Tb927.10.2750 is putatively identified as a deoxyhypusine synthase, which catalyses the 
spermidine-dependent modification of hypusine in a lysine residue for the essential 
translation factor elF5A. This reaction is performed in two steps, the first step 
deoxyhypusine synthase transfers the butylamine moiety from spermidine to a specific 
lysine residue of the of the eIF5A precursor protein with NAD+ as a cofactor (Joe et al., 
1995). However, if the elF5A precursor protein is absent, the reaction releases 1-pyrroline. 
Decreasing levels in Spermidine with corresponding increasing levels in 1-pyrroline could, 
in theory, be detected using the LC-MS platform used in this study. Gene Tb927.10.2750 
was cloned from T. brucei strain 427 using the ligase independent cloning system pET30 
Xa/LIC with primers specifically designed to create an overhang compatible with this 
system. 
Primers GGTATTGAGGGTCGCATGGCTGAGTTGGCCAAGAG (MB0639, fwd)   and 
AGAGGAGAGTTAGAGCCTCACGAGCGGATATTCTCCT (MB0640, rev) were 
designed to produce the desired insert (introduced overhang is underlined) and cloning was 
successful and confirmed by sequencing. 
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As described above the changes I would have expected to see during this experiment, if 
this protein is indeed a deoxyhypusine synthase, are decreasing levels of Spermidine and 
NAD+ and increasing levels of 1-pyrroline. However, only a minimal change in 
spermidine levels was observed during the in vitro metabolite profiling (Figure 3.12. (a)). 
The sample set containing yeast metabolites and Cofactor mix 1 (which includes NAD+), 
treated with enzyme showed a slight decrease in levels of spermidine. However, 1-
pyrroline and NAD+ were not detected. These results are not conclusive enough to identify 
the gene Tb927.10.2750 as an deoxyhypusine synthase coding gene.  
 
After this experiment was performed it was shown that this protein is indeed a 
deoxyhypusine synthase but also that this enzyme’s activity is increased 3000-fold by 
forming a heterotetramer with a catalytically dead paralog (Nguyen et al., 2013). This 
would explain why the results were inconclusive using the metabolite profiling approach.  
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Figure 3.13: Spermidine peak intensities and heatmap of metabolomics dataset from deoxyhypusine 
synthase assay. (a) Average peak height of spermidine from three sample replicates with standard deviation 
and (b) Heatmap of untargeted metabolite profiling approach with yeast extract and two cofactor mixes (3 
replicates) of Deoxhypusine synthase. No significant changes in metabolite levels between control and 
treatment samples were detected in this dataset. Abbreviations are: Co1 for cofactor 1 / metabolite mix, Co2 
for cofactor 2 / metabolite mix  with control (C) and enzyme treated (E) sample for each set and the last 
digits representing the replicate number (1-3). Heatmap colours are represented in a gradient from dark blue 
(metabolite not present or significantly decreased, green (decreased, not significant), yellow (unchanged) and 
red (significantly increased).  
 
As shown in the heatmap of this experiment (Figure 3.13) there seem to be some changes 
in the data set. However, after analysis it became clear that those changes demonstrate the 
variance between samples more than sample groups (control/treatment). This was evident 
from replicates not showing similar intensities. As IDEOM uses the average peak intensity 
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to compare control to treatment, a metabolite not detected in one replicate could indicate a 
change when indeed it is just sample variation. 
 
3.2.3.4. Deoxyribose-phosphate aldolase, putative (G159) 
 
The gene Tb927.7.5680 codes for a protein that is putatively annotated as deoxyribose-
phosphate aldolase, an enzyme which catalyses the following reaction: 
2-deoxy-D-ribose 5-phosphate → D-glyceraldehyde 3-phosphate + acetaldehyde  
To investigate the function of this protein, the gene Tb927.7.5680 was cloned from T. b. 
brucei strain 427 using target gene specific primers  and a ligase independent cloning 
system (as described in the methods section), using primers 
GGTATTGAGGGTCGCATGACCGACCTTCACATGAG (MPB0641, fwd) and 
AGAGGAGAGTTAGAGCCTTAGTATTTACTGCGGGAGC (MPB0642, rev), to create 
vector specific overhang (Introduced overhang is underlined). The untargeted 
metabolomics approach showed no significant changes regarding any potential enzyme 
activity. The substrate and product have not been detected, although previous data sets 
have shown those metabolites to be present in the yeast extract. Although the PCA analysis 
(Figure 3.14 (b)) shows a grouping of samples treatment vs control, the dataset showed no 
significant changes in individual metabolite levels between those groups (Figure 3.14 (a)). 
(a) (b) 
 
Figure 3.14: Heatmap and principal component analysis (PCA) of metabolomics dataset from 
deoxyribose-phosphate aldolase assay. (a) Heatmap of untargeted metabolite profiling approach with yeast 
extract and two cofactor mixes (3 replicates) of deoxyribose-phosphate aldolase. (b) PCA analysis of same 
data set shows clustering of treatment vs control samples (treatment samples in red and dark blue). 
Abbreviations are: Co1 for cofactor 1 / metabolite mix, Co2 for cofactor 2 / metabolite mix  with control (C) 
and enzyme treated (E) sample for each set and the last digits representing the replicate number (1-3). 
Heatmap colours are represented in a gradient from dark blue (metabolite not present or significantly 
decreased, green (decreased, not significant), yellow (unchanged) and red (significantly increased).  
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To establish if this protein is essential for bloodstream form trypanosomes, a deoxyribose-
phosphate aldolase
RNAi
 cell line (G159
RNAi
) was created and the transcription of the gene 
knocked down by RNA interference.  
 
Induction of knock down with 1 µg ml
-1
 and 5 µg ml
-1
 tetracycline showed no change in 
growth phenotype (see Figure 3.15 (a)). Reverse transcription with RT-PCR showed only a 
knockdown effect of about 10% (Figure 3.15 (b)). Therefore it could not be determined 
whether this protein is essential for cell survival. 
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Figure 3.15: Growth curve of G159
RNAi
 cell line (a) and relative RNA abundance in G159
RNAi
 cell line, 
as determined by rt RT-PCR (b) 
(a) Culture of G159
RNAi
 , induced every 24 h with 1 µg ml
-1
 tet (+) and without tet (-) , was monitored for six 
days for differences in growth rate. As seen, no differences in growth could be detected. Cell flasks were set 
up in triplicate.  
(b) Two cultures of G159
RNAi
 were set up, one was induced with 5 µg ml
-1
 tetracycline (+tet) every 24 hours. 
Samples were taken ( 5 x 10
7
 cells) at timepoint 48h, 72h and 96h and RNA extracted and relative RNA 
abundance of transcript of interest was assessed by rt RT-PCR (in triplicate). Timepoints were combined for 
graph as there were no changes in RNA abundance between different timepoints. Protein GPI-8 was used as 
standard.  
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3.2.3.5. NAD
+ 
synthase, putative (G162) 
 
NAD
+
 synthase catalyses the last step in the NAD
+
 biosynthesis pathway and the reaction 
involves either the transfer of an amino group from glutamine or ammonia to form NAD
+
 
from nicotinic acid adenine dinucleotide (NaAD or Deamido-NAD
+
) (Ozment et al., 1999). 
The reactions are shown in Figure 3.16 (glutamine dependent NAD
+
 synthase) and Figure 
3.17 (ammonium dependent NAD
+
 synthase). 
 
 
 
Figure 3.16: Reaction of L-glutamine dependent NAD
+ 
synthase, adapted from metacyc.org. In this 
reaction an amino-group is transferred from L-glutamine to deamido-NAD+ to form L-glutamate and NAD+.  
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Figure 3.17.: Reaction of ammonium dependent NAD
+
 synthase, adapted from metacyc.org. In this 
reaction ammonium and deamido-NAD
+  
form NAD
+
. 
 
E. coli favours the ammonia dependent reaction (Spencer and Preis, 1966), while 
eukaryotic NAD
+
 synthase seems to be glutamine dependant (Wojcik et al., 2006). In 
trypanosomes, gene number Tb11.01.6500 is putatively annotated as an NAD
+
 synthase 
and was investigated for its biological function using in vitro metabolite profiling and 
targeted enzyme assays. To study the function of the encoded protein from gene 
Tb11.01.6500, it was cloned from T. brucei strain 427 using target gene specific primers  
and a ligase independent cloning system (as described in the methods section), using 
primers GGTATTGAGGGTCGCATGCCGAAGGAGCCCATTCT (MPB0647, fwd) and 
AGAGGAGAGTTAGAGCCTACAGGTTCACAATACCGT (MPB0648, rev), to create 
vector specific overhang (Introduced overhang is underlined). Over-expression was 
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achieved using 1 litre cultures of transformed E. coli Rosetta pLysS cells as well as E. coli 
BL21 (DE3). The over-expression of the putatative NAD
+
 synthase showed consistently 
high amounts of protein produced, but purification, using IMAC, showed contamination in 
the eluate (see Figure 3.18). 
(a)     (b) 
Figure 3.18: Purification of recombinant putative NAD
+
 synthase. NAD
+
 synthase was heterologously 
expressed and purified using immobilised metal affinity chromatography (IMAC).   (a) Purification profile of 
recombinant protein G162 over-expressed in E. coli Rosetta pLysS, using IMAC, washed with 50 mM 
imidazole and eluted with 500 mM imidazole and (b) protein verification by SDS-PAGE, m=Marker, 
L=Lysis, FT= Flowthrough and MC=pool of eluate. 
 
Heatmap and PCA are shown in Figure 3.19 and show little variance between the samples, 
except for the QC samples. However, the pattern of decreasing metabolites throughout the 
run indicates that the volume of QC sample was too low and sample could not be picked 
up. 
(a) (b) 
 
Figure 3.19: Heatmap and principal component analysis (PCA) of metabolomics dataset from NAD
+
 
synthase assay.  (a) Heatmap of untargeted metabolite profiling approach with yeast extract and cofactor 
mix 2 (3 replicates). The visible changes occur in the quality control (QC) samples, which are run at the 
beginning, in the middle and at the end of the run, with decreasing detected metabolites from QC1 to QC 3. 
Those changes are most likely due to sample degradation. (b) Correlation between sample groups 
(control/treatment) was analysed by PCA. No clear separation is apparent between the two groups. Heatmap 
colours are represented in a gradient from dark blue (metabolite not present or significantly decreased, green 
(decreased, not significant), yellow (unchanged) and red (significantly increased).  
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Metabolic profiling by mass spectrometry did show decreasing levels of deamido-NAD
+
 or 
L-glutamine, however those changes do not seem to be significant (Figure 3.20). ATP and 
NAD
+
 were not detected in the IDEOM spreadsheet. 
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Figure 3.20: Average peak intensities of L-glutamine, L-glutamate and Deamido-NAD
+
 in 
metabolomics dataset. Detected average intensities of metabolites, assumed to be involved in reaction, of 
cofactor 2 treatment (Co2_E) and control (Co2_C) samples (three replicates). Although it appears that L-
glutamine levels go slightly down in treatment samples (a), those changes are not significant. L-glutamate 
levels show no corresponding increase (b). Deamido-NAD
+
 (c) also shows no significant decrease in 
intensity, however, when one control sample, showing significantly lower peak intensity than the other 
samples, was removed, decrease of Deamido-NAD
+
 seems to be significant (d). 3 replicates were used in this 
study. 
 
As the detected changes in the metabolomics dataset would not immediately point to this 
enzyme being a NAD
+
 synthase, a spectrophotometric enzyme assay was performed to 
determine the activity of the purified protein using an adapted coupled enzyme assay from 
Wojcik et al (2006). Instead of alcohol dehydrogenase (suggested enzyme for coupled 
reaction), glucose dehydrogenase was used. Protein purified from Rosetta pLysS seemed to 
produce NAD
+
, while protein produced in BL21 did not. 
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Figure 3.21: Results of NAD
+ 
-synthase assay on spectrophotometer. A glutamine-dependent enzyme 
assay was performed, as described by Wojcip et al (2006). Positive control with 20mM NAD
+
 was plotted 
against left y-axis and is marked in black. Negative control, enzyme assay reaction mix 1 (as described in 
method section) without enzyme is shown in dark blue. Coupled enzyme assay, reaction mix 1 and glucose 
dehydrogenase assay is shown in triplicate (light blue, light purple and pink) and plotted against the right y-
axis. Glucose dehydrogenase was added to all samples at 120 seconds. 
 
As shown in Figure 3.21, the increase of absorbance was minimal in the NAD
+
 synthase 
treated samples. However, although minimal changes in absorbance indicate that gene 
Tb11.01.6500 is indeed an NAD
+
 synthase, it is not clear if the enzyme is an ammonium 
dependent or glutamine hydrolysing NAD
+
 synthase. A spectrophotometric enzyme assay 
for ammonium dependent NAD
+
 synthase showed no activity when performed with protein 
purified from E. coli BL 21 (DE3). It is likely though, that the trypanosome NAD
+
 
synthase is ammonium dependent, but that L-glutamine can still act as an amino group 
donor, albeit not as efficiently (Spencer and Preiss, 1967). If so, it would explain the 
minimal changes in the glutamine dependent enzyme assay. A bioinformatics search on the 
predicted protein sequence (EFICAz
2.5
) suggested that the gene Tb11.01.6500 codes for 
the ammonium dependent enzyme. A further Pfam (http://pfam.xfam.org/) search for 
active domains revealed that the gene Tb11.01.6500 only contains one domain associated 
for NAD
+
 synthase activity. This result is consistent with E. coli NAD
+
 synthase. Human 
NAD
+
 synthase on the other hand shows two domains. The ‘CN hydrolase’ domain 
appears to be necessary for the glutamine dependant activity. This domain is missing from 
trypanosomes NAD
+
 synthase, however, it is found in trypanosome gene Tb927.9.1960, 
which is putatively annotated as a nitrilase. 
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3.2.3.6. Aldo/keto reductase, putative (G196) 
 
The aldo/keto reductase superfamily includes NADPH dependant oxidoreductases (Bohren 
et al., 1989). Gene Tb427tmp.02.3040 was cloned from T. b. brucei strain 427 using the 
ligase independent cloning system pET30 Xa/LIC with primers specifically designed to 
create an overhang compatible with this system. 
Primers GGTATTGAGGGTCGCATGGACCGTATTCCATATTTGG (MB0745, fwd)   
and AGAGGAGAGTTAGAGCCTTAATCTATCGTGTTGCTATGCC (MB0746, rev) 
were designed to produce the desired insert (introduced overhang is underlined).  
Protein was heterologously expressed in E. coli Rosetta (DE3) pLysS and purified using 
IMAC protocol described in method section (2.3.2). The recombinant T. brucei enzyme did 
not show any significant changes in the dataset that could lead to function of this enzyme. 
Heatmap and PCA analysis (Figure 3.22) showed no difference in control vs treatment 
samples. NADPH dependent changes should have been seen in cofactor mix 2, however, 
NADPH or NADP were not detected. 
 (a) (b) 
 
Figure 3.22: Heatmap and principal component analysis (PCA) of metabolomics dataset from 
aldo/keto reductase assay. (a) Heatmap created from dataset using R. Changes in metabolite levels show the 
variance between samples as levels vary within the replicates more than between the sample groups. (b) PCA 
analysis shows separation between the individual samples, indicating random changes between the samples. 
Abbreviations are: Co1 for cofactor 1 / metabolite mix, Co2 for cofactor 2 / metabolite mix  with control (C) 
and enzyme treated (E) sample for each set and the last digits representing the replicate number (1-3). 
Heatmap colours are represented in a gradient from dark blue (metabolite not present or significantly 
decreased, green (decreased, not significant), yellow (unchanged) and red (significantly increased).  
 
To establish if this protein is essential for bloodstream form trypanosomes an Aldo/keto 
reductase
RNAi
 cell line (G196
RNAi
) was created and the transcription of the gene knocked 
down by RNA interference. Induction of knock down with 1 µg ml
-1
 or 5 µg ml
-1
  
tetracycline showed no change in growth phenotype. Reverse transcription with RT-PCR 
showed a knockdown effect of about 40% (Figure 3.23).  
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No further studies were performed, as it was concluded that 40% knock down is not 
enough to establish if the protein is essential and therefore further metabolomics studies 
seemed uninformative.  
 
G196
G196 - tet G196 + tet
0
50
100
150
re
la
ti
v
e
 R
N
A
 a
b
u
n
d
a
n
c
e
 
Figure 3.23: Relative RNA abundance in G196
RNAi
 cell line, as determined by rt RT-PCR 
Two cultures of G196
RNAi
 were set up, one was induced with 5 µg ml
-1
 tetracycline (+tet) every 24 hours. 
Samples were taken (5 x 10
7
 cells) at timepoint 48h, 72h and 96h, RNA extracted and relative RNA 
abundance of transcript of interest was assessed by rt (reverse transcription)RT-PCR (in triplicate). 
Timepoints were combined for graph as there was no change in RNA abundance between different 
timepoints. Protein GPI-8 was used as standard.  
73 
 
3.2.3.7. Aspartate carbamoyltransferase, putative (G197) 
 
Aspartate carbamoyltransferase catalyses the first step in the pyrimidine biosynthetic 
pathway. It belongs to the enzyme class of transferases and the reaction fuses L-aspartate 
with a carbamoyl-group to form N-carbamoyl-L-aspartate (Figure 3.24). In bloodstream 
form trypanosomes, pyrimidine biosynthesis from glucose has been observed when 50 % 
U-
13
C-labelled glucose was added to the growth medium (Creek et al., 2015).  
 
Figure 3.24: Reaction of aspartate carbamoyltransferase. Adapted from metacyc.org 
 
Gene Tb427.05.3820 was cloned from T. brucei strain 427 using the ligase independent 
cloning system pET30 Xa/LIC with primers specifically designed to create an overhang 
compatible with this system. 
Primers GGTATTGAGGGTCGCATGGCGGAGCTGCAACCTG (MB0749, fwd)   and 
AGAGGAGAGTTAGAGCCTTAGGCGAGAACACTATAAAG (MB0750, rev) were 
designed to produce the desired insert (introduced overhang is underlined).  
Protein over-expression was achieved consistently with high yield in both E. coli Bl21 
(DE3) and Rosetta (DE3) pLysS.  However, Rosetta (DE3) pLysS cells were used for this 
study and 1 litre culture was induced with 1mM IPTG overnight at 18°C and protein 
purified using IMAC (Figure 3.25). 
 
(a)  (b) 
Figure 3.25: Purification of recombinant putative aspartate carbamoyltransferase. Aspartate 
carbamoyltransferase was heterologously expressed and purified using immobilised metal affinity 
chromatography (IMAC). (a) Purification profile of recombinant protein using IMAC, protein was washed 
with 50 mM imidazole and eluted with 500 mM imidazole. (b) Protein verification by SDS-PAGE, 
m=Marker, L=Lysis, FT= Flowthrough and E= eluates. 
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In vitro assay combined with metabolite profiling showed no differences between the 
control and treatment samples as shown in the heatmap and PCA (Figure 3.26). One 
Control sample (Co1_C_1) showed irregularity to the rest (see Figure 3.26 (a)). However, 
when this sample was excluded from analysis, no significant changes were seen. 
 
 (a) (b) 
 
Figure 3.26: Heatmap and principal component analysis (PCA) of metabolomics dataset from 
aspartate carbamoyltransferase assay. (a) Heatmap crerated from dataset using R. (b) PCA analysis 
created from dataset using R. Samples were analysed in triplicates. Co1_C = Control samples cofactor mix 1, 
Co1_E = Treatment samples cofactor mix 1, Co2_C= Control samples cofactor mix 2, Co2_E= Traetment 
samples cofactor mix 2 and QC= pooled samples. Heatmap shows that one Cofactor 1 control sample seemed 
not to have been picked up proper as the majority of the metabolites seemed decreased compared to the other 
samples. This sample should be discarded for analysis. No clear separation is apparent between the two 
groups. Heatmap colours are represented in a gradient from dark blue (metabolite not present or significantly 
decreased, green (decreased, not significant), yellow (unchanged) and red (significantly increased).  
 
 
To establish if this protein is essential for bloodstream form trypanosomes an aspartate 
carbamoyltransferase
RNAi
 cell line (G197
RNAi
) was created and the transcription of the gene 
knocked down by RNA interference. Induction of knock down with 1 µg ml
-1
 tetracycline 
showed no change in growth phenotype, but induction with and 5 µg ml
-1
 tetracycline did 
(see Figure 27 (a)). Reverse transcription with RT-PCR showed a knockdown effect of 
about 70% (Figure 3.27 (b)).  
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Figure 3.27.: Growth curve of G197
RNAi
 cell line (a) and relative RNA abundance in G197
RNAi
 cell line, 
as determined by rt RT-PCR (b) 
(a) Culture of G197
RNAi
 , induced every 24 h with 5 µg ml
-1
 tet (+) and without tet (-) , was monitored for five 
days for differences in growth rate. Cell flasks were set up in triplicates.  
(b) Two cultures of G197
RNAi
 were set up, one was induced with 5 µg ml
-1
 tetracycline (+tet) every 24 hours. 
Samples were taken ( 5 x 10
7
 cells) at timepoint 48h, 72h and 96h and RNA extracted and relative RNA 
abundance of transcript of interest was assessed by rt RT-PCR (in triplicate). Timepoints were combined for 
graph as there was no change in RNA abundance between different timepoints. Protein GPI-8 was used as 
standard. 
 
To establish the function of this protein knockdown was induced in G197
RNAi
 and after 72 
hours metabolites were extracted from uninduced and induced cells and analysed on LC-
MS. The most significant changes in this dataset were L-glutamate (increasing levels in 
RNAi line) and UDP and uracil (decreasing levels in RNAi line). The pathway involving 
aspartate carbamoyltransferase and metabolite levels are shown in Figure 3.28. This 
pathway has been shown to be active in bloodstream form trypanosomes and a recently 
performed study with U- 
13
C D-glucose showed labelling of L-aspartate from D-glucose 
and the downstream metabolites of the pyrimidine biosynthesis (Creek et al., 2015). 
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Figure 3.28: Pyrimidine biosynthesis pathway, adapted from metacyc.org. Red cross indicates reaction 
catalysed by aspartate carbamoyltransferase. Metabolites changing significantly in knockdown line are 
shown. L-glutamate increases in knockdown line, while uracil and UDP decrease. Abbreviations: PPP: 
Pentose phosphate pathway, PRPP: Phosphoribosyl pyrophosphate, UDP: Uridine diphosphate, UMP: 
Uridine monophosphate. 
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3.2.3.8. Arginase / Agamtinase-like protein, putative (G131) 
 
Vincent et al. (2012) discovered that the gene Tb927.8.2020, putatively annotated as 
‘arginase’ in TritrypDB, has no arginase activity. The annotation was later changed to 
agmatinase-like protein, however, several untargeted metabolite profiling approaches have 
failed to show this (Figure 3.29).  
 
(a) (b) 
 
Figure 3.29: Heatmap and principal component analysis (PCA) of metabolomics dataset from arginase 
assay. (a) Heatmap of untargeted metabolite profiling approach with yeast extract and two cofactor mixes (3 
replicates). The visible changes occur in the quality control (QC) samples, which are run at the beginning, in 
the middle and at the end of the run, with decreasing detected metabolites from QC1 to QC 4. Those changes 
are most likely due to sample degradation. (b) PCA analysis of dataset. Except for QC samples, no clear 
differences between the sample groups. Heatmap colours are represented in a gradient from dark blue 
(metabolite not present or significantly decreased, green (decreased, not significant), yellow (unchanged) and 
red (significantly increased).  
 
 
To investigate the possibility of metal-ion dependency of Tb927.8.2020, heterologously 
expressed protein from E. coli Rosetta (DE3) pLysS was purified and incubated with yeast 
extract and three additional metal-ions (10 µM: manganese (Mn
2+
), cobalt (Co
2+
) and zinc 
(Zn
2+
)). Although the availability of Mn
2+
 and Co
2+
 is very low in trypanosomes, it has 
been shown in the case of phosphoglycerate mutase that replacement of a native metal by 
an alternative can increase the activity of a metalloenzyme (Fuad et al., 2011). A heatmap 
of the created dataset of ‘arginase’ with added metal-ions (Figure 3.30) clearly shows 
changes between control and treatment samples. In total, about 20% of metabolites 
detected showed changes in levels between control and treatment samples. 
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(a) (b) 
 
Figure 3.30: Heatmap and principal component analysis (PCA) of metabolomics dataset from arginase 
assay with metal-ions added. (a) Heatmap of untargeted metabolite profiling approach with yeast extract 
and a mix of three metal ions (3 replicates). Metal-ions used were Co2+, Mn2+ and Zn2+. Changes detected 
in the quality control (QC) samples are probably due to sample degradation. However, Samples treated with 
enzymes show decreased levels in metabolites, mainly in amino acid metabolism. (b) PCA analysis of dataset 
shows a clear separation between control, treatment and QC. Heatmap colours are represented in a gradient 
from dark blue (metabolite not present or significantly decreased, green (decreased, not significant), yellow 
(unchanged) and red (significantly increased).  
 
 
According to putative metabolite annotation, a high proportion of changes taking place in 
the amino acid metabolism and a few biochemical reactions could be plausible: 
 L-histidine + NADH → L-histidinal + NAD, catalysed by histidinal dehydrogenase 
(Figure 3.31). 
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Figure 3.31: Significant changes in metal-ion ‘arginase’ dataset. (a) L-histidine and (b) L-histidinal. 
 
However, L-histidinal seems to be a fragment of the dipeptide N-glycyl L-leucine and has 
been annotated as a possible fragment in IDEOM.  
 Imidazole-5-pyruvate  
Imidazole-5-pyruvate is a metabolite within the L-histidine and imidazole-lactate 
degradation pathway. 
Reaction involving this metabolite (as taken from metacyc.org): 
(1) L-histidine + 2-oxoglutarate ↔ L-glutamate + imidazole-5-pyruvate 
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(2) imidazole-lactate + NAD(P)
+
 ↔ imidazole-5-pyruvate + NAD(P)H 
(3) L-histidine + pyruvate  ↔ imidazole-5-pyruvate + L-alanine 
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Figure 3.32: Significant changes in metal-ion ‘arginase’ dataset. (a) 2-oxoglutarate, (b) L-hsitidine, (c) 
imidazole-pyruvate and (d) L-glutamate. 
 
A peak annotated as imidazole-5-pyruvate shows increasing peak intensity in the enzyme 
treated sample. But imidazole-5-pyruvate elutes within the basepeak of S-methyl-1-thiol-
D-glycerate and has therefore been annotated as a fragment of that metabolite (Figure 
3.32). Furthermore, the reaction involving imidazole-5-pyruvate does not appear to happen 
in this dataset. Imidazole-lactate was not detected, but listed as an isomer of 4-
Imidazolone-5-propanoate, but again this metabolite seems to be a fragment of Adenosine. 
Also, levels of imidazole-lactate increases in enzyme treated sample set. Pyruvate had 2 
isomers, one increasing slightly, the other one decreasing slightly, both possible fragments 
of another metabolite. L-alanine was not detected.  
 (S)-1-Pyrroline-5-carboxylate  
(S)-1-Pyrroline-5-carboxylate could be produced from L-glutamate in an NADH or 
NADPH dependent reaction. No cofactors were added to this sample set, however, it is 
possible that NADH or NADPH was present in the yeast extract. But, similar to imidazole-
5-pyruvate, it elutes within the basepeak of S-methyl-1-thiol-D-glycerate (Figure 3.33 and 
3.34). 
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Figure 3.33: Average peak intensities of metabolites (S)-1-Pyrroline-5-carboxylate (a) and L-glutamate 
(b). 
 
 
S-methyl-1-thiol-D-glycerate
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Figure 3.34: Detected basepeak S-methyl-1-thiol-glycerate (a) with the two potential fragments, 
detected as imidazole-pyruvate (b) and (c) (s)-1-pyrroline-5-carboxylate. 
 
Although the function of the enzyme could not be determined from this experiment, the 
protein annotated as ‘arginase’ appears to decrease the levels of several amino acids. This 
could have been an indication of the enzyme being a non-specific deaminase. However, the 
corresponding keto acids were not detected or showed no differences in control and 
treatment samples. In the next step to determine the function of this enzyme, the ‘arginase’ 
was incubated in yeast extract, spiked with uniformly labelled 
13
C-L-methionine and in a 
reaction mix with metal-ions and u-
13
C-labelled L-methionine on its own. L-methionine 
was chosen as it was one amino acid decreasing the most in the previous dataset. The 
results are shown in Figure 3.35, but as previous results it only shows the decreasing level 
of the amino acids (in this case L-methionine), but no labelled product was detected. There 
could be several explanations for this, (1) ZIC-pHILIC is not a suitable column for this 
compound. (2) the levels of product are too low to be detected as a peak. As seen in Figure 
3.31. (b) the detected labelled 13C L-methionine was quite low due to the high levels of 
unlabelled L-methionine in the yeast extract. (3) product does not ionise well and was 
therefore not detected. All metabolites significantly changed in the metal-ion ‘Arginase’ 
dataset are listed in Table 3.6. 
81 
 
 
Mass
RT 
(in mins)
Formula
Is
o
m
e
rs
Putative metabolite identification Treatment Control
160.085 7.433 C6H12N2O3 4 D-Alanyl-D-alanine 9.44 1.00
139.075 7.361 C6H9N3O 3 L-Histidinal 3.63 1.00
195.053 7.601 C9H9NO4 9 Dopaquinone 3.32 1.00
154.038 7.690 C6H6N2O3 2 Imidazol-5-yl-pyruvate 3.28 1.00
113.048 7.703 C5H7NO2 6 (S)-1-Pyrroline-5-carboxylate 2.71 1.00
145.074 7.667 C6H11NO3 9 6-Amino-2-oxohexanoate 2.28 1.00
72.021 7.857 C3H4O2 4 Methylglyoxal 1.27 1.00
117.079 8.948 C5H11NO2 16 Betaine 1.19 1.00
193.074 4.919 C10H11NO3 10 Phenylacetylglycine 0.88 1.00
179.058 6.883 C9H9NO3 6 Hippurate 0.84 1.00
169.085 9.440 C7H11N3O2 5 N(pi)-Methyl-L-histidine 0.76 1.00
188.116 6.734 C8H16N2O3 7 N6-Acetyl-L-lysine 0.73 1.00
131.058 10.391 C5H9NO3 14 trans-4-Hydroxy-L-proline 0.73 1.00
103.063 10.800 C4H9NO2 14 4-Aminobutanoate 0.72 1.00
165.079 8.362 C9H11NO2 7 L-Phenylalanine 0.71 1.00
220.085 8.672 C11H12N2O3 3 5-Hydroxy-L-tryptophan 0.70 1.00
142.074 9.817 C6H10N2O2 1 Ectoine 0.69 1.00
160.048 8.965 C5H8N2O4 2 N-Formimino-L-aspartate 0.69 1.00
116.047 4.629 C5H8O3 9 5-Oxopentanoate 0.66 1.00
216.111 8.096 C9H16N2O4 3 γ-Glutamyl-γ-aminobutyraldehyde 0.65 1.00
227.079 8.357 C10H13NO5 1 L-Arogenate 0.65 1.00
218.127 6.826 C9H18N2O4 5 N2-(D-1-Carboxyethyl)-L-lysine 0.64 1.00
145.085 10.887 C5H11N3O2 3 4-Guanidinobutanoate 0.62 1.00
133.037 10.072 C4H7NO4 4 L-Aspartate 0.59 1.00
130.063 4.274 C6H10O3 17 4-Methyl-2-oxopentanoate 0.58 1.00
204.111 7.497 C8H16N2O4 5 N6-Acetyl-N6-hydroxy-L-lysine 0.56 1.00
147.053 9.914 C5H9NO4 14 L-Glutamate 0.54 1.00
200.977 11.135 C3H7NO5S2 1 S-Sulfo-L-cysteine 0.50 1.00
226.107 8.227 C9H14N4O3 3 Carnosine 0.49 1.00
181.074 9.880 C9H11NO3 11 L-Tyrosine 0.46 1.00
119.058 10.344 C4H9NO3 11 L-Threonine 0.46 1.00
165.046 9.620 C5H11NO3S 4 L-Methionine S-oxide 0.45 1.00
129.043 10.173 C5H7NO3 6 1-Pyrroline-4-hydroxy-2-carboxylate 0.44 1.00
75.032 10.980 C2H5NO2 3 Glycine 0.44 1.00
175.048 9.676 C6H9NO5 4 N-Acetyl-L-aspartate 0.42 1.00
146.069 10.575 C5H10N2O3 6 L-Glutamine 0.38 1.00
164.047 4.251 C9H8O3 13 Phenylpyruvate 0.36 1.00
131.095 8.742 C6H13NO2 12 L-Leucine 0.36 1.00
155.069 10.478 C6H9N3O2 5 L-Histidine 0.34 1.00
82 
 
 
 
Table 3.6: Significant changes detected in amino acid metabolism in MI sample set. Control samples had 
purified recombinant enzyme added after reaction was quenched, while the treatment had the enzyme added 
for 30min incubation. Metabolites identified with confidence 10 (matching authentic standard) are 
highlighted in grey. 
 
  (c) 
Figure 3.35: In vitro assay with 
13
C-labelled L-methionine. (a) Uniformly 
13
C-Methionine in 10 mM 
MOPS buffer + MI was incubated at 37°C for 30 min without (left) and with (right) ‘Arginase’. (b) Yeast 
extract in 10 mM MOPS + MI was spiked with U-
13
C-Methionine and incubated at 37°C for 30 minutes 
without (left) or with (right) ‘Arginase’. (c) shows the trend plot of labelled L-methionine between the 
different sample sets. 
 
Crystallography studies first suggested that the arginase-like protein is indeed a 
metalloenzyme and it was indicated that it binds significant quantities of Fe(II) ions, at 
least to a 1:1 ratio. The hypothesis is that Fe(II) could be liganded by a Try-His-Asp triad 
in the active site of the enzyme (Dr. David Christianson, University of Pennsylvania, 
personal correspondence). However, although changes in the dataset are evident using 
additional metal-ions as cofactors, it has recently been shown that the T. brucei ‘arginase’ 
does not bind metal-ions as previously thought (Hai et al., 2015). The observed binding of 
Fe(II) to the enzyme turned out to be  weak binding to the HIS-tag of that protein. Why the 
changes, specifically to the amino acids, occur in the metabolomics dataset is unclear.   
132.053 10.669 C4H8N2O3 6 L-Asparagine 0.32 1.00
105.043 10.983 C3H7NO3 3 L-Serine 0.31 1.00
87.032 10.535 C3H5NO2 3 2-Aminoacrylate 0.31 1.00
149.051 9.102 C5H11NO2S 5 L-Methionine 0.28 1.00
174.112 18.361 C6H14N4O2 2 L-Arginine 0.27 1.00
175.096 10.983 C6H13N3O3 3 L-Citrulline 0.26 1.00
246.133 10.931 C9H18N4O4 2 N2-(D-1-Carboxyethyl)-L-arginine 0.23 1.00
132.090 10.962 C5H12N2O2 6 (2R,4S)-2,4-Diaminopentanoate 0.17 1.00
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3.3. Discussion 
The use of metabolomics for enzyme function identification is well documented, with this 
application used in multiple studies (de Carvalho et al., 2010; Larrouy-Maumus et al., 
2013; Liscombe et al., 2010; Saito et al., 2006, 2009). However, in this project, I tried to 
apply this method to a variety of putatative enzymes to investigate its use in a high 
throughput approach for genome wide annotations and to establish a workflow to do so. 
The focus was put on protein over expression, purification and assay optimisation. For 
cloning a ligase independent cloning system was used to cut down on time spent. 
Although, the use of Xa/LIC cloning system seemed initially more expensive, the time 
saved and the benefit of not having to use restriction enzymes made this approach more 
suitable. Protein over expression was performed in E. coli Rosetta (DE3) or Rosetta (DE3) 
pLysS, due to the speed and low cost of this system. As a lot of proteins could not be over 
expressed, for future work the use of trypanosomatids over expression systems is worth to 
be considered for proteins that cannot be obtained using E. coli. Protein purification was 
optimised by changing from Ni-NTA Spin Columns (Qiagen) to Poros MC20 column 
HPLC system. The quality of purified proteins was increased, which has to be considered 
as a vital part of this workflow. A few changes were also made to the assay as it was 
originally used in our lab (E. Kerhoven, thesis). The concentration of MOPS buffer was 
lowered from 40mM to 10mM, as MOPS was seen to block the ZIC-pHILIC column used 
(K. Burgess, Glasgow Polyomics). The change of concentration did not seem to affect the 
enzyme assays, although it was not directly tested, the results obtained from S-
adenosylmethionine synthetase were performed in 10mM MOPS. A second extraction step 
was included, which increased the quality of the obtained dataset slightly. Data analysis 
was solely performed using IDEOM, as the obtained datasets were very complex, normally 
with around 1,000 putatively identified metabolites. The use of IDEOM showed to make 
those datasets manageable and easy to screen for changes in the dataset. The identified 
enzyme functions in this study, two commercial enzymes and a putative S-
adenosylmethionine synthetase, showed the most significant changes in the metabolomics 
dataset straight away, although data still needed investigation, as the changes did not 
always immediately show the ‘correct’ metabolite identification. 
 
Besides the S-adenosylmethionine synthetase, were the function could be shown, six 
additional enzymes were investigated.  Four of them showed no significant changes in the 
datasets. For deoxyhypusine synthase it was recently shown that this enzyme’s activity is 
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regulated by a catalytically dead paralogue (Ngyuen et al., 2013), which might explain why 
no changes were seen. 
 
Deoxyribose-phosphate aldolase and aldo/keto reductase also showed no significant 
changes in the dataset. RNAi lines were created to further investigate their function, but the 
knock down achieved was only 10% and 40% respectively, so no metabolomics 
experiments were performed. The putative aspartate carbamoyltransferase showed no 
significant changes in the sample set with the in vitro assay approach. However, the RNAi 
line created showed growth defect by 70% knock down. Metabolomics analysis showed 
decreasing levels in UDP and uracil and increasing levels in L-glutamate (Figure 3.27) 
indicating that the enzyme is involved in the biosynthesis of pyrimidines. 
 
The putative NAD synthase and citrate synthase need further investigation. Changes were 
seen in the obtained metabolomic datasets. However, a definite function could not be 
assigned to them. 
 
The created workflow in this project took 7 days to complete for one protein, starting with 
PCR for cloning and finishing with samples for LC-MS analysis. Although two proteins 
could be prepared at the same time, the need for the Poros MC20 column HPLC system 
slows protein purification down as proteins cannot be purified at the same time (as was 
possible with the Ni-NTA Spin Columns). As purified proteins were used immediately 
after preparation two in vitro assays could be performed per week.  
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Chapter 4 
4.1 Introduction 
Metabolomics has proven to be an excellent tool for quantitative and qualitative analysis of 
low molecular weight metabolites and their interaction within a living cell (Dunn et al., 
2011). Areas of research which have benefited from this approach include drug 
development, biomarker discovery and the exploration of new metabolic pathways. Whilst 
many metabolites can be easily identified, suggesting which pathways may be active, 
direct proof of this is missing. One possible method to circumvent this problem has been to 
combine an untargeted metabolomic approach with stable isotope labelling. This 
method has successfully been employed to study metabolic pathways in trypanosomes 
(Creek et al., 2012c); providing not only a snapshot of cellular metabolism, but also 
of direct pathway identifications by tracing labelled compounds. 
 
Trypanosomes have different life stages and can adapt quickly to changes in their 
environment. Procyclic trypanosomes utilise L-proline instead of D–glucose as an energy 
source, as their environment in the mid-gut of the tsetse fly provides amino acids more 
readily (Bursell, 1963). The glucose metabolism has been very well studied in bloodstream 
form and procyclic trypanosomes and Creek et al (2015) have recently provided an 
extended form of glucose metabolism in bloodstream form trypanosomes by combining 
stable isotope labelling with metabolomics. It was shown that glucose enters many 
branches of metabolic pathways, including for example polyamine biosynthesis (via 
glucose labelled ATP, which enters the methionine cycle), succinate fermentation pathway 
(forming malate, fumerate and succinate) and nucleotide synthesis (via ribose phosphate). 
 
In this chapter the metabolic pathways of L-methionine, L-proline and L-arginine are 
investigated using stable isoptope labelling combined with metabolomics to investigate 
their distribution within trypanosomes. 
 
L-methionine was thought to be salvaged from methylthioadenosine (MTA) via the MTA 
cycle in trypanosomes (Berger et al., 1996); however, the absence of labelled L-methionine 
from glucose (Creek et al., 2015) indicates the lack of an active MTA cycle. Data obtained 
from U-
13
C glucose showed 3-C labelled succinate and malate, which is consistent with 
their production via the succinate fermentation pathway. However, a significant amount of 
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malate and succinate were not labelled from glucose. Further experiments using U-
13
C L-
glutamine showed the labelling of malate and succinate from L-glutamine, contributing to 
the intracellular presence of those metabolites. L-proline could also contribute to the 
production of malate and succinate, but so far the use of L-proline for metabolic purposes 
was only shown for procyclic trypanosomes.  
 
Another well studied pathway is the biosynthesis of polyamines in trypanosome. L-
ornithine and putrescine are important precursors leading to the production of 
trypanothione, the main thiol in trypanosomes (Fairlamb et al., 1985). In fact, inhibition of 
the enzymes ornithine decarboxylase, which catalyses the conversion of L-ornithine to 
putrescine, by the drug eflornithine, leads to cell death (Fairlamb et al., 1989; Vincent et 
al., 2012). The classical route for biosynthesis of L-ornithine is via L-arginine and is 
catalysed by the enzyme arginase. Previous work has shown that arginase activity is absent 
in bloodstream form trypanosomes (Hai et al., 2014), but also indicated that L-ornithine 
can still be produced from L-arginine (I. Vincent, thesis). To investigate the L-arginine 
metabolism in bloodstream form trypanosomes U-
13
C L-arginine was used. 
 
4.1.1. L-methionine 
The sulfur containing amino acids L-methionine and L-cysteine play an important role in 
protein synthesis, methylation processes in the cell (L-methionine only) and biosynthesis 
of polyamines and glutathione. The importance and role of these two compounds has been 
widely discussed in several reviews for trypanosomes and other organisms (Nozaki et al., 
2005; Stipanuk, 2004; Walker and Barrett, 1997; Willert and Phillips, 2012). Not only does 
L-methionine play a vital role in cell survival, but the polyamine pathway has also been in 
research focus, due to the unique features it possesses in trypanosomes that can be useful 
for drug development against trypanosomiasis. Eflornithine, one of the drugs currently in 
use against this deadly disease, is known to inhibit the biosynthesis of polyamine pathway 
and causes cell death of the parasites (Yarlett and Bacchi, 1988; Vincent et al., 2012). In 
this chapter, I explore the metabolism of L-methionine in T. brucei, using U-
13
C L-
methionine and metabolomics. 
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4.1.1.1. Protein synthesis 
L-methionine is the starting amino acid in protein synthesis. It also plays a vital role in the 
active site of proteins as, due to its sulphur atom, it is easily oxidised (L-methionine to 
methionine sulfoxide), but does not seem to have the same importance to structure and 
stability as L-cysteine, whose highly reactive thiol-group has a big impact on structure and 
stability of proteins (Nozaki et al, 2005).  
4.1.1.2. Methylation processes and methionine cycle 
The L-methionine intermediate S-adenosylmethionine is an important methyl donor in 
many methylation processes of the cell. Binding of an adenosyl-group from ATP to the 
sulphur in L-methionine puts a positive charge to the sulphur and activates the methyl-
group to be reactive with other compounds. It is estimated that about 95% of the acquired 
S-adenosylmethionine pool gets used for methylation processes in the cells, at least in 
mammals (Walker and Barrett, 1997). For trypanosomes the estimated figure is 90% 
(Bacchi and Yarlett, 1993). The resulting S-adenosylhomocysteine is toxic to cells, so is 
quickly being converted to L-homocysteine (see Figure 4.1, reaction 3). L-homocysteine 
can be converted back to L-methionine (see Figure 4.1, reaction 4) and therefore 
concluding the methionine cycle. An alternative route for L-homocysteine is the 
transulfuration pathway, where it is being converted to cystathionine and further to L-
cysteine (Figure 4.1, reaction 5 and 8). 
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Figure 4.1: Methionine cycle as adapted from metacyc.org. This represents the parasitic protozoan 
pathway as described by Walker and Barrett (1997) Key to enzymes:  1- S-adenosylmethionine synthetase; 2-
various methyltransferase; 3- S-adenosylhomo-cysteine hydrolase; 4- 5’-Methyltetra-
hydrofolate:homocysteine methyltransferase (methionine synthase). For reaction 4 a different enzyme is 
indicated for mammalian host (Betaine:homocysteine methyltransferase, EC 2.1.1.5). Reaction involves L-
homocysteine and betaine to form L-methionine and dimethylglycine. This enzyme is supposedly absent in 
trypanosomes.  5- Cystathione β-synthase (EC 4.2.1.22), 6/8-γ-Cystathionase (EC 4.4.1.1), 7- spontaneous 
reaction 
 
In T. brucei strain 927, a gene annotated as encoding for S-adenosylmethionine synthase 
exists in multiple copies. S-adenosylmethionine synthase activity has been shown to be 
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present in trypanosome extracts (Bacchi and Yarlett, 1993) and results from an in vitro 
assay using metabolite profiling on a recombinant S-adenosylmethionine synthase 
expressed from E. coli confirms the presence of this enzyme in trypanosomes (see chapter 
3.2.3.1). When S-adenosylmethionine gets converted to S-adenosylhomocysteine various 
methyltransferases play a role in this reaction. A search in the trypanosome database 
TritrypDP (version 8.1) reveals 41 genes annotated as methyltransferases, some of them 
putative. S-adenosylhomocysteine to L-homocysteine is being catalysed by S-
adenosylhomocysteine hydrolase (or adenosylhomocysteinase (EC 3.3.1.1)). The 
trypanosome genome contains one gene that has been putatively identified as S-
adenosylhomocysteine hydrolase (Tb927.11.9590). This is the second branchpoint in the 
methionine cycle, as L-homocysteine can be converted back to L-methionine or into L-
cystathionine. To convert L-homocysteine back to L-methionine, two genes have been 
putatively identified in T. brucei strain 927 to catalyse this reaction.  
(1) Homocysteine S-methyltransferase (EC 2.1.1.10, Tb927.1.1270). This enzyme transfers 
a methyl-group from S-adenosylmethionine to L-homocysteine.  
(2) 5’-Methyltetra-hydrofolate:homocysteine methyltransferase (EC 2.1.1.14, 
Tb927.8.2610), as shown in Figure 4.1.) transfers a methyl-group from 5’-
methyltetrahydropteroyl tri-L-glutamate to form L-methionine from L-homocysteine. 
L-homocysteine can be converted to cystathione by cystathionine β-synthase. This 
pathway belongs to the biosynthesis of L-cysteine, where L-cysteine can be produced from 
L-cystathione by γ-cystathionase. 
 
4.1.1.3. Biosynthesis of polyamines 
S-adenosylmethionine can be converted into S-adenosyl-5’-deoxy-3’,5’-methylthio-
adenosine (decarboxylated S-adenosylmethionine, dSAM) by S-adenosylmethionine 
decarboxylase  (AdoMet decarboxylase) (Figure 4.2). This is where L-methionine enters 
the biosynthesis of polyamines. In comparison to the mammalian AdoMet decarboxylase, 
the trypanosome enzyme is only weakly activated by putrescine (Bitonti et al., 1986), but it 
is activated by dimerization with an inactive paralogue (Prozyme) of the active AdoMet 
decarboxylase (Pegg, 2009; Willert and Phillips, 2012). Decarboxylated S-
adenosylmethionine gets converted to 5-methylthio-adenosine and spermidine by 
spermidine synthase (Figure 4.3) 
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Figure 4.2: Methionine entering the biosynthesis of polyamines. S-adenosylmethionine gets converted to 
decarboxylated S-adenosylmethionine by SAM decarboxylase (1) 
 
 
Figure 4.3: dSAM and putrescine get converted to spermidine and S-methyl-5’-adenosine by 
Spermidine synthase (EC 2.5.1.16) (1). Spermidine is being utilised further in the synthesis of polyamines, 
while S-methyl-5’-adenosine is entering the L-methionine salvage pathway (MTA or Yang cycle). 
 
Spermidine is being further metabolised to the trypanosomatid specific trypanothione 
(Fairlamb, 1989), which is essential to those parasites by protecting them from oxidative 
stress. As seen in Figure 4.4, spermidine and glutathione form glutathionylspermidine, this 
reaction is catalysed by glutathionylspermidine synthase (EC 6.3.1.8).  
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Figure 4.4: Formation of glutathionylspermidine from spermidine and glutathione, as adapted from 
metacyc.org. 1- Glutathionylspermidine synthetase (EC 6.3.1.8) 
 
Trypanothione is formed by adding an additional glutathione to glutathionylspermidine, 
catalysed by trypanothione synthase (EC 6.3.1.9) as seen in Figure 4.5. Both trypanothione 
synthase and glutathionylspermidine synthase require ATP.  
 
Figure 4.5: Last step in biosynthesis of trypanothione. Glutathionylspermidine and glutathione form 
trypanothione, reaction adpted from metacyc.org. 1- Trypanothione synthase (EC 6.3.1.9).  
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4.1.1.5. Methiolthioadenosine or Yang cycle 
The methylthioadenosine (MTA) or Yang cycle is an L-methionine salvage pathway. Over 
seven steps the cell toxic product methylthioadenosine can be converted back to L-
methionine (see Figure 4.6). Aspartate aminotransferase has been identified as the amino 
group donor of the final step in this pathway (2-oxo-4-methylthiobutyrate to L-methionine) 
for trypanosomes (Berger et al., 2001). 
 
Figure 4.6: methylthioadenosine (MTA) or Yang cycle as adapted from metacyc.org. Enzyme key: 1-S-
adenosylmethionine synthetase, 2-SAM decarboxylase, 3-spermidine synthase, 4-methylthioadenosine 
nucleosidase, 5- methylthioribose kinase, 6- methylthioadenosine phosphorylase, 7- 5-methylthioribose-1-
phosphate isomerase, 8- 5-methylthioribulose-1-phosphate dehydratase, 9- 2,3-diketo-5-methylthio-1-
phosphopentane enolase, 10-2-hydroxy-3-keto-5-methylthio-phosphopentene phosphatase, 11- acireductone 
dioxygenase, 12 – methionine oxo-acid transaminase (metacyc). Expected carbon contribution from L-
methionine throughout this cycle is indicated by a red dot. 
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4.1.2. L-arginine metabolism 
L-arginine is reportedly involved in several metabolic pathways in trypanosomatids 
(Pereira, 2014). 
 Urea cycle 
L-arginine gives an amidino group to form urea. Catalysed by the enzyme arginase, 
L-arginine is converted to L-ornithine and urea. Arginase is present in two isoforms 
in most mammals. Arginase I is primarily located in the liver and takes part in the 
urea cycle, while Arginase II is located in the mitochondria and regulates L-
arginine and L-ornithine concentration within the cell (Morris, 2002). Arginase is 
known to be present in Leishmania parasites, but does not seem to be present in T. 
brucei. 
 Polyamine biosynthesis 
L-ornithine is converted to putrescine which is the starting diamine in the 
biosynthesis of the polyamines spermidine and trypanothione (Fairlamb et al., 
1985; Tabor and Tabor, 1984). 
 Alternative pathway for L-proline biosynthesis 
L-proline can be synthesised via L-ornithine and L-glutamate 5-semialdehyde (Hird 
et al., 1983) 
 Phosphagen synthesis 
L-arginine transfers an amidino group to an amino acceptor, forming guanidine 
derivates (Hird, 1986). Those phosphagens can be used for energy storage. Studies 
on T. cruzi and T. brucei have shown that arginine phosphates are important for 
energy storage and at least in the case of T. cruzi can protect the parasite against 
oxidative stress (Pereira, 2014) 
 Nitric oxide synthesis 
L-arginine is the precursor for the production of nitric oxide by nitric oxide 
synthase (NOS). NOS and arginase compete for L-arginine pools. 
 
4.1.2.1. Urea cycle and polyamine synthesis from L-arginine 
Previous studies from I. Vincent (University of Glasgow, thesis) have shown that arginase, 
the classical enzyme to produce L-ornithine from L-arginine, seems to be absent from T. 
brucei. Metabolomic studies using recombinant ‘arginase’ from T. brucei (Chapter 3) and 
an arginase knockout line (Hai et al., 2014) has shown no arginase activity. 
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Although it was evident that L-ornithine could be produced from L-arginine, it is unlikely 
that L-ornithine biosynthesis happens via arginase as no urea could be detected in 
bloodstream form trypanosomes cell extract using a commercial arginase detection kit 
(Vincent, thesis). That would lead to the conclusion that Ornithine is produced via a 
different pathway than the arginase route, but speculation that the urea cycle could be 
operative in bloodstream form trypanosomes in reverse direction (Arginine – Citrulline – 
Ornithine) could not be proven.  
 
Figure 4.7: Predicted metabolites involved in the biosynthesis and degradation of L-ornithine. Carbons 
transferred between metabolites, originating from L-arginine, are highlighted in red. Enzymes involved in 
those reactions are shown in italic. * Two enzymatic steps are shown in Figure 4.4 and 4.5. 
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4.1.2.2. Phosphagens from L-arginine 
Phosphoarginine has been shown to be an important phosphagen in many organisms and 
has been studied in T. cruzi where it has shown to protect the cells from oxidative stress 
(Miranda et al., 2006). T. brucei genome encodes for three arginine kinases, TbAK1-3, 
each of the isoforms is found in a specific subcellular compartment. TbAK1 is only present 
in the flagellum, while TbAK2 and TbAK3 in the glycosome and cytosol respectively 
(Voncken et al., 2013). When oxidative stress is induced in T. cruzi, levels of 
Phosphoarginine increase (Pereira, 2014). However, when a similar experiment was 
performed in T. brucei, this was not confirmed and arginine kinase knock out lines showed 
that they are not essential in T. brucei (D H Kim, unpublished data). 
 
4.1.3. L-proline 
In procyclic trypanosomes L-proline can be utilised as main carbon source for the energy 
metabolism when glucose supply is limited in the insect host (Bursell, 1963). It has been 
shown that procyclics can switch their energy metabolism regarding ATP production very 
quickly between substrate phosphorylation (D-glucose) and oxidative phosphorylation (L-
proline) and reverse when nutrition supply is changed (Coustou et al., 2008). However, in 
bloodstream form trypanosomes L-proline has not been indicated for the use in energy 
metabolism, as parasites in the bloodstream depend on the uptake of D-glucose and 
glycolysis for ATP production (Bringaud et al., 2006). The classical TCA cycle does not 
seem to be functional in trypanosomes, but part of this cycle seem to be operative 
nonetheless (van Weelden et al., 2005). L- Proline enters the TCA cycle in proline 
degradation (van Hellemond et al., 2005), with succinate and acetate being the endproducts 
(Van Weelden et al., 2005). Tracking 
13
C labelled glucose in bloodstream form 
trypanosomes also revealed malate, succinate and fumarate being labelled (Creek et al, 
2015). Malate, succinate and fumarate were also labelled from L-glutamine (DH Kim and 
F Achcar, unpublished), however, glucose and L-glutamine combined still did not account 
for the three compounds labelled. But could L-proline in bloodstream form trypanosomes 
also contribute to the production of succinate, fumarate and malate as in procyclics?  
L-proline enters the cell and gets converted to (S) 1-pyrroline-5-carboxylate by proline 
dehydrogenase. (S) 1-pyrroline-5-carboxylate forms L-glutamate-5-semialdehyde in a 
spontaneous reaction and gets further converted to L-glutamate by 1-pyrroline-5-
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carboxylase. L-glutamate enters the TCA cycle by being converted to 2-ketoglutarate, a 
reaction catalysed by glutamate dehydrogenase. 2-ketoglutarate is transformed to succinyl-
CoA and further to succinate, fumarate and malate.  
 
L-glutamate can also be involved in the biosynthesis of L-arginine, via N-acetyl-L- 
glutamate, N-acetyl-L-ornithine, L-ornithine, Citrulline, L-arginino-succinate and lastly L-
arginine. However, the above mentioned dataset from trypanosome cultures incubated with 
13
C-glutamate did not show any labelled L-arginine from L-glutamate. Vincent (thesis) 
also showed no labelling of L-arginine or L-ornithine occurring from L-proline when cells 
were incubated with 
15
N-Proline. This concludes that L-proline does not seem to play a 
part in L-arginine or L-ornithine biosynthesis. To fully investigate if bloodstream form 
trypanosomes utilise L-proline for metabolic purposes, cells were cultured and incubated 
for 48h with 
13
C-labelled L-proline. 
 
 
  
97 
 
4.2. Results 
Metabolomics with uniformly 
13
C-labelled compounds was used to study the metabolic 
pathways of L-methionine, L-arginine and L-proline in the bloodstream form T. brucei. 
Experimental design, as described in methods 2.4.2. and 2.4.3., involved adding 50 % U-
13
C L-methionine (50µM final concentration) and 100%  U-
13
C L-arginine or L-proline (at 
a final convcentration of 200 µM) to the culture medium (CMM + 10% FBS gold). 
Cultured T. brucei strain 427 were incubated for 48 hours in the presence of the labelled 
compounds, with a starting concentration of 2 x 10
4
 cells ml
-1
. After 48 hours, cells were 
cooled down rapidly to 0°C by placing the falcon tube in dry ice / ethanol bath and cells 
were collected by slow centrifugation (to avoid cell lysis). Cell pellets were resuspended in 
extraction solvent (Chloroform Methanol Water, 1:3:1) and metabolites analysed by LC-
MS (ZIC-pHILIC). Data analysis was achieved using mzMatch and mzMatch.ISO, using 
authentic standards and KEGG database for metabolite identification. 
 
 
4.2.1. Global L-methionine metabolism  
In total 17 labelled metabolites were detected in this dataset, belonging to the methionine 
cycle, L-cysteine and polyamine biosynthesis and the MTA or Yang cycle. Six metabolites 
seem to be a product of methylating processes from S-adenosyl-L-methionine and are 
shown in 4.2.6, the other metabolites were mapped into global metabolite map (Figure 
4.8). Some intermediate metabolites belonging to the pathways were not detected, but were 
mapped nonetheless to give a better understanding of the L-methionine metabolism in the 
bloodstream form trypanosomes.  
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Figure 4.8: Overview of metabolites labelled from 13C L-methionine in bloodstream form 
trypanosomes. This basic metabolic network shows the metabolites mapped into their pathway (according to 
metacyc). Yellow nodes indicate 5 carbon labelling, orange nodes: 4 carbon labelling, green nodes: 3 carbon 
labelling, blue nodes one carbon labelling and none carbon labeeling is presented in grey nodes. Metabolites 
expected to be there but not detected are marked by white nodes. Met: L-methionine, SAM: S-adenosyl-L-
methionine, SAH: S-adenosyl-L-homocysteine, HCys: L-homocysteine, Cysta: Cystathionine, amb: (2Z)-
2aminobut-2-enoate, Cys: L-cysteine, dSAM: decarboxylated S-adenosyl-L-methionine, SPMD: Spermidine, 
Glu-thio-SPMD: glutathionyl-spermidine, MTA:5’-methylthioadenosine, MTR: 5’-methylthioribose, MTR-
P: 5’-methylthioribose-1-phosphate, MTRRibu-P: 5’-methylthioribulose-1-phosphate,  P-diketo-mt-pen: 1-
Phospho-2,3-diketo-5’-methylthiopentane, H-mt-oxopent-P: 2-hydroxy-5-(methylthio)-3-oxopent-1-enyl 
phosphate, dih-mt-pent-1-en-3-one: 1,2-dihydroxy-5-(methylthio)pent-1-en-3-one, MTOB: 2-oxo-4-
methylthiobutyrate. 
 
4.2.1.1. Methionine cycle and L-cysteine biosynthesis 
L-methionine was added to cultured BSF trypanosomes in a 50% mixture of 
12
C and U-
13
C-L-methionine for 48 h. The intracellular L-methionine content was approximately 
35%. In fresh CMM this amount was about 30%. Although, the added L-methionine to the 
media was 50% labelled/unlabelled, the added FBS gold seems to dilute the L-methionine 
concentration in the fresh media. From the four metabolites that make the methionine cycle 
only three were detected in this dataset (Figure 4.9). 
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Figure 4.9: Labelling trend of the first three metabolites of the methionine cycle. (a) L-methionine, 5-C 
labelled in fresh media with 50% added U-
13
C L-methionine, trypanosome cell extract and spent media; (b) 
S-adenosylmethionine, detected in cell extract, 5-C labelled in cell extract from 50% U- 
13
C L-methionine 
culture; (c) S-adeosylhomocysteine, 4-C labelled in trypanosome extract incubated in CMM with 50% U-
13
C 
L-methionine. CMM: Fresh medium sample, Extract: Trypanosome cell extract and Spent: Spent medium 
analysis. Numbers indicate samples with and without 
13
C L-methionine (1 with 
13
C compound, 2 
without).Orange equals 5-C labelled, brown 4-C labelled and blue 1-C labelled carbons. As natural 
abundance of 
13
C occurs, when 1-C is detected it needs to be compared to the unlabelled control.  
 
As shown in Figure 4.10 formation of S-adenosylmethionine could be detected from L-
methionine, with the labelling pattern as expected (5-C). S-adenosylmethionine to S-
adenosylhomocysteine showed a resulting labelling pattern of 4-C for S-
adenosylhomocysteine. Methylated compounds were also detected and are shown in 
4.2.1.4. Conversion of S-adeosylhomocysteine to homocysteine would show a labelling of 
4-C, however L-homocysteine was not detected (the authentic standard was also not 
detected). The formation of L-methionine from L-homocysteine could not be detected. 
Although 4-C labelled L-methionine was detected in the cellular metabolome, it was only 
shown in small amounts with a very similar percentage of 4-C labelled methionine in the 
fresh culture medium. Therefore, it seems that the 4-C labelled L-methionine originates 
from a small fraction of 4-
13
C present in the supplied U-
13
C L-methionine. Therefore it 
seems unlikely that the full methionine cycle is active in cultured bloodstream form 
trypanosomes or just with a very low flux, when large quantities of methionine are 
presented to the cell. Cysteine biosynthesis can occur from L-homocysteine, which has 
been produced from L-methionine via the methionine cycle. L-homocysteine and L-serine 
form L-cystathionine (catalysed by cystathionine β-synthase), which can be transformed to 
L-cysteine and (2Z)-2-aminobut-2-enoate by cystathionine γ-lyase. L-homocysteine would 
be expected to show a 4-C labelling pattern. L-cystathionine did show a 4-C labelling 
pattern expected when labelling occurs from L-homocysteine. As L-cysteine only gets the 
sulphur-group from L-cystathionine, I cannot say for certain if L-cysteine is being 
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produced from L-methionine. However, a peak was detected and putatively annotated as 2-
aminobut-2-enoate which shows the expected labelling pattern from this reaction. It was 
shown by (Bacchi et al., 1995) that when 
35
S-methionine was added to culture medium the 
35
S-label shows up in L-cysteine, confirming that this pathway is active in T. brucei.  
 
Figure 4.10: Methionine cycle and L-cysteine biosynthesis in trypanosomes as seen from labelling data. 
Expected labelled carbons are shown in red and when compound was detected in the dataset, labelling pattern 
is shown next to the structure. Orange equals 5-C labelled, brown 4-C labelled and blue 1-C labelled carbons. 
As natural abundance of 
13
C occurs, when 1-C is detected it needs to be compared to the unlabelled control. 
Key to enzymes:  1- S-adenosylmethionine synthetase; 2-various methyltransferase; 3- S-adenosylhomo-
cysteine hydrolase; 4- 5’-Methyltetra-hydrofolate:homocysteine methyltransferase (methionine synthase). 5- 
Cystathione β-synthase (EC 4.2.1.22), 6/8-γ-Cystathionase (EC 4.4.1.1), 7- spontaneous reaction. 
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4.2.1.2. Polyamine biosynthesis 
The conversion of S-adenosylmethionine to decarboxylated S-adeosylmethionine (dSAM) 
is the first step in the synthesis of polyamines from L-methionine.  dSAM was not detected 
in this dataset. dSAM and putrescine get converted to spermidine. However, spermidine 
does not retain well on ZIC-pHILIC columns. As seen with the authentic standard of 
spermidine (see Figure 4.11) no defined peak is detectable, but many over the time period 
of about 7 to 20 min. Therefore, no identification of the compound spermidine can be 
made for analysis.  
 
Figure 4.11: Spermidine from authentic standard mix on ZIC-pHILIC column.  
 
The only metabolite detected in this pathway was trypanothione disulfide, which was 3-C 
labelled from methionine. As seen in Figure 4.12 , the detected labelling pattern for 
trypanothione is shown to be 1-C, 3-C and 4-C labelled. The detected 4-C labelled is most 
likely an artefact from the 3-C originating from L-methionine and the natural occurring 1-
13
C.  
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Figure 4.12: Polyamine biosynthesis from L-methionine. dSAM and putrescine are converted to 
spermidine and S-methyl-5’-adenosine by 1- Spermidine synthase (EC 2.5.1.16). Spermidine is utilised 
further in the synthesis of polyamines, while S-methyl-5’-adenosine enters the L-methionine salvage pathway 
(Yang cycle). Formation of glutathionylspermidine from spermidine and glutathione is catalysed by 2- 
Glutathionylspermidine synthetase (EC 6.3.1.8).  Glutathionylspermidine and glutathione form 
trypanothione, catalysed by 3- Trypanothione synthase (EC 6.3.1.9). Expected labelled carbons are shown in 
red and when compound was detected in the dataset, labelling pattern is shown next to the structure. Brown 
equals 4-C labelled, green 3-C labelled and blue 1-C labelled carbons. 
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4.2.1.3. Recycling of methionine  
It has been previously described in trypanosomes that methionine can be salvaged via the 
methylthioadenosine (MTA) pathway (Berger et al., 1996; Nozaki et al., 2005). S-methyl-
5-thioadenosine (1-C labelled from L-methionine) being converted back to L-methionine, 
going through a seven step pathway including 5’-methylthioribose-phosphate, 5’-
methylthioribulose-1-phosphate, 1-phospho-2.3-diketo 5’-methylthiopentane and 2-oxo-4-
methylthiobutyrate (see Figure 4.14.). However, in this labelling data only the 
intermediates S-methyl-5-thioadenosine and methylthioribose are being labelled. L-
methionine was detected in 1-C labelled form. However, that seems to be attributed to the 
normal natural abundance detection. Figure 4.9 (a) shows the detected L-methionine plus 
labelling pattern and there is no increase in 1-C labelled L-methionine between cells 
incubated in media with and without 13-C labelled L-methionine.  
  
Analysis of spent media from bloodstream form trypanosomes have shown, that 
methylthioribose seems to be secreted from the cells after 48 hours (D. H. Kim and F. 
Achcar, unpublished data). Methylthioribose was also detected in spent media during this 
experiment, however, only one replicate of spent media was analysed and the peak was ill-
defined. Nonetheless, together with the spent media analysis (Figure 4.13) data from Kim 
and Achcar it seems plausible that 5’-methylthioribose gets secreted from bloodstream 
form trypanosomes when L-methionine is highly abundant in the culture medium.  
 
Figure 4.13: Spent media analysis (performed by D. H. Kim and F. Achcar), shows increasing levels of 
methylthioribose secreted from the cells, starting after 48h. Trypanosomes were grown in HMI-9 and 
CMM.  Figure kindly provided by F. Achcar 
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Creek et al. (2015) showed that when bloodstream form trypanosomes were incubated with 
13
C-labelled Glucose, S-adenosylmethionine got labelled from ATP and those labelled 
carbons were transferred to MTA. However, from that point onwards no labelled carbons 
were detected.  
 
Figure 4.14: Methionine salvage pathway via 5’Methylthioadenosine and 5’Methylthioribose. Enzyme 
key: 1-S-adenosylmethionine synthetase, 2-SAM decarboxylase, 3-spermidine synthase, 4-
methylthioadenosine nucleosidase, 5-methylthioadenosine phosphorylase, 6- 5-methylthioribose-1-phosphate 
isomerase, 7- 5-methylthioribulose-1-phosphate dehydratase, 8- 2,3-diketo-5-methylthio-1-phosphopentane 
enolase, 9-2-hydroxy-3-keto-5-methylthio-phosphopentene phosphatise, 10- transaminase. Expected labelled 
carbons are shown in red and when compound was detected in the dataset, labelling pattern is shown next to 
the structure. Red equals 6-C labelled, orange 5-C labelled and blue 1-C labelled carbons. 
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Berger et al (1996) reported that the last step in methionine production via methylthio-
adenosine takes place, converting 2-oxo-4-methylthiobutyrate into L-methionine. 
However, this is inconsistent with the conclusion of this experiment. A compound 
putatively annotated as 4-methylthio-2-oxobutanoate with 5-C labelling was detected in the 
13
C l-methionine dataset in cell extract and spent media samples. So it seems more likely 
that 2-oxo-4-methylthiobutyrate is being produced from L-methionine and secreted from 
the cell, rather than the MTA cycle being active and salvaging L-methionine from 
methylthioadenosine. However, 5’methylthioadenosine phosphorylase activity was 
measured in T.b. brucei crude extract (Ghoda et al., 1988) highlighting the presence of the 
methylthioadenosine pathway. A compound putatively identified as 1,2-dihydroxy-5-
(methylthio) pent-1-en-3-one was found 1-C labelled. This compound is described as an 
intermediate of the Yang cycle for L-methionine salvage and can either be a precursor to 4-
methylthio-2-oxobutanoate or 3-(methylthio)propanoate (Figure 4.15 (b)). This reaction 
has been described to happen in bacteria, and is thought to provide a mechanism for L-
methionine regulation in vivo (Dai et al., 2001). 
 
  (1)  (2) 
Figure 4.15: 1,2-Dihydroxy-5-(methylthio) pent-1-en-3-one (1) Detected peak for 1,2-dihydroxy-5-
(methylthio) pent-1-en-3-one. Although the peak is ill-defined, the 1-C labelling appears clear in cell extract 
grown in 50% U-
13
C L-methionine for 48 hours (a) and not in the cell extract lacking the U-
13
C L-methionine 
(b).  (2) Possible fate of 1,2-dihydroxy-5-(methylthio) pent-1-en-3-one in bloodstreamform trypanosomes. 3-
(methylthio)-propanoate was not detected. enzyme key: 1- acireductone dioxygenase. 
 
 
 
4.2.1.4. Methylated metabolites 
Six methylated compounds with 
13
C labelling were detected in this dataset. Labelled 
methylated amino acids with 1-C, 2-C and 3-C labelled and 1-C labelled methylguanine. 
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Various methyltransferases use S-adenosylmethionine as a methyl donor and their targets 
include tRNA, proteins, DNA and lipids. However, those compounds are too big to be 
analysed on this platform. 41 genes are annotated as putative methyltransferases in the 
published T. brucei genome and about 90% of the SAM produced in trypanosomes is 
thought to be used for methylation processes. However, as for this study the methylated 
products were seen as by-products of the metabolic pathways associated with L-
methionine, it was not further investigated. The six compounds were: 
N6,N6, dimethyl-L-arginine,  N6 methyl L-arginine, N6 methyl L-lysine, N6, N6, N6 
trimethyl L-lysine, N-methylhistidine and 7-methylguanine (see Figure 4.16) 
 
 
Figure 4.16: Methylated metabolites detected in trypanosome cellextract, incubated with (L) or 
without (U) 
13
-C L-methionine. 
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4.2.2. U- 
13
C - L-arginine metabolite tracking 
Trypanosomes can take up L-ornithine and L-arginine, but potentially the L-ornithine 
uptake could be sufficient enough for trypanothione synthesis (I. Vincent, PhD thesis, 
2011), which could explain the absence of an arginase in trypanosomes. However, as it 
was shown that L-arginine can be converted to L-ornithine, when L-ornithine was absent 
from the incubation medium (I Vincent, thesis) an alternative route for L-ornithine 
production from L-arginine could be present. To further probe the L-arginine metabolism 
in trypanosomes, U-
13
C-L-arginine was used in an untargeted metabolomic approach. 13 
labelled compounds were detected in U-
13
C labelled L-arginine dataset, six of which were 
related to the metabolites shown and mapped in Figure 4.7. 
 
4.2.2.1. Urea cycle – Biosynthesis of L-ornithine 
L-arginine was found 6-C labelled in fresh CMM (with 200µM U-
13
C L-arginine added), 
labelled cell extract, spent labelled CMM, but also in small amounts in unlabelled cell 
extracts. The most reasonable explanation for finding labelled L-arginine in unlabelled cell 
extract is sample contamination, either during sample preparation or sample carry-over on 
the LC-MS platform. After checking the sample running order on the LC-MS platform it 
was shown that unlabelled cell extract samples (three replicates) were run directly after 
samples containing labelled L-arginine. As the L-arginine peaks are the only peaks 
showing contamination it is likely that the relatively high concentration of L-arginine 
caused minimal contamination to show up in the datsaset, while possible other 
contaminations were too low to show. L-ornithine was detected 5-C labelled from L-
arginine. It is unclear whether the reaction happened within the cells or in the medium. 
Spent media showed equally high amounts of L-ornithine 5-C labelled as cell extract, 
while fresh media only showed traces of 5-C labelled L-ornithine. However, since other 
metabolites labelled inside the cell do not show outside and the concentration of labelled 
L-ornithine was similar in cell extracts and in spent medium, it seems L-arginine converts 
to L-ornithine outside the cell by an arginase found in the added serum. A low percentage 
of 6-C labelled L-citrulline was detected in the labelled cell extract. This labelling pattern 
could only occur directly from L-arginine, as L-ornithine was 5-C labelled. The 
intermediate metabolite L-arginino-succinate was not detected in this dataset. N-acetyl-L-
ornithine and N-acetyl-L-glutamate 5-semialdehyde were detected as 5-C labelled from L-
arginine. They are pathway intermediates in the biosynthesis of L-ornithine from L-
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glutamate. L-glutamate was not labelled in this dataset so the pathway does not occur to be 
fully functional. The enzyme Acetylornithine deacetylase, which converts L-ornithine to 
N-acetyl-L-ornithine, has been putatively identified in the trypanosome genome. The 
labelling pattern for N-acetyl-L-glutamate 5-semialdehyde was ill-defined (see Figure 
4.17.). Furthermore, the enzyme Acetylornithine transaminase has not been reported to be 
present in T. brucei, so it is unclear if the detected labelling is indeed from N-acetyl-L-
glutamate 5-semialdehyde. Also, traces of labelled N-acetyl-L-glutamate 5-semialdehyde 
were detected in the cell extract from cultures without added 
13
C L-arginine.  
 
 
Figure 4.17: N-acetyl-L-glutamate 5-semialdehyde (a) Trend plot of 5-C labelled N-acetyl-L-glutamate 5-
semialdehyde in fresh and spent media (with added U-
13
C L-arginine) and labelled and unlabelled cell 
extract. Orange equals 5-C labelled and blue 1-C labelled carbons. As natural abundance of 
13
C occurs, when 
1-C is detected it needs to be compared to the unlabelled control. (b) Detected peaks from those samples.  
 
From L-ornithine, the production of trypanothione (4-C labelled) could be detected, 
although the intermediates putrescine, spermidine and glutathionylspermidine were not. 
However, putrescine, spermidine and glutathionylspermidine do not retain well on zic-
pHILIC columns. All the metabolites described here with their expected and actual 
labelling pattern are shown in Figure 4.18. 
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Figure 4.18: Predicted metabolites to be involved in L-ornithine biosynthesis and degradation (Urea 
cycle and polyamine biosynthesis included). Carbons labelled from L-arginine are highlighted in red and 
enzyme names are in italic. * Two enzymatic steps are shown in Figure 4.4 and 4.5. 
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4.2.2.2. Energy storage in T. brucei 
L-arginine phosphate (or phosphoarginine) is important for trypanosomes for energy 
storage. In this experiment phosphoarginine was found to be labelled from L-arginine at 
38% (see Figure 4.19), when about 45% labelled L-arginine was detected in fresh media 
and 40% labelled L-arginine within the cell. 
 
 
Figure 4.19: Detected peak of L-arginine phosphate, with a mass of 254.07 and retention time of: 11.08 
min. 
 
4.2.2.3. Other metabolites labelled from L-arginine  
 Methylarginine and dimethylarginine, both 6-C labelled from L-arginine, could 
have their origin from methylated proteins.  
A recent study highlights the importance of arginine methylated proteins. Five 
putative arginine methyltransferases in T. brucei genome have been described and 
proteomic analysis showed 167 arginine methylproteins which have a wide range 
of function, including metabolism, chaperoning, RNA processing, DNA 
replication, translation and function in transport. Some of those methylations are 
trypanosome specific, while others are conserved modifications (Fisk et al., 2013) 
 Ketoarginine, which has also been identified as 6-C labelled from L-arginine, could 
be a precursor for 3-methylarginine synthesis or L-arginine degradation. 
 N5-(L1-Carboxyethyl)-L-ornithine formed from L-ornithine and pyruvate. This 
compound was seen to be increased after cells were treated with Eflornithine 
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(Vincent et al., 2012). Additionally, N5-(L1-Carboxyethyl)-L-ornithine was also 
detected in U-
13
C labelled Glucose data (Creek et al.,2015). Although this is a 
metabolite known from bacteria, its function in trypanosomes is unknown (reaction, 
see Figure 4.20 (a)). 
 A metabolite with the mass of 173.069 and a retention time of 9.7 min, putatively 
identified as L-N2-(Carboxyethyl)-L-arginine (D-octopine). D-octopine plays a role 
in NAD/NADH regulation and is formed by D-octopine synthase using pyruvate 
and L-arginine (Figure 4.20 (b)). 
 
 
Figure 4.20: Labelling pattern and origin of carbons in reaction leading to (a) N5-(L1-Carboxyethyl)-
L-ornithine and (b) D-ocyopine. (a) Enzyme catalysing the reaction from pyruvate and L-ornithine to N5-
(L-1-Carboxyethyl-) L-ornithine is N5-(carboxyethyl)ornithine synthase (EC1.5.1.24). (b) Synthesis of D-
octopine by octopine dehydrogenase (EC1.5.1.11) from pyruvate nd L-arginine. Blue dots indicate carbon 
originated from D-glucose (Creek et al, 2015) and red dots indicate carbons labelled from L-arginine. 
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4.2.3. U- 
13
C - L-proline metabolite tracking 
Although L-proline seems to be taken up by bloodstream form trypanosomes, the 
intracellular concentration of labelled L-proline was very low using 50% of labelled L-
proline (50 µM final concentration U-
13
C L-proline) in growth medium for 48 hours. 
Under those conditions downstream metabolites from L-proline were not labelled to a high 
enough percentage for analysis and therefore the experiment was repeated with 100% 
added labelled L-proline (200 µM U-
13
C L-proline). Recycling of L-proline from 
protein/peptide breakdown seems a plausible explanation for the dilution of labelled L-
proline within the cell and would also explain why the first experiment was not successful.  
 
Seven labelled compounds were detected in U-
13
C labelled L-proline dataset, all with 
relatively low percentage of labelling (except for L-proline). Figure 4.7 shows the detected 
meatbolites including the percentage of labelling. 
 
The results of this experiment conclude that except for protein synthesis, L-proline seems 
to be playing a minor role in the metabolism of bloodstream form trypanosomes.  
Trypanothione was detected to be 5-C labelled from L-proline, but only 1.2%. The 
pathway for this is shown in Figure 4.21 and the intermediates are (S)-1-pyrroline-5-
carboxylate and L-glutamate-5-semialdehyde (not detected), L-glutamate (0.5% labelled, 
 
 
Figure 4.21: Distribution of labelled carbons (C13) from L-proline (Fiona Achcar).        
Colours representing the number of carbons contributed from L-proline. Red: 5-C, green: 4-C, blue: 3-C and 
pink: 2C. Not detected compounds are (S)-1-pyrroline-5-carboxylate, L-glutamate-5-semialdehyde, 2-
oxoglutarate and Succinyl-CoA. 
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5-C) and Glutathione (0.2% labelled, 5-C). The detected labelling of trypanothione 
therefore results from L-glutamate and glutathione, rather than L-ornithine and putrescine. 
Other metabolites labelled were hydroxyglutarate (0.8%) and succinate and malate (0.8% 
4-C labelled both and 0.06% (succinate) and 0.09% (malate) 3-C labelled). 
 
  
114 
 
4.3. Discussion 
4.3.1. L-methionine 
Here, the sulphur containing amino acid L-methionine and its metabolism in T. brucei was 
investigated, with the focus on the methionine cycle, polyamine biosynthesis and the MTA 
cycle. 
 
The methionine cycle shows three out of the four metabolites present. Although L-
homocysteine was not detected, due to downstream metabolites being present 
(cystathionine) it only seems plausible that it would be 4-C labelled. Interestingly, the 
methionine cycle does not seem to be a cycle at all as the lack of 4C-labelled methionine 
indicates that L-homocysteine is not being converted back to L-methionine. This 
contradicts previous published material that L-homocysteine can be converted back to L-
methionine (Walker and Barrett, 1997). It seems more likely that L-homocysteine gets 
converted to L-cysteine, over cystathionine (which showed 4-C labelling), in agreement 
with Bacchi et al (1995), who could show, with 
35
S-labelled L-methionine, the reverse 
transulfation pathway being present in trypanosomes. The trypanosome specific polyamine 
thiol conjugate trypanothione was detected as being 3-C labelled from L-methionine. 
Unfortunately, no intermediate metabolite in this pathway was detected (dSAM, 
spermidine, glutathionylspermidine). However, methylthioadenosine (a byproduct of 
spermidine synthesis from dSAM and putrescine and starting point of the MTA cycle) was 
detected 1-C labelled. The production of methylthioribose was also detected in 
bloodstream form trypanosomes when incubated with 
13
C glucose (Creek et al, 2015) and 
here it was 5-C labelled from S-adenosylomethionine (via ribose and the resulted labelling 
of ATP), which confirms the finding in the methionine labelled dataset.However, the full 
functionality of the MAT cycle could not be confirmed in either dataset. The production of 
methylthioribose from methylathioadenosine was detected, with both compounds 1-C 
labelled from L-methionine. But, it looks like methylthioribose gets secreted from the cell 
and not converted to methylthioribose 1-phosphate. Although the intermediates in the 
MTA pathway, from 5’methylthioribose-5-phosphate to 2-hydropxy-5-(methylthio)-3-
oxopent-1-enyl phosphate, were not detected, the second last metabolite (1,2-dihydroxy-5-
(methylthio)pent-1en-3-one) was. The 1-C labelling suggests that the pathway is active, 
but after that point is unclear what happens. 2-oxo-4-methylthiobutanoate is not 1-C 
labelled as would be expected. Instead 2-oxo-4-methylthiobutanoate is 5-C labelled from 
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L-methionine and seems to be secreted from the cell. As it is the corresponding keto-acid 
and it has been shown that trypanosomes are capable of doing this reaction (Creek et al., 
2013). These results conflict with research from Berger et al (1996) and Bacchi et al 
(1991), who showed that T. brucei is capable of producing L-methionine from 2-oxo-4-
methylthiobutanoate, preferably from the transamination of aromatic amino acids (Berger 
et al., 1996; Berger et al., 2001). However, as shown in the presented dataset, under the 
conditions used, L-methionine does not seem to be recycled by either methionine cycle or 
MTA cycle, which is consistent with findings from U-
13
C glucose labelling (Creek et al., 
2015). 
 
4.3.2. L-arginine 
L-ornithine is an important precursor for the synthesis of the diamine putrescine in T. 
brucei. Putrescine is involved in the synthesis of spermidine, which can be synthesised, 
with glutathione, to the trypanosome specific thiol trypanothione (Fairlamb and Cerami, 
1992). Vincent et al (2011) also found the metabolite N-acetyl-L-ornithine being increased 
after bloodstream form trypanosomes were treated with Eflornithine. N-acetyl-L-ornithine 
is the precursor of L-ornithine in the biosynthesis of L-ornithine from L-glutamate. 
Tracking metabolites using stable isotope labelling has been successfully applied before, 
most recently with 13C-labelled glucose in bloodstream form trypanosomes, resulting in a 
much better understanding of the glucose metabolism (Creek et al., 2015). It has been 
reported that bloodstream form trypanosomes can convert L-arginine into L-ornithine, 
however without the production of urea (Vincent, thesis). Using 
13
C L-arginine for 
metabolite tracking could lead to the identification of a different pathway for L-ornithine 
biosynthesis is active in bloodstream T. brucei that excludes the most direct route via 
‘arginase’.  
L-ornithine was detected as 5-C labelled from Arginine in this experiment (see 4.2.2.1). 
However, it seems that this conversion happens in the media. Possible bovine arginase 
activity in the media could explain the 5-C-labelled L-ornithine. Labelled L-ornithine was 
detected in spent media in similar high concentration (about 10%) as within the cell (about 
12%). Fresh media with added U-
13
C L-arginine only showed traces of 5-C Ornithine, 
however, this sample was prepared immediately after production and therefore the bovine 
arginase activity was stopped very quickly. As bloodstream form trypanosomes can take L-
ornithine up this seems the most reasonable explanation for the presence of 5-C-Ornithine 
within the cell. 
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Incubating U-
13
C L-arginine in cell free media with 10% FBS also showed 5-C labelled L-
ornithine after 48 hours (F. Giordani, data not shown), concluding it is most likely that L-
arginine gets converted to L-ornithine in the media by arginase activity from serum. 
However, L-citrulline has been detected as 6-C labelled, albeit at small levels. L-citrulline 
is part of the urea cycle, a precursor in L-arginine production from L-ornithine. It is 
possible that in bloodstream form trypanosomes the urea cycle is operative in the reverse 
direction; leading from L-arginine via L-citrulline to L-ornithine and this data could 
support this hypothesis.  L-citrulline was 6-C labelled, which could only occur from L-
arginine, not L-ornithine. The intermediate L-arginino-succinate was not detected in the 
dataset.  
 
L-arginine phosphate has been described to be of use in energy storage in trypanosomes, 
with three arginine kinases being described in the T. brucei genome.  
The main phosphagen for energy storage in vertebrates is creatine, but trypanosomes do 
not seem to encode a creatine kinase and use arginine phosphate instead (Canepa et al., 
2011). 
 
4.3.3. L-proline 
The percentage and labelling pattern from L-proline suggests that L-proline is only 
minimally involved in the synthesis of polyamines. The data shows that L-proline is not 
involved in the synthesis of L-ornithine, but rather transfers carbons via L-glutamate and 
glutathione to trypanothione. However, the low percentage of labelled compounds detected 
in labelled cells, imply that the main purpose for L-proline in bloodstream form 
trypanosomes is for protein synthesis.  
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Chapter 5 
5.1. Introduction 
The two described causative subspecies of HAT are T. b. rhodesiense (acute form) and T. 
b. gambiense (chronic form), with both forms present in the Central Nervous System 
(CNS) in the late stage of the disease. For T. b. brucei infections in mice, it has been shown 
that different strains of trypanosomes can manifest themselves as acute and chronic 
diseases as well. In this project, the T. b. brucei strains GVR35 (Jennings et al., 2002) and 
427 (Melville et al., 2000) were used, as GVR35 causes a chronic infection in mice and 
invades the CNS with varying parasitemia while 427 shows an acute infection with high 
parasitemia causing high mortality within days without invading the CNS (see 1.2.3). What 
causes this difference in the progression of infection? Secreted/excreted proteins from the 
parasites (secretome) have been described as being important factor for virulence and to 
avoid the host immune response (Geiger et al., 2010). Garzon et al. showed that 
excreted/secreted proteins can inhibit the maturation of dentritic cells and stop them from 
inducing a lymphocytic allogenic response (Garzón et al., 2013). Furthermore, secreted 
cysteine peptidases are thought to be an important factor in the crossing of the blood brain 
barrier (BBB). Analysing and comparing the secretome from both strains may therefore 
give an inside of what causes the difference in virulence between 427 and GVR35. 
 
Two approaches were used to determine the secretome of the two different T. b. brucei 
strains: (1) differential secreted proteins between the two strains were investigated by 
DiGE and (2) the whole set of secreted proteins for each strain using Filter Aided Sample 
Preparation (FASP) with in solution trypsin digest.  
 
 
5.2. Results 
Two strains of bloodstream form trypanosomes were grown up from stabilates. To keep the 
conditions for both strains the same, different media (HMI-9, CMM and modified HMI-9, 
see 2.1.1.) were tested for cell culture. Strain GVR35 was directly grown in modified HMI-
9 medium, while strain 427 was passaged once in HMI-9 before changed to modified 
medium or both strains were adapted to CMM + 10% FBS gold. However, strain GVR35 
did not grow in HMI-9 + 10% FBS gold. Adaption to the modified media took several 
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passages for strain 427 or strain GVR35 to adapt to CMM. To reach the desired cell count 
of 2x10
8 
(as described by Holzmueller et al., 2008) cell culture volumes were between 120 
- 150 ml for strain 427 and 150 - 170 ml for strain GVR35. Cell viability was checked 
using microscopic examination during incubation in serum-free modified medium every 30 
min for two hours. Cell morphology looked normal in strain 427 and cells had good 
motility. Strain GVR35 showed cell clumps forming after 60 min, which suggests that cells 
were starting to die. After secretome sample preparation an aliquot of the sample was run 
on SDS-PAGE to ensure a detectable amount of protein was present. 
 
5.2.1. Sample preparation for DiGE 
For quantification purposes and to determine the strain specific differences in secreted 
proteins a gel-based proteomic approach was tested. 2D-DiGE is an excellent tool to 
compare different strains of pathogens. Samples are run on one gel, which minimises the 
chances of seeing dissimilarities in proteins detected due to differences in gel running 
conditions. A drawback of this method is that a large amount of protein is needed to run 
the 2D-DiGE with two prep-gels. 550 µg protein is required per sample set to obtain 
optimal results. The amount of protein obtained from the secretome preparation for strain 
GVR35 was determined by Bradford assay and was 461.15 µg ml
-1
, while 427 was 451.97 
µg ml
-1
 with a sample volume of 1 ml. To obtain a high enough protein concentration 
samples were precipitated with acetone and resuspended in 200µl DiGE lysis buffer. Final 
protein concentration was 600 µg ml
-1
 for strain GVR35 and 700 µg ml
-1
 for strain 427. 
Therefore, even after acetone precipitation a high sample volume had to be used to reach 
desired amount of protein (50 µg for DiGE gel). For the prep gels a lesser amount of 
sample had to be used; instead of 500 µg protein, only around 90 µg was loaded onto the 
prep gels. That resulted in a loss of protein spots showing in the prep gels as compared to 
the DiGE gel. Therefore not all protein spots showing differences could be analysed.  
 
5.5.2. DiGE analysis 
Protein spots with a minimum of twofold difference between strain GVR35 and strain 427 
were picked for analysis. 35 protein spots were picked from the prep gel of strain GVR35 
and 21 were picked from the strain 427 gel (Figure 5.1.). From the 35 spots picked from 
the GVR35 prep gel 28 proteins could be identified, while for strain 427, 17 of the 21 
showed protein identification (Table 5.1. (427) and Table 5.2. (GVR35)).  
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 (a) 
 
 (b) 
Figure 5.1.: Image (DiGE) for T. b. brucei strain 427 (a) and GVR35 (b). 2-D separation was obtained 
using two step separation with an IEF strip pH 4-7 followed by SDS-Page size separation. Images were 
scanned and compared using DeCycler 2D software. Protein spots identified to show at least a twofold 
difference between the two strains were extracted from the prep gel, digested with trypsin and analysed by 
LC-MS. Protein spots extracted are marked in the images by a circle and the spot identification number for 
those were an identification could be made. The protein identifications can be seen in Table 5.1. for 427 and 
Table 5.2. for GVR35.  
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Spot 
No. 
ID Accession no. 
Volume 
Ratio 
Matches Score 
13 heat shock protein 83 Tb10.26.1080 -2.39 2(1) 37 
54 69 kDa paraflagellar rod protein Tb927.8.4970 -4.65 24(7) 186 
374 hypothetical protein, conserved Tb10.70.1130 -7.2 21(11) 313 
502 protein phosphatase 2C, putative Tb11.03.0390 -2.43 1(1) 38 
539 arginine kinase Tb09.160.4560 -2.37 2(1) 40 
544 adenosine kinase, putative Tb927.6.2360 -2.23 9(5) 119 
549 arginine kinase Tb09.160.4590 -9.33 46(17) 467 
560 beta tubulin Tb927.1.2330 -5.93 6(2) 71 
571 asparagine synthetase a, putative Tb927.7.1110 -5.66 4(0) 23 
649 
guanine nucleotide-binding protein beta 
subunit- like protein 
Tb11.01.3170 -4.09 4(0) 28 
677 
nascent polypeptide associated 
complex subunit, putative 
Tb09.211.0120 -2.37 4(1) 50 
759 
translation elongation factor 1-beta, 
putative 
Tb927.4.3570 -7.27 27(13) 328 
765 
translation elongation factor 1-beta, 
putative 
Tb10.70.1100 -7.24 26(12) 305 
804 
hypoxanthine-guanine 
phosphoribosyltransferase 
Tb10.70.6540 -3.33 4(2) 66 
888 profilin Tb11.01.5350 -2.95 10(3) 139 
891 60S acidic ribosomal protein, putative Tb09.160.4200 -2.14 13(5) 164 
Table 5.1.: Identified proteins from T. b. brucei strain 427 as extracted from gel (Figure 5.1. (a)). Spot 
no. can be matched to the location of the gel in Figure 5.1.(a). Identifications and accession no. were matched 
from mascot to TritrypDB. The volume ratio shows decreased/increased protein spot intensitiy and matches 
are the peptides matched against the protein sequence with the number in brackets hits indicating homology 
or identity. Score > 28 indicates homology or identity with p > 0.05. 
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Spot 
No. 
ID Accession no 
Volume  
Ratio 
Matches Score 
105 
2,3-bisphosphoglycerate-independent 
phosphoglycerate mutase 
Tb10.6k15.2620 5.59 13(6) 192 
111 
2,3-bisphosphoglycerate-independent 
phosphoglycerate mutase 
Tb10.6k15.2620 4.74 
 
16(5) 
 
144 
112 73 kDa paraflagellar rod protein Tb927.3.4290 4.11 16(7) 199 
176 
S-adenosylhomocysteine hydrolase, 
putative 
Tb11.01.1350 17.29 19(8) 198 
199 RuvB-like DNA helicase, putative Tb927.4.2000 8.69 4(1) 48 
213 hypothetical protein, conserved Tb927.7.3090 27.52 2(1) 40 
246 malic enzyme, putative Tb11.02.3130 7.14 2(1) 38 
279 hypothetical protein, conserved Tb927.7.3090 17.21 1(1) 41 
286 
variant surface glycoprotein (VSG, 
atypical), putative 
Tb927.5.4950 9.76 1(1) 34 
358 
variant surface glycoprotein (VSG, 
pseudogene), putative 
Tb927.6.5230 12.06   
371 enolase Tb10.70.4740 3.05 29(17) 445 
372 alpha tubulin Tb927.1.2340 11.24 1(1) 33 
417 heat shock protein 70 Tb11.01.3110 4.57 2(1) 54 
498 alpha tubulin Tb927.1.2340 17.61 1(1) 68 
519 alpha tubulin Tb927.1.2340 2.71 37(14) 406 
527 alpha tubulin Tb927.1.2340 21.49 2(1) 57 
547 arginine kinase Tb09.160.4560 8.19 6(2) 55 
678 alpha tubulin Tb927.1.2340 3.1 14(7) 218 
694 alpha tubulin Tb927.1.2340 32.44 1(1) 31 
695 alpha tubulin Tb927.1.2340 5.19 23(13) 434 
701 beta tubulin Tb927.1.2330 7.52 12(6) 193 
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Spot 
No. 
ID Accession no 
Volume  
Ratio 
Matches Score 
802 elongation factor 1 gamma, putative Tb11.01.4660 4.25 6(1) 32 
818 
ADP-ribosylation factor-like protein 3A, 
putative 
Tb927.3.3450 2.59 18(10) 216 
862 
translation elongation factor 1-beta, 
putative 
Tb10.70.1100 7.27 8(3) 84 
901 hypothetical protein, conserved Tb10.26.0680 34.16 10(1) 62 
 
Table 5.2.: Identified proteins from T. b. brucei strain GVR35 as extracted from gel (Figure 5.1. (b)). 
Spot no. can be matched to the location of the gel in Figure 5.1.(b). Identifications and accession no. were 
matched from mascot to TritrypDB. The volume ratio shows decreased/increased protein spot intensitiy and 
matches are the peptides matched against the protein sequence with the number in brackets hits indicating 
homology or identity. Score > 28 indicates homology or identity with p > 0.05. 
 
The proteins identified in both strains included one hypothetical protein in 427 and two 
hypothetical proteins in GVR35.  
 
Four proteins were identified in both datasets; however, comparing the ‘protein spot’ 
location in the gel (Figure 5.1) strongly indicates a difference between the two strains. Two 
isoforms of arginine kinase (AK) were extracted from 427 and one AK in GVR35. 427 
contained AK1 and AK2, which are located in the flagellum and cytosol respectively, 
while in GVR35 only AK1 was detected. Heat shock protein 83, beta tubulin and 
translation elongation factor 1-beta (putative) were also detected in both datasets. 
 
A first analysis of the detected proteins showed that most proteins were highly abundant in 
trypanosomes (M. Barrett, personal communication) and raised the question if the 
secretome samples might have been contaminated with proteins from lysed trypanosome 
cells. Although contamination from lysed cells cannot be excluded, a visual comparison 
between a trypanosome lysate 2-D gel and the two secretome 2-D gels showed differences 
in protein spot patterns and spot abundance. The secretome gel showed fewer spots and 
was biased towards low molecular weight proteins compared to a lysate gel (Dr R. 
Burchmore, personal communication).  
 
To further investigate whether the contained proteins could be seen as a secretome sets, the 
obtained data were compared to already published trypanosome secretome sets. 
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Except for a small number of proteins in the two sets (profilin (427), RuvB-like DNA 
helicase, translation elongation factor 1-beta and malic enzyme (GVR35)), most proteins 
identified here have been described as being secreted from different strains of trypanosome 
before.  
 
The role of profilin, identified in strain 427 dataset, in trypanosomes is unclear. It might be 
involved in the phosphoinositide signal transduction pathway in trypanosomes (Wilson and 
Seebeck, 1997). If the finding of the proteins  RuvB-like DNA helicase, translation 
elongation factor 1-beta and malic enzyme in strain GVR35 are strain specific markers or 
just the result of contamination from dead cells still needs to be determined. Microscopical 
examination of the cells during incubation in serum free medium showed that GVR 35 was 
less tolerant to the conditions than 427. 
 
RuvB-like DNA helicase, in complex with hsp 90, might be involved in cell proliferation, 
as suggested for leishmania and plasmodium (Ahmad et al., 2013) but the reason for this 
protein being potentially secreted is unclear. 
 
To get a better overview of the whole set of secreted proteins in the sample set used, 
remaining sample was prepared for a gel free proteomics approach, using FASP (2.3.10). 
The minimum amount of protein that can be analysed with this method is 5µg. For strain 
427 14µg protein was used and for strain GVR35 14µg. Analysis of the secretome 
prepared by FASP showed only a small number of proteins detected for strain 427 and 
those samples were not further analysed. As very similar amounts of proteins were used 
and the samples were on the same LC-MS/MS run, a possible explanation for this is an 
experimental error using the FASP method. The most likely reason is that the proteins 
were not completely removed from the filter, but an error during LC-MS/MS run (For 
example sample not picked up properly) cannot be excluded. 
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5.2.2. T. b. brucei strain GVR35 secretome 
After sample preparation and trypsin digest (as described in 2.3.10.), 109 proteins were 
significantly identified using MASCOT (p-value <0.05), with the identifications obtained 
from TritrypDB.  
 
23 proteins were identified as hypothetical proteins and two unspecified products. The 
remaining 84 proteins had putative identifications belonging to different classes of proteins 
and were compared to published datasets (T. congolense (Grébaut et al., 2009) and T. 
gambiense (Geiger et al., 2010)). Proteins, detected in all three datasets (T. brucei, GVR35; 
T. congolense and T. gambiense) were divided into 10 groups (as seen in Figure 5.2.), 
namely Binding, Cytoskeleton organisation and flagellar proteins, Defence, Metabolism, 
Movement, Protein degradation, Protein folding, Protein synthesis, Signalling and 
Trafficking.  
 
 
 
Figure 5.2.: Pie chart of classes of secreted proteins from T.b.brucei strain GVR35. 69 proteins were 
included in this analysis, as those proteins were also found in published secretome sets. Proteins were divided 
into classes, in accordance to published data. 23 % of the secreted proteins found in GVR 35 belonged to 
metabolism, representing the biggest group of secreted proteins. 20% of secreted proteins are involved in 
protein synthesis, the second biggest group. 13 % each belonging to Binding and Protein folding. Proteins 
belonging to the froup Defence, Protein degradation and Cytoskeleton organisiation and flagellar proteins 
were making 10%, 7% and 6% respectively. The rest (6% in total) are Signalling, Binding and Trafficking. 
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The largest group was represented by proteins involved in metabolism. This group can be 
divided into the following subgroups: Carbohydrate metabolism (9), amino acid 
metabolism (3), glutathione metabolism (2) and nucleic acid metabolism (2).   
 
The presence of enzymes related to carbohydrate metabolism, also represent the largest 
protein group that the datasets had in common (6 out of 22 proteins). 
 
Most enzymes of the glycolysis in trypanosomes are located in organelles called 
glycosomes, however, three glycolytic enzymes are described to be outside the glycosome 
(Enolase, phosphoglycerate mutase and pyruvate kinase; (Albert et al., 2005)) and those 
three enzymes were detected in all three compared datasets. A comparison between the 
GVR35 secretome and a published proteome of the glycosome (Colasante et al., 2006) 
showed 12 proteins in common (approximately 11% similarity between the two sets). The 
two sets shared five glycolytic enzymes namely fructose-bisphosphate aldolase, 
triosephosphate isomerase, glycerol kinase, glyceraldehyde 3-phosphate dehydrogenase 
and glycerol-3-phosphate dehydrogenase.  
 
Enzymes belonging to the nucleic acid metabolism, in particular IAG nucleoside 
hydrolase, are important for bloodstream form trypanosomes, as they depend on the 
salvage pathway for purines (Parkin, 1996). Two were found in the GVR35 dataset (IAG 
nucleoside hydrolase and nucleoside diphosphate kinase), while in T.b.gambiense 
secretome the nucleotide metabolism proteins made up to 14% of the secreted proteins 
(Geiger et al., 2010). 
 
The protein synthesis group is the second largest group. It is composed of ribosomal 
proteins and elongation factors. The role of these proteins in the secretome is unknown. 
 
Proteins involved in protein folding and degradation have been previously described to 
have an effect on the immune system of the host, for example cyclophilin A and hsp (heat 
shock protein) (Calderwood et al., 2007; Kim et al., 2005), both being present in GVR35 
secretome. Furthermore, it has been shown that cysteine peptidases play an important role 
in the pathogenesis of trypanosomes and it is suspected that it also helps the parasite to 
cross the blood brain barrier. However, T.b.brucei has been said to be less efficient than 
T.b.gambiense (Nikolskaia et al., 2006). The GVR35 dataset contained a calpain-like 
cysteine peptidase (Tb.927.7.4060) and metacaspase 4 (Tb10.70.5250). Metacaspase 4 
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(MCA4) belongs to the cysteine peptidases, but lacks peptidase activity (Proto et al., 
2011). However, MCA4 knockout lines showed a reduced virulence in mice (Proto et al., 
2011). Other proteins that reportedly have an impact on pathogenesis were calreticulin 
(Ferreira et al., 2004) which was not present in the GVR35 dataset and α/β-tubulin, who 
have shown to be T-cell stimulating antigens in leishmania infections (Probst et al., 2001). 
Both were detected in GVR35. Oligopeptidase B, an important virulence factor has been 
shown not to be secreted from cultured trypanosomes (Morty et al., 2001) and was also not 
detected in GVR35. A full list of all detected proteins can be found in Appendix E, Table 
E1. 
 
Although the majority of proteins present in the GVR35 secretome set have also been 
described as being secreted from other trypanosome species, the high occurrence of 
glycolytic enzymes in the GVR35 secretome data was surprising and again raised the 
question if the presented dataset could be contaminated by proteins from lysed cells. 
 
A western blot, using RAD51 (a cytosolic protein) as a control, showed minimal 
contamination in the secretome samples after 2 hours incubation (Figure 5.3). As cell 
viability during incubation in serum free medium was only checked using microscopic 
examination and strain GVR 35 showed cell clumps (sign for cell death) at the end of the 
incubation period, it cannot be ruled out that the secretome got contaminated with intra-
cellular proteins. 
 
 
Figure 5.3: Western blot after secretome preparation, using cell pellet as control and Rad51 antibodies 
to check for contamination with dead cells. 
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5.2.3. FACS and cell survival 
The original prepared and analysed secretome sets (by DiGE and FASP) indicated possible 
sample contamination from lysed parasites, due to the high number of glycolytic enzymes 
and highly abundant proteins present. To determine how many cells died during incubation 
in serum-free medium two different methods were tested: Fluorescent- activated cell 
sorting (FACS) using a MASCQuant and a propidium iodide (PI) assay based on (Gould et 
al., 2008). 
FACS analysis was kindly done by S. Sabir (University of Glasgow), with propidium 
iodide used as a live/dead stain. The data showed that during incubation in serum free 
CMM about 5% of T. brucei strain 427 cells were measured as dead with the last 
measurement showing up to 8% dead cells. Strain GVR35 revealed about 18% cells as 
dead (Figure 5.4).  
 
Figure 5.4.: FACS analysis on T. b. brucei  strain 427wt and strain GVR35 during incubation in serum 
free CMM. Samples were taken every 30mins from beginning of incubation period. FACS analysis was 
kindly done by S. Sabir (University of Glasgow). 
 
The propidium iodide assay was based on a method developed by Gould et al., who used it 
to monitor drug action in kinetoplastidae in real-time. For my purposes, cells of a known 
concentration were added to a 96 well plate and incubated with propidium iodide with 
measurements taken every 3 min. To determine the number of dead cells control samples 
of varying cell concentration were incubated with digitonin and propidium iodide. A 
standard curve with the fluorescent measurements taken from the dead cells was created, 
so the number of dead cells could be calculated (Figure 5.5). 
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Figure 5.5: Real-time PI assay showing the increase of dead trypanosomes (427) during incubation in 
serum free CMM. Live/dead stain was achieved with propidium iodide and cells were incubated at a 
concentration of 5x10
7
. Four sample sets were used. 
 
Cell death started to increase rapidly after 100 min. However, cell counts performed during 
cell incubation showed that cells kept on dividing even after being washed and kept in 
serum-free media. The analysis for the PI assay was performed for a static number of cells 
and as cell counts cannot be performed once the 96 well plate is set up for measurement 
this method does not seem accurate enough to determine the most accurate percentage of 
dead cells in the secretome. However, it did show the tolerance of the cells to serum free 
media, as shown by the rapid cell death after 100 minutes. As a consequence to this cell 
incubation time was reduced to 100 mins, however, results shown in 5.2.1 and 5.2.2 
originated from sample incubated for 2 hours. 
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5.2.4. Dimethyl-labelling strain 427 and strain GVR35 
As one aim was to compare the secretome of the strains 427 and GVR35, I made several 
attempts to repeat the DiGE secretome experiment. However, a protein concentration high 
enough to repeat the 2D-DiGE has not been achieved.  
 
Dimethyl-labelling (Hsu et al., 2003) is a useful approach to get quantitative proteomics 
data with a smaller starting quantity of protein. Differentiation between two samples is 
achieved by labelling of the α- and ε-amino group of lysine residues via reductive 
amination. 11 µg of protein from each 427 and GVR35 were used, with 427 being heavy 
labelled and GVR35 light labelled.  
 
Hit Accession Score L/H SD(geo) Description 
13 Tb09.211.3550 31 10.53 3.521 glycerol kinase, glycosomal 
 
14 Tb09.211.3540 31 10.53 3.521 glycerol kinase, glycosomal 
 
11 Tb11.01.3110 37 8.596 8.831 heat shock protein 70 
 
17 Tb11.01.3080 26 8.596 8.831 heat shock protein 70, putative 
 
28 Tb09.160.4560 16 6.108 1.593 arginine kinase  
 
18 Tb11.03.0250 25 5.746 4.287 CYPA cyclophilin a; cyclophilin 
type peptidyl-prolyl cis-trans 
isomerase 
 
2 Tb10.v4.0053 116 4.562 1.051 hypothetical protein 
 
22 Tb10.70.5650 24 4.013 2.92 elongation factor 1-alpha 
 
3 Tb10.70.4740 97 3.552 1.346 enolase 
 
5 Tb10.70.5250 89 3.442 3.252 MCA4 metacaspase  
10 Tb10.70.1370 54 3.304 1.611 fructose-bisphosphate aldolase, 
glycosomal, putative 
 
1 Tb927.1.2330 124 2.793 1.432 beta tubulin 
Table 5.3 Identified and quantified proteins from sample dimethyl-labelling. Proteins in bold have 
changed significantly between the two datasets. T. b. brucei strain GVR35 was light labelled and 427 
was heavy labelled, significant changes in proteins are down in strain 427.  
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LC-MS/MS data analysed with Mascot distiller identified 30 proteins, 12 proteins with 
quantification of which 4 were significantly changed between datasets (Table 5.3). 
 
The hypothetical protein Tb10.v4.0053 is listed as an unspecified product in TritrypDB for 
strain 427. For strain 927 and other trypanosome species and leishmania orthologs are 
identified as microtubule-associated protein. However, it needs to be taken as unidentified 
as not enough information exists to make a better annotation. 
 
The enzyme enolase has been identified before in the 427 and GVR35 datasets. The DiGE 
approach showed enolase being increased in the GVR35 data and dimethyl-labelling 
confirmed this finding. Enolase, a glycolytic enzyme, catalyses the reversible conversion 
of D-2-phosphoglycerate and phosphoenolpyruvate. In trypanosomes, the enzyme is 
located outside the glycosomes and for leishmania can also been found bound to the cell 
surface where it displays no ‘enolase’ activity (Quiñones et al., 2007).  However, enolase is 
also present on the cell surface of several mammalian cells and prokaryotic and eukaryotic 
pathogenic organisms (Avilán et al., 2011). It was found that enolase can act as a 
plasminogen-binding protein. The leishmania enolase seems to bind abound 60% of 
plasminogen to the cell surface (Vanegas et al., 2007). Plasminogen, a zymogen of serine 
protease plasmin, is part of the fibrinolytic system and it has been shown that pathogens 
can use this protease after binding it to their surface and activating it (Avilán et al., 2011).   
 
Fructose-bisphosphate aldolase was detected in the GVR35 secretome data (5.2.2) and also 
in a T. b. gambiense secretome set (Geiger et al., 2010).  However, a possible moonlighting 
function for this enzyme (similar to enolase) has not been described for trypanosomes. 
Beta tubulin has a known association with the exosomes of various cell types (Olver and 
Vidal, 2007) and has also been identified in trypanosome secretome data. 
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5.3. Discussion 
Proteomic approaches were used to identify proteins secreted from two different strains of 
T. b. brucei (namely strain 427 and strain GVR35) with the aim to establish (1) differences 
in secreted proteins between the two strains and (2) to obtain a profile of secreted proteins. 
Strain 427 and GVR35 show different pathogenesis in mice. While strain 427 causes an 
acute infection with high mortality within a few days, GVR35 establishes a chronic form 
of the disease with invasion of the CNS. Excreted/secreted proteins could be the key for a 
better understanding of the pathogenic process of those parasites, specifically in regards to 
invasion of the central nervous system. 
 
This chapter introduced three different approaches to investigate the secretome of 427 and 
GVR35. However, the data is peliminary and does only indicate the possible set of secreted 
proteins. The rising cost of proteomic samples put a stop to this experiment before enough 
data was obtained to get comprehensive results.  
 
5.3.1. Secretome production 
Secretomes were produced by incubating the cells in serum free modified medium for two 
hours at a density of 2 x 10
8
 cells ml
-1
 as described by Holzmueller et al. (2008). Cell 
viability was checked by microscopic examination throughout the incubation period. 
During the initial experiment (results 5.2.1 and 5.2.2) 427 cells showed good motility and 
minimal ‘clumping’. However, GVR35 showed less tolerance for these conditions and cell 
‘clumping’ was observed during the end of the incubation period.  
 
FACS analysis and a propidium iodide real-time assay on a repeat dataset confirmed that 
cells start to die after 100 min of incubation and a western blot analysis of secretome and 
cell lysate, using RAD51 as control, showed minimal contamination.  FACS analysis 
showed about 18% dead cells in the GVR35 incubation culture compared to 5% in 427. 
That could explain the detected glycolytic enzymes in the analysed secretome sets from 
GVR35.  
 
The propidium iodide assay indicated that cells were dying rapidly after 100 min. 
However, as cells kept on dividing in the serum free media (confirmed by cell counts) and 
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cell death was calculated assuming a static population this assay showed not to be accurate 
enough for the purpose of this experiment. 
 
As a general observation, strain GVR35 seemed to cope less well with high density 
incubation than strain 427 and continuous cell cultures had to be kept between 1.5 and 2 x 
10
6
 cells ml
-1
 to avoid GVR35 parasite death (E. Myburgh, correspondence and personal 
experience). To resolve the issue of cell death during incubation several ‘secretome 
productions’ were performed at a lower density than the suggested 2 x 108 cells ml-1, 
density tested were 1 x 10
8
 and 5 x 10
7
. Although the total number of cells was kept close 
to 2 x 10
8 
used for the experiments, the protein amount gained was on average less than 
100µg. However, lower cell density during incubation lowered cell death. A quantitative 
study on secreted proteins of T. congolense and T.evansi showed that not all species secrete 
proteins at the same level. T. congolense secreted five times less proteins than T. evansi 
under the same conditions (Holzmuller et al., 2008). 
 
Secretome production has proven difficult to achieve in this study, but the reasons for this 
are unclear. It is possible, that the two strains used secrete lower level of proteins. Another 
possibility is the use of cultured cells. Published secretome compared to my own data had 
been isolated from rats and the interaction between host immune system and pathogen 
could trigger a higher amount of proteins being secreted. However, the classes of proteins 
detected in all sets were quite similar which suggest that trypanosomes do secrete proteins 
despite the lack of environmental pressure in culture. That leaves the amount of cells used 
for this study. Strain 427 and GVR35 grow well in cultures and 427 has been successfully 
grown in culture for decades.  But the amount of culture that would be needed to achieve a 
high enough cell count to get a high enough amount of secreted protein would get 
unmanageable quite quickly. For strain GVR35, 150 to 170 ml of culture is needed to 
achieve 2 x 10
8
 cells in total as cells start dying at densities over 2 x 10
6
 (for continuous 
culture). From that amount on average 100µg of protein could be obtained. That means for 
DiGE analysis close to 1 litre of culture would be needed to get enough protein for one gel. 
Include three replicates and about three litres of culture becomes necessary. From a 
practical point of view alone this becomes unfeasible. For future experiments the use of 
trypanosomes isolated from mice might be a better approach to avoid the complications of 
cultured cells. 
   
133 
 
5.3.2. Comparison of T. b. brucei strains 427/GVR35  
A comprehensive comparison between the strains 427 and GVR35 was not achieved due to 
the difficulties obtaining a high enough protein concentration for analysis with DiGE. 
Although some differences in protein presence was shown, the relatively small 
concentration of proteins in the secretome made it impossible to obtain enough protein to 
run the prep gels according to protocol and therefore made it difficult to analyse the data 
and pick spots from the prep gel. For the DiGE analysis protein spots showing an at least 
two-fold difference in ratio were extracted from the gel, digested with trypsin and analysed 
on a LC-MS/MS platform. Some proteins (for example alpha tubulin, GVR35 sample) 
were detected (or picked from the gel) several times as the two dimensional separation of 
the gel showed the protein in different positions (differences in charge and mass). 
However, this has been described for tubulins before (Bridges et al., 2008). Geiger et al 
showed modifications of proteins between different strains. This was evident from the 
DiGE approach between 427 and GVR35 as well, as four proteins were picked in both 
strains, but showed up as different spots on the DiGE gel. 
 
A dimethyl-labelling approach identified 30 proteins but quantification was only possible 
for 12 proteins, with four proteins showing significant changes.  
 
Both DiGE and dimethyl-labeling did show significant differences between the two strains. 
However, as experiments could not be repeated a comprehensive list of differential 
secreted proteins could not be obtained and further experiments are needed to support our 
hypothesis that secreted proteins are involved in the difference of virulence between the T. 
b. brucei strains 427 and GVR35. 
 
5.3.3. T. b. brucei strain GVR 35 secretome 
Although secretory processes in African trypanosomes have been studied and reviewed 
(Bangs, 1998; Clayton et al., 1995) certain aspects of the process still remains unclear. In 
trypanosomes, endocytosis and exocytosis occur through the flagellar pocket and require 
clathrin, actin and GTPase Rab proteins (Geiger et al., 2010). Clathrin heavy chain has 
been identified in the strain GVR35 dataset. Proteins associated with the exosome 
secretion pathway were identified and from the 22 proteins described (Olver and Vidal, 
2007) 10 of them were present in this dataset, namely glyceraldehyde-3-phosphate 
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dehydrogenase, 14-3-3-like protein, alpha and beta tubulin, clathrin heavy chain, 
cyclophilin A, enolase, HSP70, pyruvate kinase and ubiquitin-conjugating enzyme. 
 
A comparison between the strain GVR35 and other published secretome data has shown 
that from the 109 proteins identified 69 proteins were also found in other datasets. 
Secretome analysis from three different strains of T. b. gambiense revealed 50 % of 
secreted proteins belonging to the categories protein folding and degradation, nucleotide 
metabolism and unassigned function (Geiger et al., 2010). In comparison, in the two 
T.b.brucei strains tested here about 21% of the proteins were hypotheticals and proteins 
belonging to the category protein folding and degradation made up 20% of the analysed 
proteins in this dataset (see Figure 6.3). Only two enzymes belonging to the nucleic acid 
metabolism were detected, making it a significantly smaller proportion compared to the 
published datasets. 
   
The proteins identified are connected to various molecular functions. Including, enzymes 
from carbohydrate metabolism, amino acid metabolism and nucleic acid metabolism, as 
well as chaperone proteins, proteins involved in protein and nucleotide binding, protein 
synthesis and cellular communication/signal transduction, which are categories known to 
be present in the secretome of trypanosomes.  
 
Although some proteins are well described as being secreted by trypanosomes, others are 
not and finding evidence of them being secreted can lead to interesting new hypotheses 
about pathogenic role of secreted proteins. Geiger et al published in 2010 that three 
glycolysis related enzymes phosphoglycerate mutase, enolase, pyruvate kinase are found to 
be secreted (The strain GVR35 dataset contains all three). They suggest that those enzymes 
could have functions unrelated to glycolysis. 
 
Comparison between the strain GVR35 and published secretome datasets showed a high 
number of enzymes from the carbohydrate metabolism, but if glycolysis related proteins in 
particular, are in fact secreted by trypanosomes or if their appearance is due to 
contamination of the secretome by cell death during incubation is unclear. However, 
glycolysis enzymes have been found in all published datasets for blood stream and 
procyclic (Atyame Nten et al., 2010) form of trypanosomes.   
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In conclusion, the comparison between my dataset and published datasets has shown that 
T. b. brucei strain GVR35 and to an extent strain 427, secrete similar proteins than other 
species of trypanosomes.    
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Chapter 6 
Discussion 
Whole genome sequencing has nowadays become more readily available with the cost 
dropping rapidly and data being made available for a variety of organisms, from bacteria to 
plants and trypanosomatids. The genome of several trypanosome species and subspecies 
has been published (Berriman et al., 2005; El-Sayed et al., 2005; Jackson et al., 2010) and 
data are available via databases, such as TritrypDB, a database dedicated to the 
trypanosomatids (Aslett et al., 2010). Gene annotation using bioinformatic approaches can 
give an indication of the possible function of a gene, but it is not guaranteed that the 
detected homology between two (or more) sequences actually means the proteins have 
functional identities. The most popular bioinformatics approaches being used are BLAST 
or Pfam. BLAST (Basic Local Alignment Search Tool) compares either nucleotide or 
protein sequences to sequences in databases. Pfam is used for protein annotation by 
searching a protein sequence for known protein domains (Punta et al., 2012). Although 
bioinformatics approaches for homology based functional assignments of genes has shown 
to be a fast approach to obtain putative gene annotations, often these annotations are 
incorrect or only based on low sequence homology (Baran et al., 2009). Identifying 
functions of hypothetical proteins or even identifying wrongly annotated genes remains a 
major challenge in the post-genomic era. 
 
However, the field of metabolomics has created applications to overcome this challenge, 
which are (1) genes with no identified function and (2) metabolic pathways present but no 
encoded enzyme in the genome identified that could catalyse the reaction. However, 
metabolomics is the study of low molecular weight metabolites within the cell and 
metabolites are often the substrate or downstream product of enzymatic reactions, so 
seeing a reaction occur means there must be a gene present. 
 
The first approach of directly identifying protein functions can be done by using 
recombinant protein or gene knock out / knock down. Analysing the changes in metabolic 
datasets can indicate the function of the protein of interest. Although this is the most direct 
approach, it is also time consuming. 
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A different approach is to look at the pathways directly. By combining stable isotope 
labelling with metabolomics, the flux of labelled compounds can be traced through the 
organism. 
The metabolomic and proteomic approaches used in this study have shown to be highly 
applicable to study the system biology of trypanosomes. 
Metabolomics and proteomics approaches have been applied to the parasitic protozoa T. 
brucei to (1) test a high throughput approach for enzyme function identification using 
metabolomics techniques, (2) identify metabolic pathways with stable isotope labelling 
coupled to metabolomics and (3) applying proteomic techniques for identification of novel 
secreted proteins from cultured parasites. 
 
6.1. Enzyme assay / Enzyme ID 
In this project, I investigated the potential of an untargeted enzyme assay using 
metabolomics techniques for a high throughput. This method has been deployed to identify 
the function of novel enzymes for E. coli (Saito et al., 2009) and Mycobacterium 
tuberculosis (De Cavallho et al., 2009; Larrouy-Maumus et al., 2013). Furthermore, three 
trypanosome enzymes have been investigated in our group (E. Kerkhoven, thesis). 
 
In this project enzymes were chosen at random from a list of putative enzyme obtained 
from TritrypDB, as the aim was to determine whether this assay was applicable for a high 
throughput approach. The only criteria for the chosen ‘enzymes’ was that they should have 
a predicted metabolic function, relatively small size, so the cloning and over-expression 
would not cause too many difficulties, and that their function had not been determined 
before using recombinant or purified protein. The assay was designed to be fast and 
relatively cheap. The workflow developed took seven days to complete, from the initial 
PCR for cloning to purifying the protein for the assay. A way this was achieved was to use 
a ligase independent cloning system to standardise primer design and cut down on cloning 
time. When the system was applicable using E. coli over expression systems allowed easy 
and fast protein production. However, more than half of the proteins were either not over 
expressed or could not be purified (inclusion body formation), therefore alternative over 
expression systems should be considered for future work when over expression from E. 
coli is not possible. During this thesis, changes were made to optimise the workflow. 
Different E. coli over expression strains were tested to achieve high protein amounts. E. 
coli Rosetta (DE3) cells improved protein expression in number of proteins that could be 
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over expressed and their yield compared to BL21 (DE3) strains. A second extraction step 
was also added to the protocol to increase the quality of the metabolomics datasets (as was 
shown with the example of Hexokinase, Chapter 3). The concentration of the MOPS buffer 
used in the enzyme assay was lowered to 10 mM from originally 40 mM, to reduce the 
possibility of ion suppression and also because MOPS was seen to block the columns. 
 
For an initial screening approach, this method seems applicable as shown for the enzyme 
S-adenosylmethionine synthetase. Using the in vitro assay the function of this enzyme was 
directly linked to a purified protein. The presence of this reaction was previously achieved 
using trypanosome cell extract (Yarlett et al., 1993), but the function was not linked 
directly to a gene. 
 
But not all proteins showed changes indicating its function, highlighting the limitations of 
this method.  
 
Currently there is no MS platform fitting for all classes of metabolites, which causes a 
problem when the substrate/products fall outwith the parameters suitable for analysis on 
the LC-MS platform used in this project. For putative enzymes in this study it is hard to tell 
if that is the case, however, the commercial hexokinase, used for validation purposes 
shows that detection of sugars is not ideal on LC-MS, as the separation is not good enough 
to differential between glucose and fructose (for example). Most sugars and sugar 
phosphates are being identified with 57 isomers on the IDEOM spreadsheet.  
  
Yeast extract has shown to be a broad, reproducible source for metabolites, which has the 
benefit, in the high throughput approach, to limit the external variance factor. The 
drawback is that trypanosome specific enzymes might not be identified as specific 
metabolites, like trypanothione, might be missing. Also, highly abundant metabolites could 
mask changes, as was shown for S-adenosylmethionine synthetase, where levels of L-
methionine were unchanged between the treatment and control samples and for the 
commercial hexokinase assay, which showed no changes in D-glucose levels.  
 
One of the proteins investigated, putatively annotated as deoxhypusine synthase, was since 
shown to form a heterotetramer with a catalytically dead paralog to enhance its activity by 
3000-fold (Nguyen et al., 2013). This form of regulation, termed prozyme, has been 
described for other trypanosome enzymes as well, namely hexokinase (Morris et al., 2006) 
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and S-adenosylmethionine decarboxylase (Velez et al., 2013). The use of the untargeted 
enzyme assay with recombinant proteins will miss those enzymes as well. 
 
When the function of a potential enzyme cannot be determined using the in vitro assay 
approach, the production of knock-out lines or knock-down lines can be of use to further 
investigate the function (Saghatellian et al., 2004). However, this process can be very time 
consuming compared to the production of recombinant protein in a well established over 
expression system such as E. coli. The benefit of this approach, next to determine the 
function of the targeted gene, is to also provide further information about the target protein, 
such as how essential this protein is for cell survival.  
 
Metabolomics analysis of knock out or knock down lines does not always allow 
identification of the function. For example, the function of the trypanosome ‘arginase’ has 
eluded our group for years now. This protein has been investigated in three PhD studies 
and all we can say about it is that it does not have ‘arginase’ activity although BLAST and 
Pfam show significant homologies to other arginases. An ‘arginase’ knock-out mutant was 
produced and using an untargeted metabolomics approach comparing knock-out to 
wildtype gave no indication of arginase or ureohydrolase activity (Hai et al., 2014).  
 
6.2. Stable Isotope Labelling / Pathway ID 
Metabolomics combined with stable isotope labelling can provide an indirect approach for 
the detection of enzymatic activity (Dalluge et al., 2005). However, this approach is mainly 
used as a tool for pathway identifications, as by adding a labelled metabolite to the cell 
culture, downstream metabolites labelled from the added compound can be detected and 
lead to the identification of novel pathways. Extensive work has been done on the energy 
metabolism of procyclic and bloodstream form trypanosome. Recent work from Creek et al 
(2015) used U- 
13
C D-glucose to label cultured bloodstream form trypanosomes, showing 
that glucose can enter many branches of the trypanosome metabolism.  
 
ATP, labelled from U-
13
C glucose, was shown to be incorporated in S-adenosylmethionine. 
Trypanosomes were thought to be capable of recycling L-methionine via the 
methylthioadenosine cycle (MTA cycle or Yang cycle). However, L-methionine was not 
detected to be labelled from glucose, ruling out the use of L-methionine salvage via the 
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MTA cycle. To further investigate those findings, U-
13
C-L-methionine was used in an 
untargeted metabolomic approach. 
The main findings are: 
 The MTA (or Yang) cycle also does not seem to be involved in methionine salvage. 
Instead MTR gets secreted from the cells, shown by rising levels of 1-C labelled 
MTR in spent medium. Also, the precursor metabolite to L-methionine (4-
methylthio-2-oxobutanoate) is 5-
13
C labelled from L-methionine, confirming the 
findings of Creek et al., 2015. 
 1,2-dihydroxy-5-(methylthio) pent-1-en-3-one from the MTA cycle is labelled       
1-
13
C, but no further information about what pathway this metabolite goes into was 
obtained. 
 The Methionine cycle, recycling S-adenosylmethionine to L-homocysteine back to 
L-methionine doesn’t seem to take place (lack of 1-C label in L-methionine) 
 
Future works, could include the detection of enzymes of the MTA cycle present in 
trypanosomes and further investigate the fate of 1,2-dihydroxy-5-(methylthio) pent-1-en-3-
one in bloodstream form trypanosomes. 
 
Another finding of the U-
13
C glucose study (Creek et al., 2015) was a significant level of 
aspartate, succinate and malate not made from glucose, suggesting alternative carbon 
source than glucose for their production. Data obtained from U-
13
C L-glutamine labelling 
in cultured trypanosomes (DH Kim and F Achcar, unpublished data) showed labelled 
carbon incorporation from L-glutamine. However, approximately 20% of aspartate, 
succinate and malate were still unaccounted for. As L-proline can be the main carbon 
source in procyclic trypanosomes, U-
13
C L-proline was used to investigate its possible 
involvement in bloodstream form trypanosomes. However, minimal labelling of 
compounds in the dataset suggests L-proline is not used as carbon source in bloodstream 
form trypanosomes. No carbon incorporation into those compounds was detected from L-
methionine and L-arginine. Further testing of other amino acids is required to answer for 
the unaccounted amounts of aspartate, succinate and malate. Enzymes for the oxidation of 
aromatic amino acids are absent from trypanosomes (Berriman et al., 2005) making their 
involvement unlikely. L-aspartate is not taken up by trypanosomes (Hasne, thesis) and 
work done by D Kim with 
13
C- L-cysteine (unpublished data) showed no labelling. 
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Previous work from I. Vincent on the L-ornithine biosynthesis showed that trypanosomes 
take up L-ornithine from the media. However, when cells were incubated in CBSS 
(Carter’s balanced saline solution) in the absence of L-ornithine and with added 14N-L-
arginine, labelling of L-ornithine occurred. The most direct route from L-arginine to L-
ornithine is via the enzyme arginase. T. b. brucei’s genome encodes for a gene annotated as 
arginase (or agmatinase-like protein), however, this enzymes has no arginase activity (Hai 
et al., 2014). To investigate an alternative route for L-ornithine production, but also to 
further probe the L-arginine metabolism in trypanosomes, U-
13
C-L-arginine was used in an 
untargeted metabolomic approach. 
The main findings are: 
 Although L-ornithine was 5-C labelled from L-arginine, equally high 
concentrations were seen intra- and extracellular (spent medium analysis). 
Therefore, it was assumed that the formation of L-ornithine happened outside the 
cell and labelled L-ornithine was taken up by the trypanosomes. This was later 
verified by Dr. F. Giordani by incubating medium with added U-C
13
 L-arginine 
without cells. 
 Arginine-phosphate is labelled from L-arginine. This has been described to be of 
use in energy storage in trypanosomes (Canepa et al., 2011), with three arginine 
kinases being encoded in the T. brucei genome. 
 
 
6.3. Secretome 
Proteomic techniques were used to identify secreted proteins from two different 
trypanosome strains, which differ in the course of disease, 427 causes an acute infection in 
mice while GVR35 remains as a more chronic form within the CNS of the mice. In this 
thesis, I showed significant differences in proteins secreted from strain 427 and GVR35, 
although the results are just preliminary. However, the preliminary data did show a high 
consensus between the possible secreted proteins from strain 427 and GVR35 to other 
published secretome datasets, including one from human infecting trypanosomes (Geiger 
et al., 2010). 
 
Although published trypanosome secretome datasets included ‘proof’ of minimal 
contamination of proteins from lysed cells by FACS and western blot analysis, the 
142 
 
occurrence of highly abundant proteins and glycolytic enzymes raises the questions if those 
proteins are actively secreted or not. 
 
Further work is needed to address this problem and for the strains used in this study 
alternative methods for secretome production are needed. 
 
 
 
 
 
 
 
 
 
  
143 
 
List of References 
Abdulla, M.-H., O’Brien, T., Mackey, Z.B., Sajid, M., Grab, D.J., and McKerrow, J.H. 
(2008). RNA Interference of Trypanosoma brucei Cathepsin B and L Affects Disease 
Progression in a Mouse Model. PLoS Negl. Trop. Dis. 2. 
Ahmad, M., Afrin, F., and Tuteja, R. (2013). Identification of R2TP complex of 
Leishmania donovaniand Plasmodium falciparum using genome wide in-silico analysis. 
Commun. Integr. Biol. 6. 
Albert, M.-A., Haanstra, J.R., Hannaert, V., Van Roy, J., Opperdoes, F.R., Bakker, B.M., 
and Michels, P.A.M. (2005). Experimental and in silico analyses of glycolytic flux control 
in bloodstream form Trypanosoma brucei. J. Biol. Chem. 280, 28306–28315. 
Alsford, S., and Horn, D. (2008). Single-locus targeting constructs for reliable regulated 
RNAi and transgene expression in Trypanosoma brucei. Mol. Biochem. Parasitol. 161, 76–
79. 
Alves, M.J.M., and Colli, W. (2008). Role of the gp85/trans-sialidase superfamily of 
glycoproteins in the interaction of Trypanosoma cruzi with host structures. Subcell. 
Biochem. 47, 58–69. 
Aman, R.A., Kenyon, G.L., and Wang, C.C. (1985). Cross-linking of the enzymes in the 
glycosome of Trypanosoma brucei. J. Biol. Chem. 260, 6966–6973. 
Antelmann, H., Tjalsma, H., Voigt, B., Ohlmeier, S., Bron, S., van Dijl, J.M., and Hecker, 
M. (2001). A proteomic view on genome-based signal peptide predictions. Genome Res. 
11, 1484–1502. 
Aslett, M., Aurrecoechea, C., Berriman, M., Brestelli, J., Brunk, B.P., Carrington, M., 
Depledge, D.P., Fischer, S., Gajria, B., Gao, X., et al. (2010). TriTrypDB: a functional 
genomic resource for the Trypanosomatidae. Nucleic Acids Res. 38, D457–D462. 
Atyame Nten, C.M., Sommerer, N., Rofidal, V., Hirtz, C., Rossignol, M., Cuny, G., 
Peltier, J.-B., and Geiger, A. (2010). Excreted/secreted proteins from trypanosome 
procyclic strains. J. Biomed. Biotechnol. 2010, 212817. 
Avilán, L., Gualdrón-López, M., Quiñones, W., González-González, L., Hannaert, V., 
Michels, P.A.M., and Concepción, J.-L. (2011). Enolase: a key player in the metabolism 
and a probable virulence factor of trypanosomatid parasites-perspectives for its use as a 
therapeutic target. Enzyme Res. 2011, 932549. 
Bacchi, C.J., and Yarlett, N. (1993). Effects of antagonists of polyamine metabolism on 
African trypanosomes. Acta Trop. 54, 225–236. 
Bacchi, C.J., Goldberg, B., Garofalo-Hannan, J., Rattendi, D., Lyte, P., and Yarlett, N. 
(1995). Fate of soluble methionine in African trypanosomes: effects of metabolic 
inhibitors. Biochem. J. 309, 737–743. 
Bangs, J.D. (1998). Surface coats and secretory trafficking in African trypanosomes. Curr. 
Opin. Microbiol. 1, 448–454. 
144 
 
Bangs, J.D., Brouch, E.M., Ransom, D.M., and Roggy, J.L. (1996). A Soluble Secretory 
Reporter System in Trypanosoma brucei STUDIES ON ENDOPLASMIC RETICULUM 
TARGETING. J. Biol. Chem. 271, 18387–18393. 
Baran, R., Reindl, W., and Northen, T.R. (2009). Mass spectrometry based metabolomics 
and enzymatic assays for functional genomics. Curr. Opin. Microbiol. 12, 547–552. 
Barrett, M.P. (2006). The rise and fall of sleeping sickness. Lancet 367, 1377–1378. 
Barrett, M.P., Burchmore, R.J.S., Stich, A., Lazzari, J.O., Frasch, A.C., Cazzulo, J.J., and 
Krishna, S. (2003). The trypanosomiases. Lancet 362, 1469–1480. 
Barrett, M.P., Boykin, D.W., Brun, R., and Tidwell, R.R. (2007). Human African 
trypanosomiasis: pharmacological re-engagement with a neglected disease. Br. J. 
Pharmacol. 152, 1155–1171. 
Barrett, M.P., Bakker, B.M., and Breitling, R. (2010). Metabolomic systems biology of 
trypanosomes. Parasitology 137, 1285–1290. 
Beckonert, O., Keun, H.C., Ebbels, T.M.D., Bundy, J., Holmes, E., Lindon, J.C., and 
Nicholson, J.K. (2007). Metabolic profiling, metabolomic and metabonomic procedures for 
NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat. Protoc. 2, 2692–2703. 
Benne, R., Van Den Burg, J., Brakenhoff, J.P.J., Sloof, P., Van Boom, J.H., and Tromp, 
M.C. (1986). Major transcript of the frameshifted coxll gene from trypanosome 
mitochondria contains four nucleotides that are not encoded in the DNA. Cell 46, 819–826. 
Berger, B.J., Dai, W.W., Wang, H., Stark, R.E., and Cerami, A. (1996). Aromatic amino 
acid transamination and methionine recycling in trypanosomatids. Proc. Natl. Acad. Sci. U. 
S. A. 93, 4126–4130. 
Berger, L.C., Wilson, J., Wood, P., and Berger, B.J. (2001). Methionine regeneration and 
aspartate aminotransferase in parasitic protozoa. J. Bacteriol. 183, 4421–4434. 
Berriman, M., Ghedin, E., Hertz-Fowler, C., Blandin, G., Renauld, H., Bartholomeu, D.C., 
Lennard, N.J., Caler, E., Hamlin, N.E., Haas, B., et al. (2005). The genome of the African 
trypanosome Trypanosoma brucei. Science 309, 416–422. 
Bitonti, A.J., Dumont, J.A., and McCann, P.P. (1986). Characterization of Trypanosoma 
brucei brucei S-adenosyl-L-methionine decarboxylase and its inhibition by Berenil, 
pentamidine and methylglyoxal bis(guanylhydrazone). Biochem. J. 237, 685–689. 
Blum, J., and Burri, C. (2002). Treatment of late stage sleeping sickness caused by T.b. 
gambiense: a new approach to the use of an old drug. Swiss Med. Wkly. 132, 51–56. 
Blum, J.A., Zellweger, M.J., Burri, C., and Hatz, C. (2008). Cardiac involvement in 
African and American trypanosomiasis. Lancet Infect. Dis. 8, 631–641. 
Breitling, R., Pitt, A.R., and Barrett, M.P. (2006a). Precision mapping of the metabolome. 
Trends Biotechnol. 24, 543–548. 
Breitling, R., Ritchie, S., Goodenowe, D., Stewart, M.L., and Barrett, M.P. (2006b). Ab 
initio prediction of metabolic networks using Fourier transform mass spectrometry data. 
Metabolomics 2, 155–164. 
145 
 
Bridges, D.J., Pitt, A.R., Hanrahan, O., Brennan, K., Voorheis, H.P., Herzyk, P., de 
Koning, H.P., and Burchmore, R.J.S. (2008). Characterisation of the plasma membrane 
subproteome of bloodstream form Trypanosoma brucei. Proteomics 8, 83–99. 
Bringaud, F., Rivière, L., and Coustou, V. (2006). Energy metabolism of trypanosomatids: 
adaptation to available carbon sources. Mol. Biochem. Parasitol. 149, 1–9. 
Brown, M., Wedge, D.C., Goodacre, R., Kell, D.B., Baker, P.N., Kenny, L.C., Mamas, 
M.A., Neyses, L., and Dunn, W.B. (2011). Automated workflows for accurate mass-based 
putative metabolite identification in LC/MS-derived metabolomic datasets. Bioinformatics 
27, 1108–1112. 
Brun, R., Blum, J., Chappuis, F., and Burri, C. (2010). Human African trypanosomiasis. 
Lancet 375, 148–159. 
Burkard, G., Fragoso, C.M., and Roditi, I. (2007). Highly efficient stable transformation of 
bloodstream forms of Trypanosoma brucei. Mol. Biochem. Parasitol. 153, 220–223. 
Bursell, E. (1963). Aspects of the metabolism of amino acids in the tsetse fly, Glossina 
(Diptera). J. Insect Physiol. 9, 439–452. 
Calderwood, S.K., Mambula, S.S., Gray, P.J., and Theriault, J.R. (2007). Extracellular heat 
shock proteins in cell signaling. FEBS Lett. 581, 3689–3694. 
Canepa, G.E., Carrillo, C., Miranda, M.R., Sayé, M., and Pereira, C.A. (2011). Arginine 
kinase in Phytomonas, a trypanosomatid parasite of plants. Comp. Biochem. Physiol. B 
Biochem. Mol. Biol. 160, 40–43. 
De Carvalho, L.P.S., Zhao, H., Dickinson, C.E., Arango, N.M., Lima, C.D., Fischer, S.M., 
Ouerfelli, O., Nathan, C., and Rhee, K.Y. (2010). Activity-based metabolomic profiling of 
enzymatic function: identification of Rv1248c as a mycobacterial 2-hydroxy-3-oxoadipate 
synthase. Chem. Biol. 17, 323–332. 
Castle, A.L., Fiehn, O., Kaddurah-Daouk, R., and Lindon, J.C. (2006). Metabolomics 
Standards Workshop and the development of international standards for reporting 
metabolomics experimental results. Brief. Bioinform. 7, 159–165. 
Cazzulo, J.J. (1992). Aerobic fermentation of glucose by trypanosomatids. FASEB J. Off. 
Publ. Fed. Am. Soc. Exp. Biol. 6, 3153–3161. 
Chambers, J.W., Kearns, M.T., Morris, M.T., and Morris, J.C. (2008). Assembly of 
heterohexameric trypanosome hexokinases reveals that hexokinase 2 is a regulable 
enzyme. J. Biol. Chem. 283, 14963–14970. 
Choi, J., and El-Sayed, N.M. (2012). Functional genomics of trypanosomatids. Parasite 
Immunol. 34, 72–79. 
Chokkathukalam, A., Jankevics, A., Creek, D.J., Achcar, F., Barrett, M.P., and Breitling, 
R. (2013). mzMatch-ISO: an R tool for the annotation and relative quantification of 
isotope-labelled mass spectrometry data. Bioinforma. Oxf. Engl. 29, 281–283. 
Clayton, C., Häusler, T., and Blattner, J. (1995). Protein trafficking in kinetoplastid 
protozoa. Microbiol. Rev. 59, 325–344. 
146 
 
Colasante, C., Ellis, M., Ruppert, T., and Voncken, F. (2006). Comparative proteomics of 
glycosomes from bloodstream form and procyclic culture form Trypanosoma brucei 
brucei. Proteomics 6, 3275–3293. 
Coustou, V., Biran, M., Breton, M., Guegan, F., Rivière, L., Plazolles, N., Nolan, D., 
Barrett, M.P., Franconi, J.-M., and Bringaud, F. (2008). Glucose-induced remodeling of 
intermediary and energy metabolism in procyclic Trypanosoma brucei. J. Biol. Chem. 283, 
16342–16354. 
Creek, D.J., Jankevics, A., Breitling, R., Watson, D.G., Barrett, M.P., and Burgess, K.E.V. 
(2011). Toward global metabolomics analysis with hydrophilic interaction liquid 
chromatography-mass spectrometry: improved metabolite identification by retention time 
prediction. Anal. Chem. 83, 8703–8710. 
Creek, D.J., Anderson, J., McConville, M.J., and Barrett, M.P. (2012a). Metabolomic 
analysis of trypanosomatid protozoa. Mol. Biochem. Parasitol. 181, 73–84. 
Creek, D.J., Jankevics, A., Burgess, K.E.V., Breitling, R., and Barrett, M.P. (2012b). 
IDEOM: an Excel interface for analysis of LC-MS-based metabolomics data. Bioinforma. 
Oxf. Engl. 28, 1048–1049. 
Creek, D.J., Chokkathukalam, A., Jankevics, A., Burgess, K.E.V., Breitling, R., and 
Barrett, M.P. (2012c). Stable isotope-assisted metabolomics for network-wide metabolic 
pathway elucidation. Anal. Chem. 84, 8442–8447. 
Creek, D.J., Nijagal, B., Kim, D.-H., Rojas, F., Matthews, K.R., and Barrett, M.P. (2013). 
Metabolomics guides rational development of a simplified cell culture medium for drug 
screening against Trypanosoma brucei. Antimicrob. Agents Chemother. 57, 2768–2779. 
Creek, D.J., Mazet, M., Achcar, F., Anderson, J., Kim, D.-H., Kamour, R., Morand, P., 
Millerioux, Y., Biran, M., Kerkhoven, E.J., et al. (2015). Probing the Metabolic Network 
in Bloodstream-Form Trypanosoma brucei Using Untargeted Metabolomics with Stable 
Isotope Labelled Glucose. PLoS Pathog. 11, e1004689. 
Cross, G. a. M. (1975). Identification, purification and properties of clone-specific 
glycoprotein antigens constituting the surface coat of Trypanosoma brucei. Parasitology 
71, 393–417. 
Cubbon, S., Antonio, C., Wilson, J., and Thomas-Oates, J. (2010). Metabolomic 
applications of HILIC-LC-MS. Mass Spectrom. Rev. 29, 671–684. 
Dai, Y., Pochapsky, T.C., and Abeles, R.H. (2001). Mechanistic studies of two 
dioxygenases in the methionine salvage pathway of Klebsiella pneumoniae. Biochemistry 
(Mosc.) 40, 6379–6387. 
Dalluge, J.J., Liao, H., Gokarn, R., and Jessen, H. (2005). Discovery of enzymatic activity 
using stable isotope metabolite labeling and liquid chromatography-mass spectrometry. 
Anal. Chem. 77, 6737–6740. 
Dettmer, K., Aronov, P.A., and Hammock, B.D. (2007). Mass spectrometry-based 
metabolomics. Mass Spectrom. Rev. 26, 51–78. 
147 
 
Dumon-Seignovert, L., Cariot, G., and Vuillard, L. (2004). The toxicity of recombinant 
proteins in Escherichia coli: a comparison of overexpression in BL21(DE3), C41(DE3), 
and C43(DE3). Protein Expr. Purif. 37, 203–206. 
Dunn, W.B. (2008). Current trends and future requirements for the mass spectrometric 
investigation of microbial, mammalian and plant metabolomes. Phys. Biol. 5, 011001. 
Dunn, W.B., and Ellis, D.I. (2005). Metabolomics: Current analytical platforms and 
methodologies. TrAC Trends Anal. Chem. 24, 285–294. 
Dunn, W.B., Broadhurst, D., Begley, P., Zelena, E., Francis-McIntyre, S., Anderson, N., 
Brown, M., Knowles, J.D., Halsall, A., Haselden, J.N., et al. (2011). Procedures for large-
scale metabolic profiling of serum and plasma using gas chromatography and liquid 
chromatography coupled to mass spectrometry. Nat. Protoc. 6, 1060–1083. 
Duszenko, M., Ivanov, I.E., Ferguson, M.A., Plesken, H., and Cross, G.A. (1988). 
Intracellular transport of a variant surface glycoprotein in Trypanosoma brucei. J. Cell 
Biol. 106, 77–86. 
Ebikeme, C., Hubert, J., Biran, M., Gouspillou, G., Morand, P., Plazolles, N., Guegan, F., 
Diolez, P., Franconi, J.-M., Portais, J.-C., et al. (2010). Ablation of succinate production 
from glucose metabolism in the procyclic trypanosomes induces metabolic switches to the 
glycerol 3-phosphate/dihydroxyacetone phosphate shuttle and to proline metabolism. J. 
Biol. Chem. 285, 32312–32324. 
El-Sayed, N.M., Myler, P.J., Bartholomeu, D.C., Nilsson, D., Aggarwal, G., Tran, A.-N., 
Ghedin, E., Worthey, E.A., Delcher, A.L., Blandin, G., et al. (2005). The genome sequence 
of Trypanosoma cruzi, etiologic agent of Chagas disease. Science 309, 409–415. 
Englund, P.T., Hajduk, S.L., and Marini, J.C. (1982). The Molecular Biology of 
Trypanosomes. Annu. Rev. Biochem. 51, 695–726. 
Engstler, M., Thilo, L., Weise, F., Grünfelder, C.G., Schwarz, H., Boshart, M., and 
Overath, P. (2004). Kinetics of endocytosis and recycling of the GPI-anchored variant 
surface glycoprotein in Trypanosoma brucei. J. Cell Sci. 117, 1105–1115. 
Engstler, M., Pfohl, T., Herminghaus, S., Boshart, M., Wiegertjes, G., Heddergott, N., and 
Overath, P. (2007). Hydrodynamic flow-mediated protein sorting on the cell surface of 
trypanosomes. Cell 131, 505–515. 
Enyaru, J.C.K., Matovu, E., Nerima, B., Akol, M., and Sebikali, C. (2006). Detection of 
T.b. rhodesiense trypanosomes in humans and domestic animals in south east Uganda by 
amplification of serum resistance-associated gene. Ann. N. Y. Acad. Sci. 1081, 311–319. 
Fairlamb, A.H. (1989). Novel biochemical pathways in parasitic protozoa. Parasitology 99 
Suppl, S93–S112. 
Fairlamb, A.H., and Cerami, A. (1992). Metabolism and functions of trypanothione in the 
Kinetoplastida. Annu. Rev. Microbiol. 46, 695–729. 
Fairlamb, A.H., Blackburn, P., Ulrich, P., Chait, B.T., and Cerami, A. (1985). 
Trypanothione: a novel bis(glutathionyl)spermidine cofactor for glutathione reductase in 
trypanosomatids. Science 227, 1485–1487. 
148 
 
Fairlamb, A.H., Henderson, G.B., and Cerami, A. (1989). Trypanothione is the primary 
target for arsenical drugs against African trypanosomes. Proc. Natl. Acad. Sci. U. S. A. 86, 
2607–2611. 
Fan, T.W.-M., Lorkiewicz, P., Sellers, K., Moseley, H.N.B., Higashi, R.M., and Lane, 
A.N. (2012). Stable isotope-resolved metabolomics and applications for drug development. 
Pharmacol. Ther. 133, 366–391. 
Ferguson, M.A., and Cross, G.A. (1984). Myristylation of the membrane form of a 
Trypanosoma brucei variant surface glycoprotein. J. Biol. Chem. 259, 3011–3015. 
Ferguson, M.A., and Williams, A.F. (1988). Cell-surface anchoring of proteins via 
glycosyl-phosphatidylinositol structures. Annu. Rev. Biochem. 57, 285–320. 
Field, M.C., and Carrington, M. (2004). Intracellular membrane transport systems in 
Trypanosoma brucei. Traffic Cph. Den. 5, 905–913. 
Fisk, J.C., Li, J., Wang, H., Aletta, J.M., Qu, J., and Read, L.K. (2013). Proteomic analysis 
reveals diverse classes of arginine methylproteins in mitochondria of trypanosomes. Mol. 
Cell. Proteomics MCP 12, 302–311. 
Franco, J.R., Simarro, P.P., Diarra, A., and Jannin, J.G. (2014). Epidemiology of human 
African trypanosomiasis. Clin. Epidemiol. 6, 257–275. 
Frevert, U., Movila, A., Nikolskaia, O.V., Raper, J., Mackey, Z.B., Abdulla, M., 
McKerrow, J., and Grab, D.J. (2012). Early Invasion of Brain Parenchyma by African 
Trypanosomes. PLoS ONE 7. 
Fridman, E., and Pichersky, E. (2005). Metabolomics, genomics, proteomics, and the 
identification of enzymes and their substrates and products. Curr. Opin. Plant Biol. 8, 242–
248. 
Garcia, A., and Barbas, C. (2011). Gas chromatography-mass spectrometry (GC-MS)-
based metabolomics. Methods Mol. Biol. Clifton NJ 708, 191–204. 
Garcia, D.E., Baidoo, E.E., Benke, P.I., Pingitore, F., Tang, Y.J., Villa, S., and Keasling, 
J.D. (2008). Separation and mass spectrometry in microbial metabolomics. Curr. Opin. 
Microbiol. 11, 233–239. 
Garzón, E., Holzmuller, P., Bras-Gonçalves, R., Vincendeau, P., Cuny, G., Lemesre, J.L., 
and Geiger, A. (2013). The Trypanosoma brucei gambiense secretome impairs 
lipopolysaccharide-induced maturation, cytokine production, and allostimulatory capacity 
of dendritic cells. Infect. Immun. 81, 3300–3308. 
Geiger, A., Hirtz, C., Bécue, T., Bellard, E., Centeno, D., Gargani, D., Rossignol, M., 
Cuny, G., and Peltier, J.-B. (2010). Exocytosis and protein secretion in Trypanosoma. 
BMC Microbiol. 10, 20. 
Ghoda, L.Y., Savarese, T.M., Northup, C.H., Parks, R.E., Garofalo, J., Katz, L., 
Ellenbogen, B.B., and Bacchi, C.J. (1988). Substrate specificities of 5’-deoxy-5’-
methylthioadenosine phosphorylase from Trypanosoma brucei brucei and mammalian 
cells. Mol. Biochem. Parasitol. 27, 109–118. 
149 
 
Gibson, W. (2007). Resolution of the species problem in African trypanosomes. Int. J. 
Parasitol. 37, 829–838. 
Gonçalves, M.F., Umezawa, E.S., Katzin, A.M., de Souza, W., Alves, M.J., Zingales, B., 
and Colli, W. (1991). Trypanosoma cruzi: shedding of surface antigens as membrane 
vesicles. Exp. Parasitol. 72, 43–53. 
Gould, M.K., Vu, X.L., Seebeck, T., and de Koning, H.P. (2008). Propidium iodide-based 
methods for monitoring drug action in the kinetoplastidae: comparison with the Alamar 
Blue assay. Anal. Biochem. 382, 87–93. 
Grébaut, P., Chuchana, P., Brizard, J.-P., Demettre, E., Seveno, M., Bossard, G., Jouin, P., 
Vincendeau, P., Bengaly, Z., Boulangé, A., et al. (2009). Identification of total and 
differentially expressed excreted-secreted proteins from Trypanosoma congolense strains 
exhibiting different virulence and pathogenicity. Int. J. Parasitol. 39, 1137–1150. 
Grønborg, M., Kristiansen, T.Z., Iwahori, A., Chang, R., Reddy, R., Sato, N., Molina, H., 
Jensen, O.N., Hruban, R.H., Goggins, M.G., et al. (2006). Biomarker discovery from 
pancreatic cancer secretome using a differential proteomic approach. Mol. Cell. 
Proteomics MCP 5, 157–171. 
Haggarty, J., Oppermann, M., Dalby, M.J., Burchmore, R.J., Cook, K., Weidt, S., and 
Burgess, K.E.V. (2015). Serially coupling hydrophobic interaction and reversed-phase 
chromatography with simultaneous gradients provides greater coverage of the metabolome. 
Metabolomics 1–6. 
Hai, Y., Kerkhoven, E.J., Barrett, M.P., and Christianson, D.W. (2015). Crystal structure 
of an arginase-like protein from Trypanosoma brucei that evolved without a binuclear 
manganese cluster. Biochemistry (Mosc.) 54, 458–471. 
Hajduk, S.L., Hager, K.M., and Esko, J.D. (1994). Human high density lipoprotein killing 
of African trypanosomes. Annu. Rev. Microbiol. 48, 139–162. 
Van Hellemond, J.J., Opperdoes, F.R., and Tielens, A.G.M. (2005). The extraordinary 
mitochondrion and unusual citric acid cycle in Trypanosoma brucei. Biochem. Soc. Trans. 
33, 967–971. 
Hird, F.J. (1986). The importance of arginine in evolution. Comp. Biochem. Physiol. B 85, 
285–288. 
Hird, F.J.R., Cianciosi, S.C., McLean, R.M., and Niekrash, R.E. (1983). On the possible 
significance of the transamidination reaction in evolution. Comp. Biochem. Physiol. Part B 
Comp. Biochem. 76, 489–495. 
Hirumi, H., and Hirumi, K. (1989). Continuous cultivation of Trypanosoma brucei blood 
stream forms in a medium containing a low concentration of serum protein without feeder 
cell layers. J. Parasitol. 75, 985–989. 
Holzmuller, P., Grébaut, P., Peltier, J.-B., Brizard, J.-P., Perrone, T., Gonzatti, M., 
Bengaly, Z., Rossignol, M., Aso, P.M., Vincendeau, P., et al. (2008). Secretome of animal 
trypanosomes. Ann. N. Y. Acad. Sci. 1149, 337–342. 
Horn, D. (2004). The molecular control of antigenic variation in Trypanosoma brucei. 
Curr. Mol. Med. 4, 563–576. 
150 
 
Horn, D., and McCulloch, R. (2010). Molecular mechanisms underlying the control of 
antigenic variation in African trypanosomes. Curr. Opin. Microbiol. 13, 700–705. 
Hsu, J.-L., Huang, S.-Y., Chow, N.-H., and Chen, S.-H. (2003). Stable-isotope dimethyl 
labeling for quantitative proteomics. Anal. Chem. 75, 6843–6852. 
Hu, Q., Noll, R.J., Li, H., Makarov, A., Hardman, M., and Graham Cooks, R. (2005). The 
Orbitrap: a new mass spectrometer. J. Mass Spectrom. JMS 40, 430–443. 
Huet, G., Richet, C., Demeyer, D., Bisiau, H., Soudan, B., Tetaert, D., Han, K.K., and 
Degand, P. (1992). Characterization of different proteolytic activities in Trypanosoma 
brucei brucei. Biochim. Biophys. Acta 1138, 213–221. 
Jackson, A.P., Sanders, M., Berry, A., McQuillan, J., Aslett, M.A., Quail, M.A., 
Chukualim, B., Capewell, P., MacLeod, A., Melville, S.E., et al. (2010). The genome 
sequence of Trypanosoma brucei gambiense, causative agent of chronic human african 
trypanosomiasis. PLoS Negl. Trop. Dis. 4, e658. 
Jennings, F.W., Rodgers, J., Bradley, B., Gettinby, G., Kennedy, P.G.E., and Murray, M. 
(2002). Human African trypanosomiasis: Potential therapeutic benefits of an alternative 
suramin and melarsoprol regimen. Parasitol. Int. 51, 381–388. 
Joe, Y.A., Wolff, E.C., and Park, M.H. (1995). Cloning and expression of human 
deoxyhypusine synthase cDNA. Structure-function studies with the recombinant enzyme 
and mutant proteins. J. Biol. Chem. 270, 22386–22392. 
Jones, N.G., Thomas, E.B., Brown, E., Dickens, N.J., Hammarton, T.C., and Mottram, J.C. 
(2014). Regulators of Trypanosoma brucei cell cycle progression and differentiation 
identified using a kinome-wide RNAi screen. PLoS Pathog. 10, e1003886. 
Kamleh, A., Barrett, M.P., Wildridge, D., Burchmore, R.J.S., Scheltema, R.A., and 
Watson, D.G. (2008). Metabolomic profiling using Orbitrap Fourier transform mass 
spectrometry with hydrophilic interaction chromatography: a method with wide 
applicability to analysis of biomolecules. Rapid Commun. Mass Spectrom. RCM 22, 
1912–1918. 
Kennedy, P.G.E. (2004). Human African trypanosomiasis of the CNS: current issues and 
challenges. J. Clin. Invest. 113, 496–504. 
Kerkhoven, E. J. (2012). Extending a dynamic mathematical model of metabolism in 
Trypanosoma brucei. Ph.D. thesis, University of Glasgow, Glasgow. 
Keseler, I.M., Bonavides-Martínez, C., Collado-Vides, J., Gama-Castro, S., Gunsalus, 
R.P., Johnson, D.A., Krummenacker, M., Nolan, L.M., Paley, S., Paulsen, I.T., et al. 
(2009). EcoCyc: a comprehensive view of Escherichia coli biology. Nucleic Acids Res. 37, 
D464–D470. 
Kieft, R., Capewell, P., Turner, C.M.R., Veitch, N.J., MacLeod, A., and Hajduk, S. (2010). 
Mechanism of Trypanosoma brucei gambiense (group 1) resistance to human trypanosome 
lytic factor. Proc. Natl. Acad. Sci. U. S. A. 107, 16137–16141. 
Kilgour, V. (1980). Trypanosoma: intricacies of biochemistry, morphology and 
environment. Int. J. Biochem. 12, 325–332. 
151 
 
Kim, H., Kim, W.-J., Jeon, S.-T., Koh, E.-M., Cha, H.-S., Ahn, K.-S., and Lee, W.-H. 
(2005). Cyclophilin A may contribute to the inflammatory processes in rheumatoid arthritis 
through induction of matrix degrading enzymes and inflammatory cytokines from 
macrophages. Clin. Immunol. Orlando Fla 116, 217–224. 
T’ Kindt, R., Jankevics, A., Scheltema, R.A., Zheng, L., Watson, D.G., Dujardin, J.-C., 
Breitling, R., Coombs, G.H., and Decuypere, S. (2010). Towards an unbiased metabolic 
profiling of protozoan parasites: optimisation of a Leishmania sampling protocol for 
HILIC-orbitrap analysis. Anal. Bioanal. Chem. 398, 2059–2069. 
Kingdon, K.H. (1923). A Method for the Neutralization of Electron Space Charge by 
Positive Ionization at Very Low Gas Pressures. Phys. Rev. 21, 408–418. 
Koek, M.M., Jellema, R.H., van der Greef, J., Tas, A.C., and Hankemeier, T. (2011). 
Quantitative metabolomics based on gas chromatography mass spectrometry: status and 
perspectives. Metabolomics Off. J. Metabolomic Soc. 7, 307–328. 
Kohl, L., Robinson, D., and Bastin, P. (2003). Novel roles for the flagellum in cell 
morphogenesis and cytokinesis of trypanosomes. EMBO J. 22, 5336–5346. 
Lamour, N., Rivière, L., Coustou, V., Coombs, G.H., Barrett, M.P., and Bringaud, F. 
(2005). Proline metabolism in procyclic Trypanosoma brucei is down-regulated in the 
presence of glucose. J. Biol. Chem. 280, 11902–11910. 
Langousis, G., and Hill, K.L. (2014). Motility and more: the flagellum of Trypanosoma 
brucei. Nat. Rev. Microbiol. 12, 505–518. 
Larrouy-Maumus, G., Biswas, T., Hunt, D.M., Kelly, G., Tsodikov, O.V., and de Carvalho, 
L.P.S. (2013). Discovery of a glycerol 3-phosphate phosphatase reveals 
glycerophospholipid polar head recycling in Mycobacterium tuberculosis. Proc. Natl. 
Acad. Sci. U. S. A. 110, 11320–11325. 
Lee, S.H., Stephens, J.L., Paul, K.S., and Englund, P.T. (2006). Fatty acid synthesis by 
elongases in trypanosomes. Cell 126, 691–699. 
Lee, S.H., Stephens, J.L., and Englund, P.T. (2007). A fatty-acid synthesis mechanism 
specialized for parasitism. Nat. Rev. Microbiol. 5, 287–297. 
Liesener, A., and Karst, U. (2005). Monitoring enzymatic conversions by mass 
spectrometry: a critical review. Anal. Bioanal. Chem. 382, 1451–1464. 
Lillico, S., Field, M.C., Blundell, P., Coombs, G.H., and Mottram, J.C. (2003). Essential 
Roles for GPI-anchored Proteins in  African Trypanosomes Revealed Using Mutants 
Deficient in GPI8. Mol. Biol. Cell 14, 1182–1194. 
Liscombe, D.K., Usera, A.R., and O’Connor, S.E. (2010). Homolog of tocopherol C 
methyltransferases catalyzes N methylation in anticancer alkaloid biosynthesis. Proc. Natl. 
Acad. Sci. U. S. A. 107, 18793–18798. 
Mackenzie, N.E., Hall, J.E., Flynn, I.W., and Scott, A.I. (1983). 13C nuclear magnetic 
resonance studies of anaerobic glycolysis in Trypanosoma brucei spp. Biosci. Rep. 3, 141–
151. 
152 
 
Makarov, A. (2000). Electrostatic Axially Harmonic Orbital Trapping:  A High-
Performance Technique of Mass Analysis. Anal. Chem. 72, 1156–1162. 
Makarov, A., Denisov, E., Lange, O., and Horning, S. (2006). Dynamic range of mass 
accuracy in LTQ Orbitrap hybrid mass spectrometer. J. Am. Soc. Mass Spectrom. 17, 977–
982. 
Matthews, K.R. (2005). The developmental cell biology of Trypanosoma brucei. J. Cell 
Sci. 118, 283–290. 
Mazet, M., Morand, P., Biran, M., Bouyssou, G., Courtois, P., Daulouède, S., Millerioux, 
Y., Franconi, J.-M., Vincendeau, P., Moreau, P., et al. (2013). Revisiting the central 
metabolism of the bloodstream forms of Trypanosoma brucei: production of acetate in the 
mitochondrion is essential for parasite viability. PLoS Negl. Trop. Dis. 7, e2587. 
Melville, S.E., Leech, V., Gerrard, C.S., Tait, A., and Blackwell, J.M. (1998). The 
molecular karyotype of the megabase chromosomes of Trypanosoma brucei and the 
assignment of chromosome markers. Mol. Biochem. Parasitol. 94, 155–173. 
Melville, S.E., Leech, V., Navarro, M., and Cross, G.A. (2000). The molecular karyotype 
of the megabase chromosomes of Trypanosoma brucei stock 427. Mol. Biochem. Parasitol. 
111, 261–273. 
Michels, P.A.M., Bringaud, F., Herman, M., and Hannaert, V. (2006). Metabolic functions 
of glycosomes in trypanosomatids. Biochim. Biophys. Acta 1763, 1463–1477. 
Miézan, T.W., Bronner, U., Doua, F., Cattand, P., and Rombo, L. (1994). Long-term 
exposure of Trypanosoma brucei gambiense to pentamidine in vitro. Trans. R. Soc. Trop. 
Med. Hyg. 88, 332–333. 
Miranda, M.R., Canepa, G.E., Bouvier, L.A., and Pereira, C.A. (2006). Trypanosoma 
cruzi: Oxidative stress induces arginine kinase expression. Exp. Parasitol. 114, 341–344. 
Molina-Portela, M. del P., Lugli, E.B., Recio-Pinto, E., and Raper, J. (2005). Trypanosome 
lytic factor, a subclass of high-density lipoprotein, forms cation-selective pores in 
membranes. Mol. Biochem. Parasitol. 144, 218–226. 
Moreno, B., Urbina, J.A., Oldfield, E., Bailey, B.N., Rodrigues, C.O., and Docampo, R. 
(2000). 31P NMR Spectroscopy of Trypanosoma brucei, Trypanosoma cruzi, and 
Leishmania major EVIDENCE FOR HIGH LEVELS OF CONDENSED INORGANIC 
PHOSPHATES. J. Biol. Chem. 275, 28356–28362. 
Morris, S.M. (2002). Regulation of Enzymes of the Urea Cycle and Arginine Metabolism. 
Annu. Rev. Nutr. 22, 87–105. 
Morris, M.T., DeBruin, C., Yang, Z., Chambers, J.W., Smith, K.S., and Morris, J.C. 
(2006). Activity of a second Trypanosoma brucei hexokinase is controlled by an 18-amino-
acid C-terminal tail. Eukaryot. Cell 5, 2014–2023. 
Morty, R.E., Lonsdale-Eccles, J.D., Mentele, R., Auerswald, E.A., and Coetzer, T.H. 
(2001). Trypanosome-derived oligopeptidase B is released into the plasma of infected 
rodents, where it persists and retains full catalytic activity. Infect. Immun. 69, 2757–2761. 
153 
 
Nerima, B., Nilsson, D., and Mäser, P. (2010). Comparative genomics of metabolic 
networks of free-living and parasitic eukaryotes. BMC Genomics 11, 217. 
Nguyen, S., Jones, D.C., Wyllie, S., Fairlamb, A.H., and Phillips, M.A. (2013). Allosteric 
activation of trypanosomatid deoxyhypusine synthase by a catalytically dead paralog. J. 
Biol. Chem. 288, 15256–15267. 
Nicholson, J.K., Connelly, J., Lindon, J.C., and Holmes, E. (2002). Metabonomics: a 
platform for studying drug toxicity and gene function. Nat. Rev. Drug Discov. 1, 153–161. 
Nikolskaia, O.V., de A Lima, A.P.C., Kim, Y.V., Lonsdale-Eccles, J.D., Fukuma, T., 
Scharfstein, J., and Grab, D.J. (2006). Blood-brain barrier traversal by African 
trypanosomes requires calcium signaling induced by parasite cysteine protease. J. Clin. 
Invest. 116, 2739–2747. 
Nozaki, T., Ali, V., and Tokoro, M. (2005). Sulfur-containing amino acid metabolism in 
parasitic protozoa. Adv. Parasitol. 60, 1–99. 
Nwagwu, M., and Opperdoes, F.R. (1982). Regulation of glycolysis in Trypanosoma 
brucei: hexokinase and phosphofructokinase activity. Acta Trop. 39, 61–72. 
O’Farrell, P.H. (1975). High resolution two-dimensional electrophoresis of proteins. J. 
Biol. Chem. 250, 4007–4021. 
Olver, C., and Vidal, M. (2007). Proteomic analysis of secreted exosomes. Subcell. 
Biochem. 43, 99–131. 
Opperdoes, F.R., and Borst, P. (1977). Localization of nine glycolytic enzymes in a 
microbody-like organelle in Trypanosoma brucei: the glycosome. FEBS Lett. 80, 360–364. 
Ozment, C., Barchue, J., DeLucas, L.J., and Chattopadhyay, D. (1999). Structural Study of 
Escherichia coli NAD Synthetase: Overexpression, Purification, Crystallization, and 
Preliminary Crystallographic Analysis. J. Struct. Biol. 127, 279–282. 
Parkin, D.W. (1996). Purine-specific nucleoside N-ribohydrolase from Trypanosoma 
brucei brucei. Purification, specificity, and kinetic mechanism. J. Biol. Chem. 271, 21713–
21719. 
Peacock, L., Ferris, V., Bailey, M., and Gibson, W. (2008). Fly transmission and mating of 
Trypanosoma brucei brucei strain 427. Mol. Biochem. Parasitol. 160, 100–106. 
Pegg, A.E. (2009). Mammalian polyamine metabolism and function. IUBMB Life 61, 
880–894. 
Pereira, C.A. (2014). Arginine kinase: a potential pharmacological target in 
trypanosomiasis. Infect. Disord. Drug Targets 14, 30–36. 
Pils, B., and Schultz, J. (2004). Inactive enzyme-homologues find new function in 
regulatory processes. J. Mol. Biol. 340, 399–404. 
Poulin, R., Lu, L., Ackermann, B., Bey, P., and Pegg, A.E. (1992). Mechanism of the 
irreversible inactivation of mouse ornithine decarboxylase by alpha-
difluoromethylornithine. Characterization of sequences at the inhibitor and coenzyme 
binding sites. J. Biol. Chem. 267, 150–158. 
154 
 
Priotto, G., Kasparian, S., Ngouama, D., Ghorashian, S., Arnold, U., Ghabri, S., and 
Karunakara, U. (2007). Nifurtimox-Eflornithine Combination Therapy for Second-Stage 
Trypanosoma brucei gambiense Sleeping Sickness: A Randomized Clinical Trial in 
Congo. Clin. Infect. Dis. 45, 1435–1442. 
Probst, P., Stromberg, E., Ghalib, H.W., Mozel, M., Badaro, R., Reed, S.G., and Webb, 
J.R. (2001). Identification and Characterization of T Cell-Stimulating Antigens from 
Leishmania by CD4 T Cell Expression Cloning. J. Immunol. 166, 498–505. 
Prosser, G.A., Larrouy-Maumus, G., and de Carvalho, L.P.S. (2014). Metabolomic 
strategies for the identification of new enzyme functions and metabolic pathways. EMBO 
Rep. 15, 657–669. 
Proto, W.R., Castanys-Munoz, E., Black, A., Tetley, L., Moss, C.X., Juliano, L., Coombs, 
G.H., and Mottram, J.C. (2011). Trypanosoma brucei metacaspase 4 is a pseudopeptidase 
and a virulence factor. J. Biol. Chem. 286, 39914–39925. 
Punta, M., Coggill, P.C., Eberhardt, R.Y., Mistry, J., Tate, J., Boursnell, C., Pang, N., 
Forslund, K., Ceric, G., Clements, J., et al. (2012). The Pfam protein families database. 
Nucleic Acids Res. 40, D290–D301. 
Quiñones, W., Peña, P., Domingo-Sananes, M., Cáceres, A., Michels, P.A.M., Avilan, L., 
and Concepción, J.L. (2007). Leishmania mexicana: Molecular cloning and 
characterization of enolase. Exp. Parasitol. 116, 241–251. 
Ranganathan, S., and Garg, G. (2009). Secretome: clues into pathogen infection and 
clinical applications. Genome Med. 1, 113. 
Redmond, S., Vadivelu, J., and Field, M.C. (2003). RNAit: an automated web-based tool 
for the selection of RNAi targets in Trypanosoma brucei. Mol. Biochem. Parasitol. 128, 
115–118. 
Reguera, R.M., Redondo, C.M., Pérez-Pertejo, Y., and Balaña-Fouce, R. (2007). S-
Adenosylmethionine in protozoan parasites: Functions, synthesis and regulation. Mol. 
Biochem. Parasitol. 152, 1–10. 
Rivière, L., Weelden, S.W.H. van, Glass, P., Vegh, P., Coustou, V., Biran, M., Hellemond, 
J.J. van, Bringaud, F., Tielens, A.G.M., and Boshart, M. (2004). Acetyl:Succinate CoA-
transferase in Procyclic Trypanosoma brucei GENE IDENTIFICATION AND ROLE IN 
CARBOHYDRATE METABOLISM. J. Biol. Chem. 279, 45337–45346. 
Robinson, M.D., Souza, D.P.D., Keen, W.W., Saunders, E.C., McConville, M.J., Speed, 
T.P., and Likić, V.A. (2007). A dynamic programming approach for the alignment of 
signal peaks in multiple gas chromatography-mass spectrometry experiments. BMC 
Bioinformatics 8, 419. 
Rodgers, J. (2009). Human African trypanosomiasis, chemotherapy and CNS disease. J. 
Neuroimmunol. 211, 16–22. 
Saghatelian, A., Trauger, S.A., Want, E.J., Hawkins, E.G., Siuzdak, G., and Cravatt, B.F. 
(2004). Assignment of endogenous substrates to enzymes by global metabolite profiling. 
Biochemistry (Mosc.) 43, 14332–14339. 
155 
 
Saito, N., Robert, M., Kitamura, S., Baran, R., Soga, T., Mori, H., Nishioka, T., and 
Tomita, M. (2006). Metabolomics approach for enzyme discovery. J. Proteome Res. 5, 
1979–1987. 
Saito, N., Robert, M., Kochi, H., Matsuo, G., Kakazu, Y., Soga, T., and Tomita, M. (2009). 
Metabolite profiling reveals YihU as a novel hydroxybutyrate dehydrogenase for 
alternative succinic semialdehyde metabolism in Escherichia coli. J. Biol. Chem. 284, 
16442–16451. 
Schauer, N., Steinhauser, D., Strelkov, S., Schomburg, D., Allison, G., Moritz, T., 
Lundgren, K., Roessner-Tunali, U., Forbes, M.G., Willmitzer, L., et al. (2005). GC–MS 
libraries for the rapid identification of metabolites in complex biological samples. FEBS 
Lett. 579, 1332–1337. 
Scheltema, R.A., Jankevics, A., Jansen, R.C., Swertz, M.A., and Breitling, R. (2011). 
PeakML/mzMatch: a file format, Java library, R library, and tool-chain for mass 
spectrometry data analysis. Anal. Chem. 83, 2786–2793. 
Schumann Burkard, G., Jutzi, P., and Roditi, I. (2011). Genome-wide RNAi screens in 
bloodstream form trypanosomes identify drug transporters. Mol. Biochem. Parasitol. 175, 
91–94. 
Sherwin, T., and Gull, K. (1989). Visualization of detyrosination along single microtubules 
reveals novel mechanisms of assembly during cytoskeletal duplication in trypanosomes. 
Cell 57, 211–221. 
Da Silveira, J.F., Abrahamsohn, P.A., and Colli, W. (1979). Plasma membrane vesicles 
isolated from epimastigote forms of Trypanosoma cruzi. Biochim. Biophys. Acta 550, 
222–232. 
Silverman, J.S., and Bangs, J.D. (2012). Form and function in the trypanosomal secretory 
pathway. Curr. Opin. Microbiol. 15, 463–468. 
Simarro, P.P., Cecchi, G., Franco, J.R., Paone, M., Diarra, A., Ruiz-Postigo, J.A., Fèvre, 
E.M., Mattioli, R.C., and Jannin, J.G. (2012). Estimating and mapping the population at 
risk of sleeping sickness. PLoS Negl. Trop. Dis. 6, e1859. 
Simpson, L., and Shaw, J. (1989). RNA editing and the mitochondrial cryptogenes of 
kinetoplastid protozoa. Cell 57, 355–366. 
Smith, T.K., and Bütikofer, P. (2010). Lipid metabolism in Trypanosoma brucei. Mol. 
Biochem. Parasitol. 172, 66–79. 
Spencer, R.L., and Preiss, J. (1967). Biosynthesis of diphosphopyridine nucleotide. The 
purification and the properties of diphospyridine nucleotide synthetase from Escherichia 
coli b. J. Biol. Chem. 242, 385–392. 
Stephens, J.L., Lee, S.H., Paul, K.S., and Englund, P.T. (2007). Mitochondrial fatty acid 
synthesis in Trypanosoma brucei. J. Biol. Chem. 282, 4427–4436. 
Stipanuk, M.H. (2004). SULFUR AMINO ACID METABOLISM: Pathways for 
Production and Removal of Homocysteine and Cysteine. Annu. Rev. Nutr. 24, 539–577. 
156 
 
Stuart, K.D., and Gelvin, S.B. (1982). Localization of kinetoplast DNA maxicircle 
transcripts in bloodstream and procyclic form Trypanosoma brucei. Mol. Cell. Biol. 2, 
845–852. 
Sutton, R.E., and Boothroyd, J.C. (1986). Evidence for Trans splicing in trypanosomes. 
Cell 47, 527–535. 
Tabor, C.W., and Tabor, H. (1984). Polyamines. Annu. Rev. Biochem. 53, 749–790. 
Tetaud, E., Lecuix, I., Sheldrake, T., Baltz, T., and Fairlamb, A.H. (2002). A new 
expression vector for Crithidia fasciculata and Leishmania. Mol. Biochem. Parasitol. 120, 
195–204. 
Tjalsma, H., Bolhuis, A., Jongbloed, J.D., Bron, S., and van Dijl, J.M. (2000). Signal 
peptide-dependent protein transport in Bacillus subtilis: a genome-based survey of the 
secretome. Microbiol. Mol. Biol. Rev. MMBR 64, 515–547. 
Tomlinson, S., Jansen, A.M., Koudinov, A., Ghiso, J.A., Choi-Miura, N.H., Rifkin, M.R., 
Ohtaki, S., and Nussenzweig, V. (1995). High-density-lipoprotein-independent killing of 
Trypanosoma brucei by human serum. Mol. Biochem. Parasitol. 70, 131–138. 
Triggs, V.P., and Bangs, J.D. (2003). Glycosylphosphatidylinositol-Dependent Protein 
Trafficking in Bloodstream Stage Trypanosoma brucei. Eukaryot. Cell 2, 76–83. 
Vanegas, G., Quiñones, W., Carrasco-López, C., Concepción, J.L., Albericio, F., and 
Avilán, L. (2007). Enolase as a plasminogen binding protein in Leishmania mexicana. 
Parasitol. Res. 101, 1511–1516. 
Vanhamme, L., Paturiaux-Hanocq, F., Poelvoorde, P., Nolan, D.P., Lins, L., Van Den 
Abbeele, J., Pays, A., Tebabi, P., Van Xong, H., Jacquet, A., et al. (2003). Apolipoprotein 
L-I is the trypanosome lytic factor of human serum. Nature 422, 83–87. 
Velez, N., Brautigam, C.A., and Phillips, M.A. (2013). Trypanosoma brucei S-
adenosylmethionine decarboxylase N terminus is essential for allosteric activation by the 
regulatory subunit prozyme. J. Biol. Chem. 288, 5232–5240. 
Vincent, I. M. (2011). Using metabolomic analyses to study mode of action and resistance 
to Eflornithine in Trypanosoma brucei. Ph.D. thesis, University of Glasgow, Glasgow.  
Vincent, I.M., Creek, D.J., Burgess, K., Woods, D.J., Burchmore, R.J.S., and Barrett, M.P. 
(2012). Untargeted metabolomics reveals a lack of synergy between nifurtimox and 
eflornithine against Trypanosoma brucei. PLoS Negl. Trop. Dis. 6, e1618. 
Voncken, F., Gao, F., Wadforth, C., Harley, M., and Colasante, C. (2013). The 
phosphoarginine energy-buffering system of trypanosoma brucei involves multiple 
arginine kinase isoforms with different subcellular locations. PloS One 8, e65908. 
Walker, J., and Barrett, J. (1997). Parasite sulphur amino acid metabolism. Int. J. Parasitol. 
27, 883–897. 
Watson, D.G. (2010). The potential of mass spectrometry for the global profiling of 
parasite metabolomes. Parasitology 137, 1409–1423. 
157 
 
Van Weelden, S.W.H., van Hellemond, J.J., Opperdoes, F.R., and Tielens, A.G.M. (2005). 
New functions for parts of the Krebs cycle in procyclic Trypanosoma brucei, a cycle not 
operating as a cycle. J. Biol. Chem. 280, 12451–12460. 
Van der Werf, M.J., Jellema, R.H., and Hankemeier, T. (2005). Microbial metabolomics: 
replacing trial-and-error by the unbiased selection and ranking of targets. J. Ind. Microbiol. 
Biotechnol. 32, 234–252. 
Whisstock, J.C., and Lesk, A.M. (2003). Prediction of protein function from protein 
sequence and structure. Q. Rev. Biophys. 36, 307–340. 
Wickstead, B., Ersfeld, K., and Gull, K. (2004). The small chromosomes of Trypanosoma 
brucei involved in antigenic variation are constructed around repetitive palindromes. 
Genome Res. 14, 1014–1024. 
Willert, E., and Phillips, M.A. (2012). Regulation and function of polyamines in African 
trypanosomes. Trends Parasitol. 28, 66–72. 
Willert, E.K., Fitzpatrick, R., and Phillips, M.A. (2007). Allosteric regulation of an 
essential trypanosome polyamine biosynthetic enzyme by a catalytically dead homolog. 
Proc. Natl. Acad. Sci. U. S. A. 104, 8275–8280. 
Wilson, W., and Seebeck, T. (1997). Identification of a profilin homologue in 
Trypanosoma brucei by complementation screening. Gene 187, 201–209. 
Winder, C.L., Dunn, W.B., and Goodacre, R. (2011). TARDIS-based microbial 
metabolomics: time and relative differences in systems. Trends Microbiol. 19, 315–322. 
Wojcik, M., Seidle, H.F., Bieganowski, P., and Brenner, C. (2006). Glutamine-dependent 
NAD+ synthetase. How a two-domain, three-substrate enzyme avoids waste. J. Biol. 
Chem. 281, 33395–33402. 
 
  
158 
 
Appendix A 
Growth media for T. b.brucei 
 
(1) Modified HMI-9 
 
For 500 ml modified HMI-9: 
 
Iscoves modified Dulbecco’s medium  + glutamax (Gibco)    365 ml 
Methyl cellulose (Sigma)       0.55g 
add: 
 
Compound 
Concentration (mM) 
Stocksolution 
Concentration final 
in modified HMI-9 
Bathocuproinedisulfonic acid 5 0.5 µM 
L-cysteine 100 1 mM 
Sodium pyruvate 200 2 M 
Thymidine 16 160 µM 
Hypoxanthine  2 mM 
D-glucose  5.5 mM 
Adenosine  0.5 mM 
Guanosine  0.5 mM 
Mercaptoethanol  3 µM 
Pen/Strep  5000 Units 
FBS Gold (PAA)  20% 
Serum plus  20% 
 
 
Table A1: Modified HMI-9 (adapted from Paul Voorheis). 
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(2) Creek’s minimal medium (CMM) 
 
Compound Concentration (µM) 
Bathocuproine disulfonic acid 52 
Phenolsulfonphtalein 42 
HEPES 10,000 
NaCl 77,590 
CaCl2 1,490 
KCl 4,400 
MgSO4 814 
NaHCO3 35,950 
D-glucose 10,000 
L-glutamine 1,000 
L-cysteine 1,000 
Mercaptoethanol 192 
FBS Gold (PAA) 10% 
 
Table A2: Creek’s minimal media (CMM) (Creel et al., 2013).  If a different brand FBS does not 
support growth in this medium, L-arginine, L-tyrosine, L-methionine, L-leucine, L-phenylalanine and 
L-tryptophan should be added (100µM). 
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Appendix B 
Gene ID Gene name Description Sequence 
Tb427.01.1130 glycerol-3-phosphate dehydrogenase Recombinat expression, fwd GGTATTGAGGGTCGCATGGGTCGCTATACGCGCCG 
    Recombinat Expresssion, rev AGAGGAGAGTTAGAGCCTCATGTGAGAGCCGTGGCGG 
Tb427.06.4920 S-adenosylmethionine synthetase Recombinat expression, fwd GGTATTGAGGGTCGCATGTCCGTGCGCCAG 
    Recombinat Expresssion, rev AGAGGAGAGTTAGAGCCCTACTGCACGTCACTAAGACC 
Tb427.07.4390 threonine synthase Recombinat expression, fwd GGTATTGAGGGTCGCATGCTCACCTTACGCG 
    Recombinat Expresssion, rev AGAGGAGAGTTAGAGCCTCAGCAAGAGCCCTCACTGG 
Tb427.08.3800 nucleoside phosphatase Recombinat expression, fwd GGTATTGAGGGTCGCATGTTGCACTCAAACCACCC 
    Recombinat Expresssion, rev AGAGGAGAGTTAGAGCCTCACACACAGTGCTCCTCTAAGC 
Tb427.10.12980 methyltransferase Recombinat expression, fwd GGTATTGAGGGTCGCATGTGGAAACCGAAACAGCG 
    Recombinat Expresssion, rev AGAGGAGAGTTAGAGCCTCAAGGATCACGCACGTCTGGC 
Tb427.10.13130 UTP-glucose-1-phosphate uridylyltransferase Recombinat expression, fwd GGTATTGAGGGTCGCATGCCGCTAAACCCTCCTTCAGC 
    Recombinat Expresssion, rev AGAGGAGAGTTAGAGCCCTACTCGACTACCACAACC 
Tb427.10.13430 citrate synthase Recombinat expression, fwd GGTATTGAGGGTCGCATGTGCATGCGTGCTCG 
    Recombinat Expresssion, rev AGAGGAGAGTTAGAGCCCTACGCTATGTTGTACTTTGTG 
Tb427tmp.01.3640 acyl-CoA dehydrogenase Recombinat expression, fwd GGTATTGAGGGTCGCATGTTTCGTCGTAGCCTTTCCC 
    Recombinat Expresssion, rev AGAGGAGAGTTAGAGCCTCACCTAAGATCCCATGTCG 
Tb427tmp.02.0530 phosphoribosylpyrophosphate synthetase Recombinat expression, fwd GGTATTGAGGGTCGCATGGGTTGTGCCATGCATTTCGC 
    Recombinat Expresssion, rev AGAGGAGAGTTAGAGCCCTATGTGCGGAACAAAGAGG 
Tb427tmp.02.3040 aldo/keto reductase Recombinat expression, fwd GGTATTGAGGGTCGCATGGACCGTATTCCATATTTGG 
    Recombinat Expresssion, rev AGAGGAGAGTTAGAGCCTTAATCTATCGTGTTGCTATGCC 
Tb427.10.2490 glucose-6-phosphate 1-dehydrogenase Recombinat expression, fwd GGTATTGAGGGTCGCATGGACGGTGATCTTTCCC 
    Recombinat Expresssion, rev AGAGGAGAGTTAGAGCCTTACAAATGATGAAGCTTCCGC 
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Gene ID Gene name Description Sequence 
Tb427.05.3820 aspartate carbamoyltransferase Recombinat expression, fwd GGTATTGAGGGTCGCATGGCGGAGCTGCAACCTG 
    Recombinat Expresssion, rev AGAGGAGAGTTAGAGCCTTAGGCGAGAACACTATAAAG 
Tb427.10.2010  Hexokinase I Recombinat expression, fwd GGTATTGAGGGTCGCATGTCTAGACGCCTAAACAATATCC 
    Recombinat Expresssion, rev AGAGGAGAGTTAGAGCCTTACTTGTCGTTCACCACCATTGCG 
Tb427.05.4560 guanine deaminase Recombinat expression, fwd GGTATTGAGGGTCGCATGNAAACCGCCGTGCCTGTGCG 
    Recombinat Expresssion, rev AGAGGAGAGTTAGAGCCCTAAAGTTCTACCCTCCCGTGGACC 
Table B1: Oligonucleotides used in this study for protein over expression. The inserted overhang necessary for ligase independent cloning is underlined.  
 
Gene ID Gene name Description Sequence 
Tb427.05.3820 aspartate carbamoyltransferase G197
RNAi
, fwd GGGGACAAGTTTGTACAAAAAAGCAGGCTGTGACGTACTTGTGCTGCGT 
    G197
RNAi
, rev GGGGACCACTTTGTACAAGAAAGCTGGGTAATGACGATATCCGCCTTTG 
Tb427tmp.02.3040 aldo/keto reductase G196
RNAi
, fwd GGGGACAAGTTTGTACAAAAAAGCAGGCTCATTGATTACGCCGATTGTG 
    G196
RNAi
, rev GGGGACCACTTTGTACAAGAAAGCTGGGTGCTCCCTCCGAGAAGAAACT 
Tb11.01.6500 NAD+ synthase G162
RNAi
, fwd GGGGACAAGTTTGTACAAAAAAGCAGGCTTGGTTGGAGGAATACCGAAG 
    G162
RNAi
, rev GGGGACCACTTTGTACAAGAAAGCTGGGTGTAGCCATCCTCGTCCATGT 
Tb927.7.5680 deoxyribose-phosphate aldolase G159
RNAi
, fwd GGGGACAAGTTTGTACAAAAAAGCAGGCTCTAAAACCTGAGGCAACCCA 
    G159
RNAi
, rev 
 
GGGGACCACTTTGTACAAGAAAGCTGGGTGCAGCGACTGACAGGATACA 
Table B2: Oligonucleotides used in this study for creation of RNAi lines 
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Appendix C 
General buffers and solutions 
 
0.1% coomassie blue stain (200 mL) 
Coomassie blue 0.2 g   
Methanol  80 mL  
Acetic acid  20 mL   
dH2O   100 mL  
 
Destaining solution for protein gels (500 mL) 
Methanol  100 mL   
Acetic acid  50 mL    
dH2O   350 mL   
 
LB medium (Luria Bertani broth, pH 7) 
LB powder (Sigma-Aldrich)  25 g 
dH2O     1 L 
 
LB agar 
Luria Agar (Sigma-Aldrich)  35 g 
dH2O     1 L 
 
DiGE lysis buffer: 
Urea   6 M 
Thiourea  2 M 
CHAPS  4% 
Tris base  25mM 
 
Rehydration buffer: 
Urea    6 M 
Thiourea   2 M 
CHAPS   4% 
IPG buffer   0.5% 
DTT    65 mM 
Trace of bromophenol blue 
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Appendix D 
Table of the three authentic standard mixes run with every metabolomics experiment. 
Shown are the metabolite name and formula. The polarity mode (positive or negative) the 
metabolite was best detected in and the expected retention time. 
 
Mix Compound Name Formula Polarity Expected RT 
1 1-Naphthylacetic acid C12H10O2 + 4.21 
  Serotonin C10H12N2O + 4.28 
  Melatonin C13H16N2O2 + 4.67 
  Phenylhydrazine C6H8N2 + 5.08 
  Nicotinate C6H5NO2 + 6.99 
  Pyridoxine C8H11NO3 + 7.45 
  riboflavin C17H20N4O6 + 7.62 
  Glycerol C3H8O3 + 8.12 
  Adenine C5H5N5 + 8.34 
  Creatinine C4H7N3O + 8.42 
  L-Phenylalanine C9H11NO2 + 8.34 
  L-Leucine C6H13NO2 + 8.74 
  4-Aminobenzoate C7H7NO2 + 9.35 
  Inosine C10H12N4O5 + 8.96 
  2-Phenylglycine C8H9NO2 + 8.9 
  Selenomethionine C5H11NO2Se + 9.03 
  L-Methionine C5H11NO2S + 9.07 
  Imidazole-4-acetate C5H6N2O2 + 9.03 
  L-Tryptophan C11H12N2O2 + 9.35 
  N-Acetyl-D-glucosamine C8H15NO6 + 9.33 
  Cytidine C9H13N3O5 + 9.53 
  Guanine C5H5N5O + 9.98 
  L-Valine C5H11NO2 + 9.59 
  L-Proline C5H9NO2 + 9.75 
  sn-glycero-3-Phosphocholine C8H20NO6P + 10.23 
  L-Threonine C4H9NO3 + 10.4 
  trans-4-Hydroxy-L-proline C5H9NO3 + 10.52 
  L-Histidine C6H9N3O2 + 10.48 
  N2-Acetyl-L-lysine C8H16N2O3 + 10.57 
  D-Glucosamine C6H13NO5 + 10.72 
  L-Glutamine C5H10N2O3 + 10.65 
  Taurine C2H7NO3S + 10.94 
  L-Aspartate C4H7NO4 + 10.52 
  L-Asparagine C4H8N2O3 + 10.76 
  beta-Alanine C3H7NO2 + 10.94 
  Glycine C2H5NO2 + 11.13 
  dGMP C10H14N5O7P + 10.52 
  L-Serine C3H7NO3 + 11.09 
  Ethanolamine phosphate C2H8NO4P + 10.72 
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 1 L-Citrulline C6H13N3O3 + 11.04 
  L-Cystine C6H12N2O4S2 + 10.87 
  meso-2_6-Diaminoheptanedioate C7H14N2O4 + 11.8 
  Putrescine C4H12N2 + 11.56 
  L-2_4-Diaminobutanoate C4H10N2O2 + 12.27 
  Thiamin C12H16N4OS + 16.71 
  L-Lysine C6H14N2O2 + 15.38 
  L-Arginine C6H14N4O2 + 16.42 
  S-Adenosyl-L-methionine C15H22N6O5S + 0 
  Phenolsulfonphthalein C19H14O5S - 5.11 
 
Thymidine C10H14N2O5 - 6.79 
  MOPS C7H15NO4S - 6.73 
  Pyruvate C3H4O3 - 7.41 
  Deoxyuridine C9H12N2O5 - 7.52 
  4-Coumarate C9H8O3 - 7.39 
  pyrazinoate C5H4N2O2 - 7.72 
  (R)-3-Hydroxybutanoate C4H8O3 - 7.87 
  3'_5'-Cyclic AMP C10H12N5O6P - 7.93 
  Uridine C9H12N2O6 - 8.47 
  D-glucose C6H12O6 - 10.77 
  Orotate C5H4N2O4 - 8.58 
  L-Rhamnose C6H12O5 - 9.16 
  Xanthine C5H4N4O2 - 9.28 
  3_4-Dihydroxyphenylacetate C8H8O4 - 10.15 
  Pyridoxal phosphate C8H10NO6P - 0 
  Phthalate C8H6O4 - 10.24 
  D-Gluconic acid C6H12O7 - 10.17 
  UMP C9H13N2O9P - 9.93 
  Thiamin diphosphate C12H18N4O7P2S - 9.86 
  L-Glutamate C5H9NO4 - 10.34 
  IMP C10H13N4O8P - 10.15 
  Methylmalonate C4H6O4 - 10.54 
  CMP C9H14N3O8P - 10.43 
  (R)-2-Hydroxyglutarate C5H8O5 - 10.62 
  L-Cysteate C3H7NO5S - 11.08 
  D-ribose 5-phosphate C5H11O8P - 10.66 
  Malonate C3H4O4 - 10.95 
  D-Galacturonate C6H10O7 - 11.28 
  Fumarate C4H4O4 - 9.89 
  D-glucose 6-phosphate C6H13O9P - 11.12 
  D-Galactarate C6H10O8 - 11.48 
  Phosphoenolpyruvate C3H5O6P - 11.52 
  6-Phospho-D-gluconate C6H13O10P - 11.39 
  cis-Aconitate C6H6O6 - 11.77 
  Gallate C7H6O5 - 13.11 
  D-Erythrose C4H8O4 - 0 
  Maltose C12H22O11 - 0 
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2-oxobutanoate C4H6O3 - 0 
 1 2-Methylcitrate C7H10O7 - 0 
  Glyoxylate C2H2O3 - 0 
  glycolate C2H4O3 - 0 
  methylglyoxal C3H4O2 - 0 
  IDP C10H14N4O11P2 - 0 
  ADP C10H15N5O10P2 - 0 
  D-Fructose 1_6-bisphosphate C6H14O12P2 - 0 
  CoA C21H36N7O16P3S - 0 
  2_3-Bisphospho-D-glycerate C3H8O10P2 - 0 
  3-Hydroxyphenylacetate C8H8O3 - 0 
  Cholesterol C27H46O + 0 
 
1-Butanol C4H10O + 0 
  Oxaloacetate C4H4O5 + 0 
  Imidazole C3H4N2 + 0 
  glyceraldehyde C3H6O3 + 0 
2 Menadione C11H8O2 + 15.65 
  Dopamine C8H11NO2 + 8.28 
  Thiopurine S-methylether C6H6N4S + 6.35 
  5'-Methylthioadenosine C11H15N5O3S + 6.52 
  Nicotinamide C6H6N2O + 6.8 
  4-(beta-Acetylaminoethyl)imidazole C7H11N3O + 6.92 
  Pyridoxal C8H9NO3 + 7.74 
  6-Methylaminopurine C6H7N5 + 7.36 
  Deoxyadenosine C10H13N5O3 + 7.46 
  Pantothenate C9H17NO5 + 7.46 
  Uracil C4H4N2O2 + 7.85 
  Picolinic acid C6H5NO2 + 7.55 
  thymine C5H6N2O2 + 7.11 
  Adenosine C10H13N5O4 + 7.94 
  Hypoxanthine C5H4N4O + 8.75 
  5-Oxoproline C5H7NO3 + 8.36 
  HEPES C8H18N2O4S + 8.36 
  L-Kynurenine C10H12N2O3 + 8.81 
  Betaine C5H11NO2 + 9.03 
  cytosine C4H5N3O + 9.39 
  FAD C27H33N9O15P2 + 8.47 
  L-isoleucine C6H13NO2 + 9.3 
  Methylcysteine C4H9NO2S + 9.18 
  Ala-Gly C5H10N2O3 + 9.14 
  Guanosine C10H13N5O5 + 9.98 
  dAMP C10H14N5O6P + 9.14 
  1-Aminocyclopropane-1-carboxylate C4H7NO2 + 9.59 
  N(pi)-Methyl-L-histidine C7H11N3O2 + 9.47 
  L-Carnitine C7H15NO3 + 9.89 
  Eflornithine C6H12F2N2O2 + 9.98 
  L-Tyrosine C9H11NO3 + 9.98 
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 2 4-Trimethylammoniobutanoate C7H15NO2 + 9.77 
  S-Adenosyl-L-homocysteine C14H20N6O5S + 9.68 
  AMP C10H14N5O7P + 9.59 
  NAD+ C21H27N7O14P2 + 0 
  Glycylglycine C4H8N2O3 + 9.98 
  Phenol C6H6O + 0 
  D-Glucosamine-6-phosphate C6H14NO8P + 10.79 
  L-Alanine C3H7NO2 + 10.73 
  Choline phosphate C5H14NO4P + 10.21 
  dCMP C9H14N3O7P + 10.1 
  L-2-Aminoadipate C6H11NO4 + 10.38 
  L-homoserine C4H9NO3 + 10.75 
  N-Acetylornithine C7H14N2O3 + 10.7 
  4-Aminobutanoate C4H9NO2 + 10.94 
 
L-Cystathionine C7H14N2O4S + 11.22 
  agmatine C5H14N4 + 11.15 
  Spermine C10H26N4 + 12.23 
  Trypanothione disulfide C27H47N9O10S2 + 12.17 
  Choline C5H13NO + 15.65 
  1-Aminopropan-2-ol C3H9NO + 15.65 
  L-Ornithine C5H12N2O2 + 14.24 
  5-Methoxytryptamine C11H14N2O + 4.59 
  Methylguanidine C2H7N3 + 0 
  Biotin C10H16N2O3S + 0 
  L-2_3-Diaminopropanoate C3H8N2O2 + 11.31 
  1_3-Diaminopropane C3H10N2 + 14.04 
  Taurocholate C26H45NO7S - 4.54 
  Lipoate C8H14O2S2 - 4.54 
  Phenylacetylglycine C10H11NO3 - 5.89 
  Phenylpyruvate C9H8O3 - 4.6 
  D-Threose C4H8O4 - 8.27 
  succinate semialdehyde C4H6O3 - 8.27 
  N-Acetylglutamine C7H12N2O4 - 8.46 
  3-(4-Hydroxyphenyl)pyruvate C9H8O4 - 6.36 
  D-Ribose C5H10O5 - 8.91 
  FMN C17H21N4O9P - 8.52 
  L-Gulono-1_4-lactone C6H10O6 - 9.31 
  Orotidine C10H12N2O8 - 9.5 
  N-Acetylneuraminate C11H19NO9 - 9.74 
  dUMP C9H13N2O8P - 9.72 
  allantoin C4H6N4O3 - 11.02 
  dIMP C10H13N4O7P - 9.95 
  sn-Glycerol 3-phosphate C3H9O6P - 10.32 
  sucrose C12H22O11 - 10.78 
  D-Erythrose 4-phosphate C4H9O7P - 10.85 
  Succinate C4H6O4 - 10.61 
  D-Glucuronolactone C6H8O6 - 10.85 
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 2 Mesaconate C5H6O4 - 10.8 
  2-Oxoglutarate C5H6O5 - 10.91 
  GMP C10H14N5O8P - 10.67 
  (S)-Malate C4H6O5 - 11.04 
  UDP-glucose C15H24N2O17P2 - 10.95 
  Folate C19H19N7O6 - 11.1 
  DL-Glyceraldehyde 3-phosphate C3H7O6P - 0 
  NADP+ C21H28N7O17P3 - 10.78 
  ATP C10H16N5O13P3 - 10.85 
  3-Phospho-D-glycerate C3H7O7P - 11.19 
  Oxalate C2H2O4 - 12.02 
  GDP C10H15N5O11P2 - 11.56 
  citrate C6H8O7 - 11.85 
  CTP C9H16N3O14P3 - 11.67 
  GTP C10H16N5O14P3 - 12.11 
  2-Deoxy-D-glucose C6H12O5 - 8.65 
 
(R)-Lactate C3H6O3 - 5.37 
  Acetyl-CoA C23H38N7O17P3S - 0 
3 Dihydrolipoamide C8H17NOS2 + 8.11 
  lipoamide C8H15NOS2 + 4.94 
  2-Aminobutan-4-olide C4H7NO2 + 6.62 
  2-hydroxyethyldisulfide C4H10O2S2 + 6.8 
  Isonicotinic acid C6H5NO2 + 7.01 
  L-cysteine C3H7NO2S + 7.16 
  L-Noradrenaline C8H11NO3 + 7.42 
  Biopterin C9H11N5O3 + 7.86 
  O-Acetylcarnitine C9H17NO4 + 8.74 
  O-Acetyl-L-serine C5H9NO4 + 8.55 
  L-Homocysteine C4H9NO2S + 9.94 
  5-Aminolevulinate C5H9NO3 + 9.77 
  gamma-L-Glutamyl-L-cysteine C8H14N2O5S + 10.05 
  glutathione C10H17N3O6S + 10.05 
  Acetylcholine C7H15NO2 + 12.79 
  L-Cystine C6H12N2O4S2 + 10.84 
  Homocystine C8H16N2O4S2 + 0 
  S-glutathionyl-L-cysteine C13H22N4O8S2 + 0 
  Mercaptoethanol C2H6OS + 21.5 
  trypanothione C27H49N9O10S2 + 10.46 
  Glutathione disulfide C20H32N6O12S2 + 11.05 
  Bis-gamma-glutamylcystine C16H26N4O10S2 + 11.32 
  Benzoate C7H6O2 - 6.41 
  acetylcysteine C5H9NO3S - 7.11 
  D-Glucono-1_4-lactone C6H10O6 - 9.26 
  Acetoacetate C4H6O3 - 7.55 
  Maleic acid C4H4O4 - 9.86 
  D-Arabinose C5H10O5 - 10.42 
  D-Fructose C6H12O6 - 10.34 
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 3 Orthophosphate H3O4P - 10.64 
  NADH C21H29N7O14P2 - 9.44 
  L-Dehydroascorbate C6H6O6 - 11.81 
  N-acetyl-L-glutamate C7H11NO5 - 9.99 
 
ascorbate C6H8O6 - 10.64 
  Itaconate C5H6O4 - 10.64 
  D-Fructose 6-phosphate C6H13O9P - 10.74 
  Adenosine 2'_5'-bisphosphate C10H15N5O10P2 - 10.68 
  2-phospho-D-glycerate C3H7O7P - 11.11 
  pyrophosphate H4O7P2 - 11.49 
  NADPH C21H30N7O17P3 - 0 
 
Table D1: Authentic standard mixes run with every metabolomics experiment  
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Appendix E 
Chapter 5.2.2.: Table of secreted proteins from T. b. brucei GVR35, with 109 proteins 
significantly identified using MASCOT (p-value <0.05).   
 
Accesion no. 
 (TritrypDB) ID Matches Score 
Tb11.01.1290 14-3-3-like protein, putative 
a,b 10(6) 104 
Tb11.02.4700 14-3-3-like protein, putative 
a,b 9(2) 44 
Tb11.01.3020 40S ribosomal protein L14, putative 2(1) 32 
Tb10.6k15.3340 40S ribosomal protein S24E, putative 2(0) 17 
Tb10.70.3360 40S ribosomal protein S3a, putative 
b 5(2) 57 
Tb11.02.1085 40s ribosomal protein S4, putative 
a 3(1) 33 
Tb09.211.0110 60S ribosomal protein L10, putative 3(1) 42 
Tb09.211.4550 60S ribosomal protein L12, putative 6(2) 44 
Tb927.7.5170 60S ribosomal protein L23a 1(0) 24 
Tb09.244.2730 60S ribosomal protein L5, putative 6(1) 63 
Tb10.70.7010 60S ribosomal protein L9, putative 3(1) 33 
Tb09.211.3180 6-phosphogluconate dehydrogenase, decarboxylating, putative 2(1) 29 
Tb11.02.1120 adenylosuccinate synthetase, putative 
b 9(2) 57 
Tb09.211.4460 ADP-ribosylation factor, putative 
a 4(0) 26 
Tb927.3.3450 ADP-ribosylation factor-like protein 3A, putative 
a 1(0) 17 
Tb927.1.2340 alpha tubulin 
a,b 108(84) 2274 
Tb09.160.4590 arginine kinase 
a,b
 20(5) 116 
Tb10.70.3710 aspartate aminotransferase 
a,b 10(1) 37 
Tb927.1.2330 beta tubulin 
a 48(16) 524  
Tb927.7.4060 calpain-like cysteine peptidase, putative 
a 20(2) 48 
Tb10.70.0830 clathrin heavy chain 
a 36(5) 132 
Tb927.2.1560 cyclophilin type peptidyl-prolyl cis-trans isomerase precursor, putative 3(0) 14 
Tb11.03.0250 cyclophilin a 
a 12(6) 226  
Tb11.01.8470 dihydrolipoyl dehydrogenase 
a 2(0) 27 
Tb10.70.5650 elongation factor 1-alpha 
a,b 37(4) 116 
Tb11.01.4660 elongation factor 1 gamma, putative 
a 8(1) 28 
Tb10.70.2650 elongation factor 2 
a,b 58(33) 942 
Tb10.70.4740 enolase 
a,b 135(59) 1528 
Tb09.160.3270 eukaryotic initiation factor 4a, putative 
a,b 4(3) 91 
Tb10.70.1370 fructose-bisphosphate aldolase, glycosomal 
a 7(4) 153  
Tb11.02.5450 glucose-regulated protein 78, putative 
a 4(2) 53 
Tb10.6k15.3850 glyceraldehyde 3-phosphate dehydrogenase, cytosolic 
a,b
 4(1) 58 
Tb09.211.3540 glycerol kinase, glycosomal 
a 13(4) 168 
Tb927.8.3530 glycerol-3-phosphate dehydrogenase [NAD+], glycosomal 
a,b 7(0) 44 
Tb11.01.3170 guanine nucleotide-binding protein beta subunit- like protein 
a 3(0) 25 
Tb11.01.0120 haloacid dehalogenase-like hydrolase, putative 
a 5(2) 56 
Tb11.01.3110 heat shock protein 70 
a,b 113(41) 914 
Tb11.01.3080 heat shock protein 70 
a,b 19(7) 237  
Tb927.7.710 heat shock 70 kDa protein  6(4) 145 
Tb10.26.1080 heat shock protein 83 
a,b 38(15) 371 
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Tb10.389.0880 heat shock protein, putative 
a,b 14(3) 114 
Tb927.3.5340 Hsc70-interacting protein (Hip), putative  5(2) 42 
Tb927.7.1320 HSP10 10 kDa heat shock protein, putative 5(2) 77  
Tb10.70.0280 HSP60 chaperonin Hsp60, mitochondrial precursor 
b 7(5) 116 
Tb10.v4.0053 hypothetical protein  29(13) 280 
Tb10.70.1130 hypothetical protein 7(4) 150 
Tb927.2.2550 hypothetical protein, conserved 2(0) 23 
Tb927.4.2740 hypothetical protein, conserved 6(1) 78 
Tb11.01.5680 hypothetical protein, conserved 6(3) 77  
Tb09.160.5530 hypothetical protein, conserved 9(2) 72 
Tb927.6.4140 hypothetical protein, conserved 1(1) 55 
Tb11.01.1625 hypothetical protein, conserved 3(1) 51 
Tb927.6.5000 hypothetical protein, conserved 13(8) 47 
Tb10.389.0720 hypothetical protein, conserved 5(1) 37 
Tb927.8.4820 hypothetical protein, conserved 3(1) 35 
Tb11.47.0016 hypothetical protein, conserved 2(1) 35 
Tb10.406.0610 hypothetical protein, conserved 9(2) 35 
Tb09.211.3955 hypothetical protein, conserved 2(0) 34 
Tb927.7.1420 hypothetical protein, conserved 120(1) 30 
Tb09.211.1690 hypothetical protein, conserved 2(0) 27 
Tb10.61.2620 hypothetical protein, conserved 2(0) 24 
Tb927.6.3170 hypothetical protein, conserved 4(0) 24 
Tb10.26.0680 hypothetical protein, conserved 6(0) 23 
Tb927.1.4310 hypothetical protein, conserved 11(0) 22 
Tb927.8.6330 hypothetical protein, conserved 15(0) 22 
Tb11.01.4700 hypothetical protein, conserved 1(0) 18 
Tb10.70.3070 hypothetical protein, conserved 1(0) 17 
Tb927.3.3560 hypothetical protein, conserved 2(0) 16 
Tb10.6k15.1500 hypothetical protein, conserved 1(0) 15 
Tb10.61.0540 hypothetical protein, conserved 2(0) 13 
Tb09.160.0465 hypothetical protein, conserved 3(0) 13 
Tb10.6k15.0210 hypothetical protein, conserved  2(0) 14 
Tb927.7.3440 I/6 autoantigen 
a 
5(3) 68 
Tb927.3.2960 inosine-adenosine-guanosine-nucleosidehydrolase 
a 5(2) 56 
Tb11.02.2260 kinesin, putative  5(1) 45 
Tb10.61.1750 C-terminal motor kinesin, putative 
a 15(5) 118 
Tb10.70.5840 major vault protein, putative 10(0) 20 
Tb10.70.5250 metacaspase MCA4; cysteine peptidase, putative 
a 1(0) 26 
Tb09.211.0120 nascent polypeptide associated complex subunit, putative 
b 1(1) 50 
Tb11.01.7800 nucleoside diphosphate kinase 
a 19(2) 110 
Tb927.3.4290 PFR1 73 kDa paraflagellar rod protein 
a,b 7(1) 40 
Tb10.6k15.2620 2,3-bisphosphoglycerate-independent phosphoglycerate mutase 
b 4(0) 29 
Tb10.70.5520 piwi-like protein 1  42(10) 75 
Tb11.01.1680 polyubiquitin, putative 
a 12(4) 91 
Tb927.7.4770 cyclophilin-type peptidyl-prolyl cis-trans isomerise 
a,b 4(3) 79 
Tb10.100.0170 proteasome alpha 2 subunit, putative 1(0) 19 
171 
 
Accesion no. 
 (TritrypDB) ID Matches Score 
Tb10.70.0850 proteasome alpha 1 subunit, putative 
a 2(0) 20 
Tb10.100.0120 proteasome alpha 5 subunit, putative 2(0) 20 
Tb11.02.4040 protein transport protein Sec31, putative 2(0) 15 
Tb10.61.2680 pyruvate kinase 1
a 8(5) 166 
Tb11.01.1350 S-adenosylhomocysteine hydrolase 
a,b 11(6) 159 
Tb10.70.7050 TCP-1-delta t-complex protein 1, putative 2(1) 32 
Tb09.211.2570 TCP-1-eta t-complex protein 1, putative 3(0) 14 
Tb927.8.3150 TCP-1-gamma t-complex protein 1, putative 5(0) 29 
Tb10.6k15.2330 TCP-1-theta t-complex protein 1, putative 3(0) 26 
Tb11.02.0750 TCP-1-zeta t-complex protein 1, putative 4(0) 18 
Tb11.03.0670 transcription factor, putative 7(1) 29 
Tb11.02.3210 triosephosphate isomerise 
a,b 
6(2)  73 
Tb927.3.3760 tryparedoxin 
a,b 22(3) 79 
Tb09.160.4250 tryparedoxin peroxidase 
a,b 23(0) 32 
Tb927.7.1120 
trypanothione/tryparedoxin dependent  
peroxidase 1, cytosolic 5(1) 55 
Tb10.406.0520 trypanothione reductase 
a,b 7(1) 41 
Tb09.211.3610 ubiquitin-activating enzyme E1, putative 
a 6(0) 30 
Tb11.02.0815 ubiquitin-conjugating enzyme 
a,b 12(8) 229 
Tb927.5.4950 variant surface glycoprotein (VSG, atypical), putative 14(1) 31 
Tb11.21.0005 variant surface glycoprotein (VSG, pseudogene), putative 2(0) 20 
Tb10.v4.0136 variant surface glycoprotein (VSG, pseudogene), putative 7(0) 14 
Tb10.v4.0124 variant surface glycoprotein (VSG, pseudogene), putative 9(0) 13 
Tb927.6.5630 variant surface glycoprotein (VSG, pseudogene), putative 7(0) 13 
 
Table E1: Secreted proteins from T. b. brucei strain GVR35 (obtained with FASP, 5.2.2.). 
Identifications and accession no. were matched by mascot to TritrypDB.  
Matches indicated the number of peptides matched against the protein sequence with the number in 
brackets showing significant hits, indicating homology or identity. Score > 29 indicates homology or 
identity to compared protein sequences with p > 0.05. 
a
 protein identified in T. gambiense (Geiger et al., 2010) 
b
 protein identified in T. congolense (Grébaut et al., 2009) 
 
